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ABSTRACT
Viral Factors Influencing Early Infection Events During Ex-Vivo KSHV Infection
by Ramina Nabiee

The enigma of Kaposi Sarcoma Herpes Virus infection, and its persistence despite a
quarter century of research on the virus, has given rise to an immediate need for
addressing fundamental questions about basic immunology and virology knowledge
regarding this virus. Kaposi Sarcoma Herpes Virus (KSHV), also known as Human
Herpesvirus 8 (HHV8), is the etiological agent of Kaposi Sarcoma (KS) and other
lymphoproliferative cancers, such as Multicentric Castleman’s Disease (MCD), Primary
Effusion Lymphoma (PEL), and a newly discovered rare disease called KSHV
Inflammatory Cytokines Syndrome (KICS). Epidemic KS, also known as AIDS-KS, is
the most common cancer in untreated HIV patients. This epidemic in western countries
mostly affects the homosexual population, while in the malaria-belt, both men and
women can be affected equally. All forms of diseases caused by KSHV are uniformly
fatal highlighting the need for research into KSHV virology for the identification of
possible druggable targets to address the public health burden and help further develop
vaccines, therapies, or treatments.
The thesis presented herein will focus on the study of early infection events and the
persistence of infection within the oral cavity. We have identified and characterized
virion-associated factors critical for the earliest stages of KSHV infection; in three
specific aims:

VII

1. Examining Host-Specific Differences and Viral Tropism in KSHV Infection of
Tonsil-Derived B Lymphocytes
2. Validating the Proteomic Composition of KSHV Virions
3. Establishing the Contribution of KSHV-ORF11 Tegument Protein in de novo
Infection of B Lymphocytes.
We have demonstrated that gamma-herpesvirus conserved tegument factors play critical
but uncharacterized roles in the establishment of infection in B lymphocytes, and that
utilizing our study model provides us with the unique chance to observe this infection
process at an early stage. Thus, in short, we have attempted to provide an answer to the
long-forgotten questions within the field of KSHV virology about the proteins the virion
packages and introduces in early stages of infection and what that could mean in the
bigger picture for the host -pathogen interactions.
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1. CHAPTER I: KSHV Early Infection Events and Host-Pathogen Interactions, A
Road Less Traveled

1

1.1 Introduction
Kaposi Sarcoma (KS) is now the 4th most common cancer caused by an infectious
agent. KS has a high prevalence among AIDS patients, but the enigma of Kaposi’s
Sarcoma Herpes Virus (KSHV) infection, and its persistence despite quarter
century of research on the virus, has given rise to immediate need for addressing
fundamental questions about basic immunology and virology knowledge regarding
this virus (Martin JN, 2007). Kaposi’s Sarcoma was first discovered by Dr. Moritz
Kaposi in 1872, when he observed a peculiar multifocal pigmented sarcoma in
elderly European males who died within a few years of symptom emergence
(Classic KS) (Kaposi, 1872). Years later, several reports described a
lymphadenopathic form of KS in African children (Endemic KS) (D’Oliveira,
1972). However, it was the onset of the AIDS epidemic that KS became a major
public health burden and a research priority (Epidemic KS) (Gottlieb, 1981),
(Ariyoshi, 1998). It is worth noting that there have been two other forms of KS
detected: Iatrogenic KS, occurring in people with iatrogenic immunodeficiencies,
or people undergoing tissue transplant surgeries (Grulich, 2015); and a newer
increasing form of KS in men who have sex with men (MSM) without HIV
infection (Denis, 2018).
It was not until 1994 that a directed study suggested that this cancer had an
infectious origin independent of HIV (Chang, et al., 1994).
2

KSHV also known as Human Herpesvirus 8 (HHV8) is known today as the
etiological causative of Kaposi Sarcoma (KS) and other lymphoproliferative
cancers (Mesri EA, 2010 ) such as Multicentric Castleman’s Disease (MCD), and
Primary Effusion Lymphoma (PEL), and a newly discovered rare disease called
KSHV Inflammatory Cytokines Syndrome (KICS) (Karass M. e., 2017).
Epidemic KS also known as AIDS-KS is the most common cancer in untreated
HIV patients, and this epidemic in western countries mostly affects the
homosexual population, while in the malaria belt both men and women can be
affected equally (Wabinga HR, 1993 ).
All forms of diseases caused by KSHV are uniformly fatal (Mesri EA, 2010 ),
highlighting the major need for study and development of possible druggable
targets within the virus to address the public health burden and help further
develop vaccines, therapies, and treatments.
1.1.1 KSHV Discovery
KSHV was first discovered twenty-five years ago through the use of
representational difference analysis by Chang et.al (Chang, et al., 1994) and about
a year later Moore et al. looked into similarities of this virus with other known
gamma-herpesviruses and were able to identify it as most similar to HVS
(Herpesvirus Saimiri). However, through gene alignment and amino acid
sequencing alignments on ORFs suitable for phylogenetic analysis, they noted that
3

the divergence between them is ancient. Furthermore, they classified the virus as
the first human gamma(γ)-2 herpesvirus (Moore, et al., 1996).
KSHV is the only viral agent of the rhadinoviral subfamily capable of infecting
humans (Chang, et al., 1994). The gamma-herpesvirus subfamily was first
classified and distinguished from the other herpesviruses (alpha and beta
subfamilies) because of their cellular tropism for lymphocytes (Longnecker R,
2007. ) The Gammaherpesvirinae subfamily is further divided into two
superfamilies: Lymphocryptoviridae including EBV, and Rhinoviruses which
includes KSHV (Fig.1.1).
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Figure 1. 1 Divergence of Gamma Herpesviruses from the other Herpesvirus Families. In
1996 Moore et al. looked into similarities of KSHV virus with other known gamma-herpesviruses
of the day and identified it as most similar with HVS (Herpesvirus Saimiri) through gene
alignment and amino acid sequencing alignments on ORFs suitable for phylogenetic analysis. He
furthermore, classified the virus as the first human gamma(γ)-2 herpesvirus.
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KSHV’s seroprevalence has been connected with KS prevalence (Mesri EA, 2010
). It is highest in sub-Saharan Africa (up to 90% seroprevalence in some adult
populations). In contrast, its prevalence in Europe, AsiaAsia, USA where it is
prevalent in less than 10% of population (Fig1.2) (Cesarman, 2019).
Aside from the infection of endothelial cells that leads to different forms of KS,
KSHV is also capable of infecting human B cells, where it can lead to different B
cell tumors (Hassman LM, 2011 ), all of which are not only fatal but the current
therapy available for them can only prolong patients’ lifespan up to two years at
most (Carbone A G. A., 2008), (Waterston A, 2004 ).

6

Figure 1. 2 Worldwide KSHV seroprevalence (cumulative data from several studies
conducted between 1998-2015). Figure modified from Cesarman et al. (Cesarman, 2019) and
Mesri et al. (Mesri EA, 2010).

7

1.1.2 KSHV’s Pathophysiology
KSHV can infect and interact with a range of host cells including B lymphocytes,
dendritic cells, endothelial cells, epithelial cells, fibroblasts, and monocytes
(Bechtel J. T., 2003). KSHV uses different surface receptors to interact with
different host cells, for example it has been recognized that KSHV uses integrins
such as heparin sulfate and tyrosine protein kinase receptor EPHA2 for endothelial
cell entry (Kumar, 2016), while it has been suggested that KSHV relies on DCSIGN for B cell entry (Rappocciolo G, 2008 ).
KSHV virions average 120-150 nm in size. The central nucleocapsid has a T = 16
icosahedral structure with vertices formed out of 12 pentons interconnected with
320 triplexes and 150 hexons, that form the faces and edges that together constitute
a capsid structure similar to other herpesviruses (Trus BL, 2001). KSHV has a
linear double stranded DNA (Damania, 2013) of 165–170 kb, that is encapsulated
within the capsid surrounded by a layer of non-structural proteins, and RNA. This
amorphous proteinaceous layer is called the tegument layer and proteins in this
layer critically affect the cellular and viral biology immediately following viral
entry (Minhas, 2014). The tegument layer also separates the capsid from the
glycoprotein containing envelope (Roizman, et al., 1981 ). The glycoproteins
residing within the envelope interact with cell type specific receptors and facilitate
entry (Kumar, 2016), which leads to direct delivery of the viral capsid into host
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cytoplasm. Once within the cytoplasm, capsids are transported to the nuclear
membrane where KSHV genomes are released and penetrate the nucleus. During
latency, the viral genome resides in the form of an extrachromosomal episome and
can switch to sporadic onsets of lytic activation (Fig1.3) (Bechtel J. T., 2003).
In the very early stages of viral entry, the virion releases tegument proteins within
the host cell, which immediately begin modulating host and viral processes
including cell cycle modulation (De Oliveira, Ballon, & Cesarman, 2010 ),
transcriptional activation of viral genes (Sathish N, 2012 ) inhibition of host gene
expression activation (Zhu, Sathish, & Yuan, 2010), translocation of the virion
capsid to the nucleus and modulation of innate immune responses (Bergson, et al.,
2014 ) in the infected cells.

9

Figure 1. 3 KSHV Structure and its simplified interaction with Host cell during entry. The
glycoproteins residing within the envelope interact with cell type specific receptors and facilitate
entry leading to direct delivery of viral capsid into host cytoplasm. Once within the cytoplasm
KSHV genome will be unsheathed, however the virion packaged proteins will be released in the
early preliminary stages, manipulating the cellular environment
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As with other herpesviruses, infection with KSHV is lifelong, and the virus
primarily establishes latency and only expresses a few selective loci, such as
ORF71 (also called ORFK13; encoding viral FLICE inhibitory protein (vFLIP),
ORF72 (encoding vCyclin), ORF73 (encoding latency-associated nuclear protein
(LANA), ORFK12, and low levels of expression for some other ORFS such as
ORFK15, ORFK1 and viral IL-6 (vIL6), as well as several microRNAs (miRNAs)
(Cai, 2005), (Chandriani, 2010). The latent genes are expressed in most KSHVinfected tumor cells and are thought to promote tumorigenesis. Also, the viral
miRNAs that are expressed during KSHV latency are believed to help keep the
infected cell alive, by inhibiting apoptosis, and maintaining virus latency (Dittmer,
2016); these viral miRNAs are also expressed in KS, PEL and MCD (O’Hara,
2009). Similarly, in B cell studies using animals it has been observed that the
expression of some latent genes as well as miRNAs leads to lymphoma (Sin,
2013) as well as vascular proliferation and an inflammatory phenotype when
expressed in endothelial cells (Ballon, 2015).
Some studies have attempted therapeutic targeting of these latent genes. However,
due to a lack of proper cell models, or clinical infeasibility, there have not been
significant therapeutic successes (Briggs, 2017) . Another approach has also
focused on targeting the host cellular genes that are activated / regulated by KSHV.
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This approach seems to have a higher degree of success, especially in the case of
mTOR pathway targeting due to its overexpression in latently infected tumor cells
of PEL as well as KS (Krown, 2012) and the fact that it acts as a general sensing
pathway within all cells.
KSHV is also capable of a lytic life cycle, however, it is not yet clear what
physiological stimuli allows spontaneous reactivation (Cesarman, 2019). In the
lytic life cycle, KSHV genes have different time-based clusters of expression.
Immediate-Early (IE) genes are expressed first. The protein products of most IE
genes control transcription and ORF45/RTA, a key protein also known as the
reactivation switch, which ensures the expression of viral genes required for
replication. The next cluster of lytic genes are Delayed-Early (DE) genes followed
finally by late genes (Damania, 2013). The DE genes, in general, control and
facilitate viral DNA replication via rolling circle mechanism resulting in linear
genomes ready for packaging within the capsids. In the late phase, all viral
structural genes are expressed. In contrast to latent genes that are expressed in all
tumor cells, lytic genes and the encoded viral proteins are produced by a low
proportion of tumor cells (Damania, 2013). Lytic phase genes have also been
studied as therapeutic targets. However, the results are inconsistent within distinct
patient groups’, highlighting the immediate need for development of more
effective therapeutics (Uldrick, 2011), (Krown S. E., 2011).
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1.1.3 KSHV Host Cell Tropism
Although KSHV’s route of transmission is still unknown, KSHV has consistently
been detected in circulating peripheral blood mononuclear cells (PBMC; mostly of
B cell lineage), saliva, prostate, bone, and nerve tissues of AIDS patients with or
without KS (Ambroziak JA, 1995). Pauk et al. (Pauk, et al., 2000) showed that, in
comparison to other bodily fluids, the percentage of KSHV detection in saliva is
the highest. Thus, they concluded that oral exposure to infectious saliva is a
potential risk factor for the acquisition of KSHV. In addition, KSHV has been
detected in hyperplastic lymph nodes of immune-competent persons, strengthening
the hypothesis that HHV-8 may establish persistent infection without inducing
clinically evident disease (He, et al., 1998).
The origin of the cell types resulting in KSHV-related diseases is still not fully
determined, and how a certain cell types become infected with KSHV needs more
research (Ensoli, et al., 2001). In early KS development, it has been observed that
the KS nodes are rich in immune cells, suggesting a potential role for immune cells
during macule formation. However, the increase in immune cells could be driven
by infected cells and not be the source of the virus (Cesarman, Mesri, &
Gershengorn, 2000). It has been hypothesized that infected B cells residing in the
proximity of endothelial cells may play a role in KS formation. Clinical research
has shown that B cells are of critical importance to KSHV by: (1) providing a
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reservoir for KSHV latent life cycle in the host (2) being the cell type of origin for
PEL and MCD and (3) as a possible source of KSHV in the saliva (Myoung J,
2011). However, B cells are largely refractory to KSHV infection in cell culture
models (Akula SM, 2001 ), (Dyson, Traylen, & Akula, 2010). One plausible
reason for this observation could be the utilization of PBMC cells instead of
secondary lymphoid tissue residing cells (Hassman LM, 2011 ).
In B cell cancers it has long been believed that the transformed B cells will still
mirror the phenotype of their cell type of origin (Salmon & Seligmann, 1974 )
However, it has been a topic of discussion in the infectious lymphoma field, that B
cells could also be first infected and then undergo malignant transformation
following differentiation (Campbell, Jenkins, & Rinaldo, 2014). Recently, it was
shown that infection may drive alternate light chain expression in (from κ to λ) for
reasons that are still unclear (Totonchy J, 2018 ). It is worth noting that PEL and
MCD are believed to arise from B cells of various stages of development
(Chadburn A, 2008), (Du, et al., 2001). It is still unknown which type or types of B
lymphocyte precursors are susceptible to KSHV. To this day, the potential range of
B cells that may be critical for disease and the difficulty infecting them hinders the
study of B cell infection (Dollery, 2019 ).
Taken together it can be concluded that the therapies that inhibit B cell infection
may prove especially useful in KSHV infection prevention.
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1.1.4 Difficulties in KSHV Research
Despite the extensive body of work revolving around the role of individual KSHV
factors in varying aspects of tumorigenesis, there is a lack of reliable models for
KSHV infection in vitro as well as difficulty in in vitro viral particle production
and challenges in production of recombinant virions (Zhou, 2002). All these
factors together have coerced scientists to substitute non-relevant cell lines in
models. This limits our knowledge of early events during de novo infection
including, but not limited to, the cell types involved, viral and cellular factors
influencing de novo infection, persistence, and the establishment of latency in
disease-relevant cell types or how these factors might contribute to disease.
Another challenge in the field of KSHV has been the lack of evidence for the viral
transmission route, but recent data has indicated that there is a noticeable amount
of viral shedding in saliva. Thus, establishing saliva as an important infectious
reservoir and the most likely mode of KSHV transmission (Newton, et al., 2018).
Furthermore, given the fact that this virus has lymphocyte tropism, we believe that
the tonsil and oral lymphoid tissues represent the most relevant physiological niche
in which to study the earliest stages of KSHV infection and spread.

1.2 Rationale and Hypothesis
Assuming that saliva is a primary route of KSHV spread and given the fact that
this virus has tropism for B Lymphocytes and lymphatic endothelial cells, we
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believe that the oral lymphoid tissues, such as the tonsil, represent the most
relevant physiological niche to study the earliest stages of KSHV infection and
spread.
Moreover, some of KSHV tegument proteins are specific to and highly conserved
within the gamma herpesvirus family (Bai Z, 2014). These conserved factors
could potentially be contributing to the gamma-herpesvirus family exclusive
behaviors and characteristics (i.e., lymphocyte tropism). Therefore, identifying
specific tegument proteins and further characterizing their specific roles in
initiation, spread and persistence of infection will lead to valuable and critical
knowledge that can help further the development of novel therapeutics, as well as
discoveries about the human immune system.
As mentioned above, despite the many years of research on KSHV, the route of
transmission is still not determined. However, in recent years there has been
significant findings showcasing noticeable levels of virion shedding within the
saliva of infected people. Thus, it is likely that transfer of the virion from infected
patients to other subjects happens through exchange of saliva. In this scenario, one
of the earliest points of contact between KSHV virions and susceptible target cells
is going to occur in the subjects’ tonsils (Non-keratinized stratified squamous
tissues containing a considerable level of lymphocytes among other cells). Thus,
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tonsil derived B lymphocytes are important cell type to study the initiation and
establishment of KSHV infection in a new human host.
Given our labs previous experience with KSHV in development of molecular tools
for the study of KSHV as well as establishment of a unique cellular model system
for infection tonsil-derived B lymphocytes and mesenchymal cells (Fig.1.4); the
research proposed herein will focus on the study of early infection events and the
persistence of infection within the oral cavity.
We will identify and characterize virion-associated factors critical for the earliest
stages of KSHV infection. We hypothesize that gamma-herpesvirus conserved
tegument factors play critical but uncharacterized roles in the establishment of
infection in B lymphocytes, and that utilizing our study model will provide us with
the unique chance of observing related cells in this infection process at an early
stage.
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Figure 1. 4 Scheme of the infection model used in our studies. Lymphocytes are seperated via
magnetic sort, then Naïve B cells of different donors are used at the same density for infection,
later on the other cells are also added back to the experimental condition well.
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1.3 Specific Aims
1.3.1 Examining Host-Specific Differences in KSHV Infection of TonsilDerived B Lymphocytes
Hypothesis
From the time B Lymphocytes are produced in the bone marrow, they constantly
undergo complex maturation and differentiation, especially within the secondary
lymphoid tissues where they are exposed to signals introduced from other cells.
This results in a robust mixed population of B lymphocyte subtypes coexisting
within the tonsil and other lymphoid tissues. As KSHV interacts with B
lymphocytes, different B lymphocyte subsets might respond differently to viral
infection and persistence. To date, the susceptibility of different B lymphocyte
lineages to KSHV infection has not been fully characterized.
Our lab previously developed an in vitro model system to determine phenotypic
changes associated with KSHV-infection of primary B lymphocytes from human
tonsil tissue over an elongated period. This model met two important criteria: (1)
stable detectable infection of sufficient cell numbers and (2) maintenance of B cell
immunophenotypes over time in culture. In this system, concentrated cell-free
virions are used to infect a variety of B lymphocyte lineages in either bulk
infection from total B cell fraction or isolated subsets sorted from human tonsil
(Totonchy J, 2018 ) We have recently improved on this model system (Fig.1.2)
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allowing us to examine infection of different B cell lineages while also providing a
way to standardize infection of samples with different compositions to allow
between samples comparisons.
1.3.2 Validating the Proteomic Composition of KSHV Virions
Hypothesis
KSHV virions package a substantial number of proteins in the tegument layer
which interact with the host cells in the early stages of infection and affect the
cellular tropism of virions. Tegument proteins affect changes to the host cell such
as cell cycle modulation (De Oliveira, Ballon, & Cesarman, 2010), transcriptional
activation of viral genes (Sathish N, 2012 ) inhibition of host gene expression
activation (Zhu, Sathish, & Yuan, 2010) and translocation of the virion capsid
within the nuclei (Bergson, et al., 2014 ). The composition of the tegument layer
of KSHV has not been revisited in a decade. Thus, in order to understand how
tegument proteins may be influencing the establishment of infection in human
tonsil, we aim to independently validate and extend our understanding of the
protein composition of KSHV virions.
This aim will ultimately serve as an establishment phase for the next specific aim
which would be the study of selected viral tegument factors and their contribution
to early events of infection in tonsil lymphocytes.
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1.3.3 To Establish the Contribution of KSHV-ORF11 Tegument Protein in de
novo Infection of B Lymphocytes.
Hypothesis
We hypothesize that systematic knockout of individual KSHV tegument factors
will reveal that multiple tegument components are essential for KSHV infection,
and that some of these factors may have cell type-specific effects. As mentioned
previously, KSHV tegument proteins play a very crucial role in the establishment
of infection, and only de novo infection systems can be used to determine which
tegument proteins are essential for KSHV infection in disease-relevant cell types.
One of these tegument factors is ORF11, a tegument protein of about 48kDa
exclusive to KSHV virus only, which is poorly studied. But given the fact that only
KSHV genome and virion contains this protein and considering that only KSHV,
among the Rhadnoviral subfamily, has the B lymphocyte tropism previously
mentioned. By combining gain-and loss-of-function study approaches, we will
reveal previously uncharacterized functions of the KSHV tegument factor ORF11.
We hypothesize that ORF11 has a role in early manipulation of KSHV infection
specifically in B lymphocytes and thus may represent a therapeutic target for
inhibiting KSHV infection and spread within the lymphocyte compartment.
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1.4 Justification for and Significance of the Study
This study aims to address particularly important questions and increase the overall
current knowledge of this field; using our unique in-house developed biological
model, that closely represents MCD disease, we can classify the significance of the
study in five categories.
1.4.1 Global Impact of KSHV on Public Health
In western countries, specifically, AIDS-KS has been a rising pandemic for the
past 38 years (Gonçalves PH, 2017 ) Along with the rise of HIV infection there
are reports of KS developing in up to 30% of AIDS patients. It has been reported
that HIV-infected patients are almost 600 times more likely to develop KS (Rabkin
CS, 1991 ), (Chaturvedi AK, 2008). It should be noted that unlike other KS forms,
this form of KS is not only fast progressing but also uniformly fatal. Despite the
invention of antiretroviral therapeutics (ART) that have been able to help control
the incidence of KS in HIV+ people, the demand for targeted therapeutics is still
present. Unfortunately, this need has not been answered in the last decade. One
important reason for this could be the lack of a suitable animal model, as well as
the limited number of patients which have made the clinical trials and in vivo
studies difficult (Lukac DM, 2007. ). The goal of the current study here, is to
provide novel druggable targets for KSHV. Furthermore, given our unique model
we will be able to provide more information on early effects of de novo infection
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with KSHV, as well as susceptibility of different B cell subsets to the infection,
which will in serve to broaden the range of efficacy for the therapeutics.
1.4.2. The Black Box of Basic KSHV Virology
We have extensive knowledge about some individual KSHV genes and their
possible role in tumorigenesis and malignancies; however, the role of specific viral
genes in de novo KSHV infection, particularly in disease-relevant cell types, has
not been extensively explored.
Up to recent years, the common laboratory procedures were not able to produce
high-titered cell-free infectious viral particles from mutant KSHV genomes
(Brulois, et al., 2012). Thus, the contribution of viral factors, specifically in
preliminary stages of the infection has been poorly studied, leading to lack of
knowledge about the druggable targets responsible for viral spread. Our study
focuses on the contribution of highly preserved viral factors exclusive to KSHV
and their potential role in early stages of de novo infection of tonsil-derived B
cells.
1.4.3. Implementation of Tonsil Lymphatic Tissue as a Novel Study System
Although up to this day, the route of KSHV transmission has not been conclusively
established. However, there is a convincing body of literature indicating that saliva
may be the primary mode of transmission for KSHV (Minhas, 2014). These data
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highlight the significance of oral cavity for establishment of KSHV infection,
particularly given the fact that KSHV is a lymphotropic virus and lymphoid tissue
is highly enriched with B cells. However, due to a lack of de novo infection models
for KSHV, the oral biology of early KSHV infection and its contribution to
KSHV-associated malignancy remains largely unexplored. The successful
completion of the proposed project will provide critical insights and novel targets
for therapeutic interventions in this important physiological niche.
1.4.4. Targeting Tegument Factors as Potential Novel Druggable Targets
As previously stated, KSHV virions contain many of non-structural viral factors,
some of which have been highly preserved during KSHV’s evolution. Like in other
herpesviruses, these viral factors assist the virus in establishment of infection and
affect the host cell environment upon binding and entry of viral particles. Thus,
making them strong candidates as targets for therapeutic interventions aimed at
preventing viral spread. Such a study, if done on relevant host cells, can provide a
better understanding for the role of these tegument proteins especially in early
infection events, and could lead to development of novel therapeutics.
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1.4.5. Studying the Mechanism of Action and Effects of Specific Tegument
Proteins
Old-world gamma-herpesviruses have some highly conserved genes, some of
which have not been extensively studied, particularly in the context of their
contribution to the establishment and progress of infection. This study therefore
aims to address this lack of understanding in this field by approaching these
poorly-studied factors through protein expression and further gain of function
studies to not only discover the active contribution of these tegument proteins, but
also discover new attributes of these novel proteins.
1.5 Innovations of the Study
To date, the majority of the research done in KSHV virology has been done in one
of the following three models:
1.5.1. Study of the KSHV virology in naturally infected lymphoma cell lines
(Drexler, 1998 ).
1.5.2. Study of KSHV virology in cells infected with lymphoma-derived
KSHV-WT (Friborg J Jr, 1998 ).
1.5.3. Study of KSHV virology in non-relevant cell lines like HEK-293
(Alkharsah KR, 2011 ).
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These models are not ideal for answering questions about the early events in de
novo infection. In the recent years there has been some innovative studies
conducted focusing on tonsillar B cells, and infection of whole tonsil with KSHV,
however the existing studies of KSHV infection in tonsil-derived B cells have
explored a limited number of cell surface markers including IgM, immunoglobulin
lambda light chains and activation markers on infected cells (Hassman:2011dj),
(Nicol:2016ga), (Totonchy:2018ir). However, no studies to date have
comprehensively explored the specific B lymphocyte lineages targeted by KSHV
infection in human tonsil specimens. On the contrary, the studies conducted here
will use a unique model developed to study de novo infection of multiple diseaserelevant cell types, which also gives us the ability to study early events in the
infection as well. This model will not only help us important biological questions
and establish a solid foundation for extensive future research but will also provide
a unique opportunity for developing therapeutic paradigms with broad efficacy and
shed light on critical aspects of early KSHV infection in physiologically relevant
contexts.

1.6 Scope of this study
KSHV is a lymphotropic herpesvirus, but despite the many years of research in this
field, the route of transmission however is still not determined. However, in recent
years there has been significant findings demonstrating noticeable levels of virion
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shedding within the saliva of infected people, so a possible mechanism of KSHV
transmission is the transfer of the virion from infected patients to other subjects
through exchange of saliva. In this context, one of the earliest points of contact for
the newly introduced virions is going to be the subjects’ tonsils (secondary
lymphoid organs containing a considerable amount of B lymphocytes), making the
tonsil derived B lymphocyte cells an important model to study the initiation and
establishment of KSHV infection.
Given our labs previous experience with this virus in development of molecular
tools for the study of KSHV as well as establishment of a unique cellular model
system for infection tonsil-derived B lymphocytes, the research presented herein
has focused on the study of early infection events and the persistence of infection
within the oral cavity.
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Abstract
Despite 25 years of research, the basic virology of Kaposi Sarcoma Herpesviruses
(KSHV) in B lymphocytes remains poorly understood. This study seeks to fill
critical gaps in our understanding by characterizing the B lymphocyte lineagespecific tropism of KSHV. Here, we use lymphocytes derived from 40 human
tonsil specimens to determine the B lymphocyte lineages targeted by KSHV early
during de novo infection in our ex vivo model system. We characterize the
immunological diversity of our tonsil specimens and determine that overall
susceptibility of tonsil lymphocytes to KSHV infection varies substantially
between donors. We demonstrate that a variety of B lymphocyte subtypes are
susceptible to KSHV infection and identify CD138+ plasma cells as a highly
targeted cell type for de novo KSHV infection. We determine that infection of
tonsil B cell lineages is primarily latent with few lineages contributing to lytic
replication. We explore the use of CD138 and heparin sulfate proteoglycans as
attachment factors for the infection of B lymphocytes and conclude that they do
not play a substantial role. Finally, we determine that the host T cell
microenvironment influences the course of de novo infection in B lymphocytes.
These results improve our understanding of KSHV transmission and the biology of
early KSHV infection in a naïve human host and lay a foundation for further
characterization of KSHV molecular virology in B lymphocyte lineages.
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Author summary
KSHV infection is associated with cancer in B cells and endothelial cells,
particularly in the context of immune suppression. Very little is known about how
KSHV is transmitted and how it initially establishes infection in a new host. Saliva
is thought to be the primary route of person-to-person transmission for KSHV,
making the tonsil a likely first site for KSHV replication in a new human host. Our
study examines KSHV infection in B cells extracted from the tonsils of 40 human
donors in order to determine what types of B cells are initially targeted for
infection and examine how the presence (or absence) of other immune cells
influence the initial stages of KSHV infection. We found that a variety of B cell
subtypes derived from tonsils can be infected with KSHV. Interestingly, plasma
cells (mature antibody-secreting B cells) were a highly targeted cell type. These
results lay the foundation for further studies into the specific biology of KSHV in
different types of B cells, an effort that may help us ultimately discover how to
prevent the establishment of infection in these cells or reveal new ways to halt the
progression of B cell cancers associated with KSHV infection.
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2.1 Introduction
Kaposi Sarcoma-associated Herpesvirus (KSHV/HHV-8) is a lymphotropic gammaherpesvirus. In addition to its role in the pathogenesis of Kaposi Sarcoma (KS)
(Chang, et al., 1994), KSHV infection is associated with two lymphoproliferative
disorders, multicentric Castleman disease (MCD) and primary effusion lymphoma
(PEL) (Cesarman E, 1995), (Soulier J, 1995), as well as a recently characterized
inflammatory disorder KSHV inflammatory cytokine syndrome (KICS) (Uldrick
TS, 2010 ). Although KSHV-associated lymphoproliferative disorders are rare, their
incidence has not declined as HIV treatment has improved (Powles T, 2009 ),
(Bhutani M, 2015 ) suggesting that, in contrast to KS, immune reconstitution is not
sufficient to prevent KSHV-associated lymphoproliferative disease in people living
with HIV/AIDS. Moreover, the KSHV-associated lymphoproliferative diseases are
uniformly fatal with few effective treatment options (Carbone A V. E., 2014 ).
Despite the fact that KSHV is lymphotropic and causes pathological
lymphoproliferation in vivo, study of de novo KSHV infection in B lymphocytes has
historically been difficult (Kang S, 2017). Resting peripheral B cells and many
established B cell-derived cell lines are refractory to KSHV infection but
unstimulated tonsil-derived lymphocytes are susceptible to infection (Rappocciolo
G, 2008 ) To date, several other groups, including our own, have been successful in
infecting B lymphocytes derived from human tonsils (Hassman LM, 2011 ),
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(Myoung J, 2011 ), (Myoung J, 2011), (Bekerman E, 2013 ), (Totonchy J, 2018 ),
(Nicol SM, 2016 ). KSHV DNA is detectable in human saliva and salivary
transmission is thought to be the primary route of person-to-person transmission for
KSHV (Casper C K. E.-L., 2007 ), (Pauk J, 2000 ), (Casper C R. M.-L., 2004),
(Vieira J, 1997 ) making the oral lymphoid tissues a likely site for the initial infection
of B lymphocytes in a naïve human host. Thus, in addition to being susceptible to ex
vivo infection, tonsil lymphocytes represent a highly relevant model for
understanding early infection events in KSHV transmission.
The existing studies of KSHV infection in tonsil-derived B cells have explored a
limited number of cell surface markers including IgM, immunoglobulin light chains
and activation markers on infected cells (Hassman LM, 2011 ) (Totonchy J, 2018 ),
(Nicol SM, 2016 ). One study using PBMC-derived B lymphocytes identified naïve,
memory and plasma cell-like lineages as infection targets in both in vitro infection
experiments and blood samples from KS patients (Knowlton ER, 2014 ). However,
no studies to date have comprehensively explored the specific B lymphocyte
lineages targeted by KSHV infection in human tonsil specimens.
In this study, we performed KSHV infection of 40 human tonsil specimens from
diverse donors and utilized lineage-defining immunological markers by flow
cytometry to establish the primary B cell lineage tropism of KSHV. Our results
demonstrate that the susceptibility of tonsil-derived B lymphocytes to ex vivo KHSV
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infection varies substantially from donor-to-donor, and that a variety of B cell
lineages are susceptible to KSHV infection and that, at least at early stages postinfection KSHV is primarily latent in most cell types. In particular, CD138+ plasma
cells are highly targeted by KSHV infection despite the fact that they are present at
low frequencies in tonsil tissue. We demonstrate that high susceptibility of plasma
cells to KSHV infection is not due to the presence of CD138 heparin sulfate
proteoglycan as an attachment factor. Moreover, HSPG are not generally important
for infection of primary B lymphocytes. Finally, we demonstrate that although the
baseline T cell microenvironment does not seem to influence overall susceptibility
of tonsil specimens to KSHV infection, the specific lineage distribution of KSHV
infection is affected by the T cell microenvironment and manipulation of CD4/CD8
T cell ratios can alter the targeting of specific B cell lineages by KSHV. These results
provide new insights into early events driving the establishment of KSHV infection
in the human immune system and demonstrate that alterations in immunological
status can affect the dynamics of KSHV infection in B lymphocytes.
2.2 Materials and Methods
2.2.1 Ethics Statement.
Human specimens used in this research were de-identified prior to receipt from
NDRI and thus were not subject to IRB review as human subjects’ research.
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2.2.2 Reagents and Cell Lines.
CDw32 L cells (CRL-10680) were obtained from ATCC and were cultured in
DMEM

supplemented

with

20%

FBS

(Sigma

Aldrich)

and Penicillin/Streptomycin/L-glutamine (PSG/Corning). For preparation of feeder
cells CDw32 L cells were trypsinized and resuspended in 15 ml of media in a petri
dish and irradiated with 45 Gy of X-ray radiation using a Rad-Source (RS200)
irradiator. Irradiated cells were then counted and cryopreserved until needed for
experiments. Cell-free KSHV.219 virus derived from iSLK cells

(Myoung &

Ganem, 2011 ) was a gift from Javier G. Ogembo (City of Hope). Human tonsil
specimens were obtained from NDRI. Human fibroblasts were derived from primary
human tonsil tissue and immortalized using HPV E6/E7 lentivirus derived from
PA317 LXSN 16E6E7 cells (ATCC CRL-2203). Antibodies for flow cytometry
were from BD Biosciences and Biolegend and are detailed below.
2.2.3 Isolation of primary lymphocytes from human tonsils.
De-identified human tonsil specimens were obtained after routine tonsillectomy by
NDRI and shipped overnight on wet ice in DMEM+PSG. All specimens were
received in the laboratory less than 24 hours post-surgery and were kept at 4˚C
throughout the collection and transportation process. Lymphocytes were extracted
by dissection and maceration of the tissue in RPMI media. Lymphocyte-containing
media was passed through a 40µm filter and pelleted at 1500rpm for 5 minutes. RBC
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were lysed for 5 minutes in sterile RBC lysing solution (0.15M ammonium chloride,
10mM potassium bicarbonate, 0.1M EDTA). After dilution to 50ml with PBS,
lymphocytes were counted, and pelleted. Aliquots of 5(10)7 to 1(10)8 cells were
resuspended in 1ml of freezing media containing 90% FBS and 10% DMSO and
cryopreserved until needed for experiments.
2.2.4 Infection of primary lymphocytes with KSHV.
Lymphocytes were thawed rapidly at 37˚C, diluted dropwise to 5ml with RPMI and
pelleted. Pellets were resuspended in 1ml RPMI+20%FBS+100µg/ml DNase
I+ Primocin 100µg/ml and allowed to recover in a low-binding 24 well plate for 2
hours at 37˚C, 5% CO2. After recovery, total lymphocytes were counted, and Naïve
B

cells

were

isolated

using Mojosort Naïve

B

cell

isolation

beads

(Biolegend 480068) or Naïve B cell Isolation Kit II (Miltenyi 130-091-150)
according to manufacturer instructions. Bound cells (non-naïve B and other
lymphocytes)

were

retained

and

kept

at

37˚C

in

RPMI+20%

FBS+ Primocin 100µg/ml during the initial infection process. 1(10)6 Isolated naïve
B cells were infected with iSLK-derived KSHV.219 (dose equivalent to the ID20 at
3dpi on human fibroblasts) or Mock infected in 400ul of total of virus + serum free
RPMI in 12x75mm round bottom tubes via spinoculation at 1000rpm for 30 minutes
at 4˚C followed by incubation at 37˚C for an additional 30 minutes. Following
infection, cells were plated on irradiated CDW32 feeder cells in a 48 well plate,
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reserved bound cell fractions were added back to the infected cell cultures, and FBS
and Primocin (Invivogen) were added to final concentrations of 20% and 100µg/ml,
respectively. Cultures were incubated at 37˚C, 5% CO2 for the duration of the
experiment. At 3 days post-infection, cells were harvested for analysis by flow
cytometry.
2.2.5 Flow cytometry staining and analysis of KSHV infected tonsil
lymphocytes.
A proportion of lymphocyte cultures at baseline or 3dpi representing ~500,000 cells
were pelleted at 1400 rpm for 3 minutes into 96-well round bottom plates. Cells were
resuspended in 100µl PBS containing (0.4ng/ml) fixable viability stain (BD 564406)
and incubated on ice for 15 minutes. Cells were pelleted and resuspended in 100µl
cold PBS without calcium and magnesium containing 2% FBS,0.5% BSA (FACS
Block) and incubated on ice for 10 minutes after which 100µl cold PBS containing
0.5% BSA and 0.1% Sodium Azide (FACS Wash) was added. Cells were pelleted
and resuspended in FACS Wash containing B cell phenotype panel as follows for 15
minutes on ice: (volumes indicated were routinely used for up to 0.5(10) ^6 cells and
were based on titration of the individual antibodies on primary tonsil lymphocyte
specimens) CD19-PerCPCy5.5 (2.5µl, BD 561295), CD20-PE-Cy7 (2.5ul, BD
560735), CD38-APC (10µl, BD 555462), IgD-APC-H7 (2.5µl, BD 561305),
CD138-v450 (2.5µl, BD 562098), CD27-PE (10µl BD 555441). After incubation,
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150µl FACS Wash was added and pelleted lymphocytes were washed with a further
200µl of FACS Wash prior to being resuspended in 200µl FACS Wash for analysis.
Data was acquired on a BD FACS VERSE Flow Cytometer and analyzed
using FlowJo software. Readers should note that the BD FACS VERSE analysis
instrument lacks a 561nm laser so RFP lytic reporter expression from the KSHV.219
genome is not detectable in the PE channel. For baseline T cell frequencies 0.5e6
cells from baseline uninfected total lymphocyte samples were stained and analyzed
as

above

with

phenotype

(2µl, Biolegend 305611),

antibody

CCR7-PE

(2µl,

panel
BD

as

follows:

566742),

CD95-APC

CD28-PE

Cy7

(2µl, Biolegend 302925), CD45RO-FITC (3µl, Biolegend 304204), CD45RAPerCP Cy5.5 (2µl, 304121), CD4-APC H7 (2µl, BD 560158), CD19-V510 (3µl, BD
562953), CD8-V450 (2.5µl, BD 561426)
2.2.6 B lymphocyte lineage isolation by cell sorting.
At 3 days post-infection cells were collected and pelleted at 1400 rpm for 3 minutes
into 12x75mm round bottom tubes. Cells were resuspended in 200µl PBS containing
(0.4ng/ml) fixable viability stain (BD 565388) and incubated on ice for 15 minutes.
Cells were pelleted and resuspended in 200µl cold MACS buffer containing 5% FBS
(Sort Block) and incubated on ice for 10 minutes after which 200µl cold MACS
buffer was added. Cells were pelleted and resuspended in MACS buffer containing
B cell phenotype panel as follows for 15 minutes on ice: (volumes indicated are for
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each 1(10) ^6 cells and were scaled depending upon the number of cells being
stained for sorting). For single cell sorting of plasma cells, the panel was follows:
CD19-PerCPCy5.5 (5µl, BD 561295), CD20-PE-Cy7 (5ul, BD 560735), and
CD138-APC (5µl, Biolegend 352307). For other lineages, the panel was as follows:
CD19-PerCPCy5.5 (5µl, BD 561295), CD38-APC (20µl, BD 555462), IgD-PE-Cy7
(5, BD 561314), CD27-PE-Cy5 (5µl eBioscience 15-0279-42). After incubation,
500µl MACS buffer was added and pelleted lymphocytes were washed with a further
500µl of MACS buffer prior to being resuspended in 200µl MACS buffer and put
through a cell strainer before sorting using the 70-micron nozzle on a
BD FACSAria Fusion Cell Sorter.

2.2.7 RT-PCR.
At 3 days post infection, lymphocytes were harvested into Trizol or sorted
into Trizol LS reagent 300µl Trizol was used for >1e5 cells and 100µl Trizol was
used for <1e5 cells. An equal volume of DNA/RNA shield (Zymo Research R110250) was added after collection and RNA extraction was performed
using Zymo Directzol Microprep (Zymo Research

R2060)

according

to

manufacturer instructions. RNA was eluted in 10µl H2O containing 2U RNase
inhibitors and a second DNase step was performed for 30 minutes using the Turbo
DNA-Free kit (Invitrogen AM1907M) according to manufacturer instructions. Onestep RT-PCR cDNA synthesis and preamplification of GAPDH, LANA and K8.1
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transcripts was performed on 5µl of RNA using the Superscript III One-step RTPCR kit (ThermoFisher 12574026) and 2µM outer primers for each target gene as
follows: GAPDH outer forward (5’-TCGGAGTCAACGGATTTGGT-3’), GAPDH
outer reverse (5’- GGGTCTTACTCCTTGGAGGC-3’), LANA outer forward (5’AATGGGAGCCACCGGTAAAG-3’),

LANA

CGCCCTTAACGAGAGGAAGT-3’),

K8.1

ACCGTCGGTGTGTAGGGATA-3’),

K8.1

outer

reverse

(5’-

outer

forward

(5’-

outer

reverse

(5’-

TCGTGGAACGCACAGGTAAA-3’). Duplicate no RT (NRT) control reactions
were assembled for each lineage/sample containing only Platinum Taq DNA
polymerase (Thermofisher 15966005) instead of the Superscript III RT/Taq DNA
polymerase mix. After cDNA synthesis and 40 cycles of target pre-amplification,
0.002µl of pre-amplified cDNA or NRT control reaction was used as template for
multiplexed real-time PCR reactions using TaqProbe 5x qPCR MasterMix Multiplex (ABM MasterMix-5PM), 5% DMSO, primers at 900nM and probes at
250nM

against

target

genes

as

follows:

TCGGAGTCAACGGATTTGGT-3’),

GAPDH

GAPDH

GGGTCTTACTCCTTGGAGGC-3’),

reverse

GAPDH

ACGCCACAGTTTCCCGGAGG-BHQ13’)
AATGGGAGCCACCGGTAAAG-3’),

probe

LANA
LANA

CGCCCTTAACGAGAGGAAGT-3’),

LANA
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forward

probe

(5’(5’-

(5’HEX-

forward

(5’-

reverse

(5’-

(5'

6FAM-

ACACAAATGCTGGCAGCCCG-BHQ13’),
ACCGTCGGTGTGTAGGGATA-3’),

K8.1
K8.1

TCGTGGAACGCACAGGTAAA-3’),

K8.1

forward
reverse
probe

(5’(5’(5’FAM-

TGCGCGTCTCTTCCTCTAGTCGTTG-TAMRA3’) and analyzed using a 40
cycle program on a ThermoFisher QuantStudio 3 real time thermocycler. Data is
represented as quantitation cycle (Cq) and assays in which there was no
detectable Cq value were set numerically as Cq=41 for analysis and data
visualization.
2.2.8 Single Cell RT-PCR.
At 3 days post-infection, cells were stained for sorting as described above. Single
cells meeting lineage sort criteria were sorted into each well of a 0.2ml 96-well PCR
plate containing 4µl of 0.5x PBS, 10mM DTT (Pierce no-weigh A39255), 1.2U
RNase inhibitor (Lucigen 30281-2). After sorting, plates were sealed, centrifuged
briefly to collect all material in the bottom of the well and stored at -80˚C prior to
analysis. Plates were thawed on ice and 2µl of DNase buffer (Invitrogen 18068-015)
containing 0.5µl 10x buffer, 0.1U DNase, 0.4µl H2O) were added to each well. After
incubation at room temperature for 15 minutes, EDTA (Thermofisher AM9260G)
was added to a final concentration of 2mM and DNase was inactivated by incubation
for 10 minutes at 65˚C. One-Step RT-PCR reactions and no RT (NRT) controls were
assembled using outer primers to GAPDH, LANA, and K8.1 as described above.
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2µl of pre-amplified cDNA was used in the real time PCR reactions for GAPDH,
K8.1, LANA as described above with the exception that the assay was multiplexed
with all three targets using the same K8.1 probe sequence labeled with 5’Cy5 and
3’BHQ-2 quencher and analyzed on a BioRad CFX96 real time PCR thermocycler.
KSHV neutralization via soluble CD138 Syndecan-1. Infections were performed as
described above except KSHV.219 virus was pre-incubated for 30 minutes on ice
with serum free RPMI only or serum free RPMI containing recombinant human
syndecan-1 protein (srCD138, Bio Vision, 7879-10) prior to being added to Naïve
B lymphocytes. srCD138 concentrations noted in the text indicate the final
concentration of recombinant syndecan-1 in the reconstituted total lymphocyte
culture. Infection was analyzed at 3 days post-infection by flow cytometry for B cell
lineages and KSHV infection as detailed above. For experiments involving human
fibroblasts virus was added to cells in serum free media, cells were spinoculated for
30 minutes at 1000rpm, incubated at 37˚C for 1 hour, then infection media was
removed and replaced with complete media. At 3dpi cells were harvested via
trypsinization and analyzed for infection by flow cytometry.
2.2.9 Heparinase treatment of human fibroblasts and lymphocytes.
Total lymphocytes were thawed and recovered as described above and treated with
Heparinase I and III Blend from Flavobacterium heparinum (Sigma-Aldrich #
H3917) at 9U/25e6 of lymphocytes and incubated over irradiated CDW32 feeder
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cells at 37˚C, 5% CO2 for 24 hours in complete media. E6/E7 transformed
fibroblasts from human tonsil were treated at 4.5U/1e6 for 24hrs at 37˚C, 5% CO2.
To evaluate the effectiveness of the Heparinase treatment the samples were stained
for flow cytometry, as described above, with Heparan Sulfate (10E4 epitope) (FITC)
(United States Biological # H1890) at 2 µl/5e5 of the lymphocytes or E6/E7
transformed fibroblasts and analyzed with flow cytometry for loss of HSPG signal.
Control untreated or Heparinase-treated samples were either Mock infected or
infected with KSHV as described above. At 3 days post infection, fibroblasts
were trypsinized and analyzed for GFP expression by flow cytometry and
lymphocytes were harvested, stained for B cell lineages, and analyzed by flow
cytometry as described above.
2.2.10 T cell depletion studies.
Infections were performed as described above except a sub-population of total
lymphocytes were depleted of either CD4 or CD8 T cells using positive selection
magnetic beads (Biolegend MojoSort Human CD4 T Cell Isolation Kit
480009, MojoSort Human CD8 T Cell Isolation Kit 480011). The resulting depleted
fractions or unmanipulated total lymphocytes were used to reconstitute naïve B
lymphocytes following infection rather than bound lymphocyte fractions as
described above.
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2.2.11 Statistical Analysis.
Data plots and statistical analysis were performed in R software using ggplot2
ggcorrplot (ggcorrplot:2018tg) and RColorBrewer Specific methods of statistical
analysis and resulting values for significance and correlation are detailed in the
corresponding figure legends.
2.3 Results
2.3.1 Variable immunological composition of human tonsil specimens.
In order to explore the B cell lineages targeted by KSHV infection in human
tonsils, we procured a cohort of 40 de-identified human tonsil specimens from
donors of diverse age, sex, and self-reported race (Fig 2.1A and Table 2.1).
Analysis of the baseline frequencies of B and T cell lineages by multi-color flow
cytometry (Appendix A.1, Appendix A.2 and Table 2.2) revealed that the
composition of individual human tonsil specimens is highly variable (Fig
2.1B&D). This variation was independent of donor age for many lineages.
However, overall B cell frequencies declined with age as did germinal
center, plasmablast and transitional B cell populations while memory and naïve
populations increased in frequency with donor age (Fig 2.1C). Similarly, most T
cell lineages were not significantly correlated with donor age except for CD4+
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transitional memory and CD8+ terminal effector lineages which were both
moderately, but significantly, negatively correlated with donor age (Fig 2.1E).
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Table 0.1Donor demographics for the tonsil specimens used in the study (n = 40).
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Figure 2. 2 Variability and age-dependence of B lymphocyte lineage distribution in human
tonsils. (A)Donor demographics for human tonsil specimens used in this study. Plotted by age (yaxis), sex (x-axis) and self-reported race (color) ND = not determined. (B) Frequency
distributions of B cell lineages in tonsil specimens (see S1A Fig and Table 2 for lineage
definitions). All B cells are shown as frequency of viable lymphocytes, other B cell subsets are
shown as frequency of viable, CD19+ B cells unless otherwise specified in parenthesis. (C)
Frequency of B cell lineages based on donor age. Pearson correlation coefficients (r) with an
absolute value greater than or equal to 0.4 are shown as red or blue inset text in the subset panels.
(D) Frequency distributions of T cell lineages in tonsil specimens (see S1B Fig and Table 2 for
lineage definitions). All T cells are shown as frequency of viable CD4+ (top) or CD8+ (bottom) T
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cell except total CD4+ and total CD8+ (far left) which are shown as frequency of viable
lymphocytes. (E) Frequency of CD4+ (left) and CD8+ (right) T cell lineages based on donor age.
Pearson correlation coefficients (r) with an absolute value greater than or equal to 0.4 are shown
as red or blue inset text in the subset panels.
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Table 0.2 Lineage definitions for lymphocyte subsets used in the study.
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2.3.2 Variable susceptibility of tonsil-derived B cells to ex vivo KSHV
infection.
Because of the heterogeneous nature of the tonsil samples, we predicted that each
sample would also have variable levels of susceptible B cell subtypes. Therefore,
we employed a method for normalizing infectious dose from donor-to-donor in
order to obtain cross-sectional data that was directly comparable (Fig 2.2A). For
each sample we used magnetic sorting to isolate untouched naïve B cells, which
are a known susceptible cell type (Totonchy J, 2018 ), and infected 1 million naïve
B cells with equivalent doses of cell-free KSHV.219 virus. After infection, bound
lymphocytes from the magnetic separation were added back to each sample to
reconstitute the total lymphocyte environment. Infected cultures were incubated for
three days and analyzed for both B cell lineage markers and the GFP reporter
present in the KSHV.219 genome to identify infected cells. We restricted our
analysis to a single timepoint at 3 days post-infection in order to observe the
establishment of infection in different lineages with minimal contribution of virusmediated shifting of cellular immunophenotypes, which we observed in our
previous study (Totonchy J, 2018 ), We first compared the overall lymphocyte
populations between baseline (day 0 uninfected), Mock, and KSHV infected
conditions to determine whether our infection and culture system and/or KSHV
infection itself was causing significant shifts in the B lymphocyte composition of
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the samples. These results demonstrate that most lineages were not substantially
altered by our culture system or KSHV infection compared to the baseline samples
(Fig 2.2B, Appendix A.2, Appendix A.3). However, naïve B cells were
significantly reduced compared to baseline levels in both Mock and KSHV
infected samples at 3 dpi, suggesting that the infection method may reduce naïve
cell survival in this mixed model or that the culture model drives differentiation of
naïve cells into a different immunophenotype. Interestingly, B cells with a
transitional phenotype are significantly increased compared to baseline in both
Mock and KSHV-infected cultures. Given that there is a relationship between
transitional (IgD+, CD38mid) and naïve (IgD+, CD38low, CD27-) it is possible
that naïve B cells are acquiring increased CD38 expression as a result of the
infection and culture process and are thus falling into the transitional lineage gate
at 3 dpi. Finally, this analysis shows that our culture system does not favor the
survival of CD138+ plasma cells indicated by a significant decrease comparing
baseline and Mock at 3dpi. However, this effect was lower in the KSHV-infected
cultures. This result suggests that KSHV infection is either providing a survival
advantage for CD138+ cells in the culture system or driving the differentiation of
new CD138+ cells during infection.
Overall, susceptibility of B cells to KSHV infection varied substantially within the
cohort with the majority of samples showing between 1 and 2% GFP+ B cells at 3
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dpi and an overall range of 0.76-3.27% (Fig 2.2C, Appendix A.2). Analysis by
point-biserial correlation revealed that susceptibility was not significantly
correlated with sex (rpb=0.17). Kruskal-Wallis rank sum test showed no significant
association of race and susceptibility (p=0.6) and both Pearson (r=0.09) and
Spearman (r=0.01) correlation tests indicated no linear or monotonic relationship
between donor age and susceptibility in our data set. Thus, we can conclude that
donor demographics do not substantially contribute to the variable susceptibility
we observe in our tonsil lymphocyte samples.
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Figure 2. 2 Tonsil-derived B lymphocytes from diverse donors display variable
susceptibility to KSHV infection. (A) Schematic of lymphocyte infection procedure.
Untouched naïve B cells are magnetically separated from total lymphocytes and 1e6 naïve B cells
are infected per condition. Following infection, bound fractions are added back to reconstitute a
total lymphocyte environment and cells are plated on X-ray irradiated CDw32 feeder cells.
Analysis is performed by flow cytometry at 3 days post-infection for B cell lineage markers as
shown in S1 Fig and Table 2 and GFP reporter expression for KSHV infection. (B) The effect of
KSHV infection and the culture system on overall B cell lineage frequency was examined by
comparing the frequency of B cell lineages at baseline (BL, unmanipulated samples) and 3 days
post infection in Mock infected and KSHV infected cultures. Student’s T test was used to
determine statistical significance for all comparisons **p<0.004, ***p<0.0002, ****p<1e-6 (C)
Infection frequency data for viable, CD19+GFP+ lymphocytes at 3 dpi n = 50 from 40 tonsil
specimens with biological replicates for 10 specimens displayed with respect to donor age (xaxis, left panel), sex (color), and self-reported race (shape, left panel). The histogram in the right
panel is included to show the distribution of infection frequencies with the majority of infections
resulting in 1–2% GFP+ B lymphocytes at 3 dpi.
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2.3.3 Specific targeting of individual B cell lineages by KSHV infection

We next sought to establish the B lymphocyte tropism of KSHV in human tonsil
lymphocytes by determining which B cell lineages are targeted for KSHV infection
at early timepoints. Because levels of individual B cell lineages are highly variable
between samples (Fig 2.1B), we have generally represented lineage-specific
susceptibility data as the percentage of GFP+ cells within each lineage so that data
could be directly compared cross-sectionally within the sample cohort. Our
analysis of specific B cell lineages targeted for infection by KSHV revealed that,
although they represent a small proportion of the B cells within human tonsils (Fig
2.1B), CD138+ plasma cells are infected at high frequencies at this early timepoint.
Indeed, CD19+ CD20- plasma cells displayed the highest within-lineage
susceptibility of any cell type with several replicates showing 100% infection of
this lineage at 3 dpi (Fig 2.3A). Other B cell lineages were susceptible to infection
but were infected at relatively low within-population frequencies compared to
plasma cells (Fig 2.3A&B, Appendix A.2). Most B cell lineages showed linear
correlation between within-lineage infection and overall infection, while others
like Plasmablast, double negative, and CD20- plasma cells showed no significant
correlation between within-subset infection frequency and overall infection (Fig
2.3B).
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The observation that plasma cells are highly targeted for infection is interesting
given that we observed a decrease in overall plasma cell numbers in our cultures
system that was somewhat abrogated in the KSHV-infected conditions (Fig 2.2B).
Thus, we wanted to determine whether the apparent survival advantage for plasma
cells in the KSHV-infected cultures was a direct result of infection. Interestingly,
subset analysis for the plasma cells into total, CD20+ and CD20- plasma cells
showed that the greatest survival effect (KSHV-Mock for the lineage) was within
the CD20- population (Fig 2.3C, left panel), which was also the population with
the highest level of infection among B lymphocytes (Fig 2.3A) When we plotted
survival of each plasma cell sub-population against the percent of infection for that
population, there was no significant correlation observed (Fig 2.3C, right panels).
This data supports a conclusion of an indirect effect of KSHV infection on survival
or differentiation of a different B cell lineage into CD138+ cells in our KSHVinfected tonsil lymphocyte cultures rather than KSHV conferring a survival
advantage only to infected cells.
We next calculated within-subset frequency of infection for each lineage as a
proportion of the total B lymphocytes (i.e. within-lineage % GFP x frequency of
lineage within B lymphocytes) for each sample in order to determine the
contribution of each lineage to the overall infection (Fig 2.3D & E). When shown
on a per-sample basis, the data reveals high variability between donors with no

54

discernable contribution of the overall susceptibility (shown by the order of the
samples on the x-axis) (Fig 2.3D). When shown on a per-lineage basis, the data
reveals that germinal center, transitional and memory cells make the largest
contributions to overall infection, plasma cells and MZ-like cells are intermediate
contributors and double negative, naïve and plasmablast lineages make up a minor
proportion of the infected cells (Fig 2.3E).
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Figure 2. 3 B lymphocyte lineage tropism of KSHV. Naïve B lymphocytes from 40 individual
human tonsil specimens (n = 50) were infected with KSHV.219 as in Fig 2A. Cells were collected at
3dpi, stained for B cell lineages as shown in S1A Fig and Table 2 and analyzed flow cytometry for B
cell lineages and KSHV infection based on GFP reporter expression. The within-lineage infection
frequency (y-axis) as a function of overall B cell infection frequency (x-axis) at 3dpi in for n = 50
infections from 40 individual tonsil specimens shown (A) normalized to 100% or (B) scaled to each
individual lineage population. Pearson correlation coefficients (r) with an absolute value greater than
or equal to 0.4 are shown in (B) as red inset text in the subset panels. (C) The survival of plasma cell
lineages (frequency of viable B lymphocytes in KSHV-Mock samples at 3 dpi) was plotted for all
CD138+, CD20-CD138+ and CD20+CD138+ lineages (left panel) and each lineage’s frequency of
KSHV infection was plotted against its survival (right three panels) with individual tonsil samples
designated by color. Statistical analysis was performed for both linear (Pearson) and monotonic
(Spearman) correlations. For all plasma cells r = 0.15, ρ = 0.2; for CD20- plasma cells r = 0.3, ρ =
0.32, for CD20+ plasma cells r = 0.15, ρ = 0.13. The contribution of specific B cell lineages to overall
infection in each sample was calculated as % GFP within lineage * % of lineage within viable B cells
in each sample, and results are shown in (D) for each tonsil sample ordered from highest to lowest
(right to left) based on overall GFP+ B lymphocytes (overall susceptibility) and (E) by lineage with
individual samples designated by color and the mean infection frequency of each lineage shown as a
red diamond. Correlation matrix analysis showing linear relationships (Pearson’s correlation
coefficient) between within-lineage infection frequency and (F) baseline (pre-infection) overall
frequency or (G) 3 dpi overall frequency in KSHV-infected cultures for B lymphocytes and their
subsets. Statistical power analysis indicates that this dataset can predict correlations at the level of r >
|0.4| with alpha = 0.05 and power = 0.8. Thus, r values ≥ 0.4 can be considered a statistically
significant correlation for this data. (H) KSHV transcripts LANA and K8.1 as well as GFP and
GAPDH transcripts analyzed for n = 20 tonsil specimens by RT-PCR in bulk lymphocyte cultures at 3
dpi. Left panels show Ct values with individual Naïve B lymphocytes from 40 individual human tonsil
specimens (n = 50) were infected with KSHV.219 as in Fig 2A. Cells were collected at 3dpi, stained
for B cell lineages as shown in S1A Fig and Table 2 and analyzed flow cytometry for B cell lineages
and KSHV infection based on GFP reporter expression. The within-lineage infection frequency (yaxis) as a function of overall B cell infection frequency (x-axis) at 3dpi in for n = 50 infections from
40 individual tonsil specimens shown (A) normalized to 100% or (B) scaled to each individual lineage
population. Pearson correlation coefficients (r) with an absolute value greater than or equal to 0.4 are
shown in (B) as red inset text in the subset panels. (C) The survival of plasma cell lineages (frequency
of viable B lymphocytes in KSHV-Mock samples at 3 dpi) was plotted for all CD138+, CD20CD138+ and CD20+CD138+ lineages (left panel) and each lineage’s frequency of KSHV infection
was plotted against its survival (right three panels) with individual tonsil samples designated by color.
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Statistical analysis was performed for both linear (Pearson) and monotonic (Spearman) correlations.
For all plasma cells r = 0.15, ρ = 0.2; for CD20- plasma cells r = 0.3, ρ = 0.32, for CD20+ plasma cells
r = 0.15, ρ = 0.13. The contribution of specific B cell lineages to overall infection in each sample was
calculated as % GFP within lineage * % of lineage within viable B cells in each sample, and results
are shown in (D) for each tonsil sample ordered from highest to lowest (right to left) based on overall
GFP+ B lymphocytes (overall susceptibility) and (E) by lineage with individual samples designated by
color and the mean infection frequency of each lineage shown as a red diamond. Correlation matrix
analysis showing linear relationships (Pearson’s correlation coefficient) between within-lineage
infection frequency and (F) baseline (pre-infection) overall frequency or (G) 3 dpi overall frequency
in KSHV-infected cultures for B lymphocytes and their subsets. Statistical power analysis indicates
that this dataset can predict correlations at the level of r > |0.4| with alpha = 0.05 and power = 0.8.
Thus, r values ≥ 0.4 can be considered a statistically significant correlation for this data. (H) KSHV
transcripts LANA and K8.1 as well as GFP and GAPDH transcripts analyzed for n = 20 tonsil
specimens by RT-PCR in bulk lymphocyte cultures at 3 dpi. Left panels show Ct values with
individual samples designated by color and the mean Ct values for each condition shown as a red
diamond. Student’s T-test was used to determine statistical significance for all comparisons ***p<1e7, ****p<2e-10. (I) At 3 dpi, 10 million KSHV-infected lymphocytes from three tonsil specimens
were stained for B lymphocyte surface markers and lineages were sorted into Trizol LS. RNA was
extracted, reverse transcribed (black triangles) or amplified without reverse transcriptase (NRT, red
circles) and analyzed by nested RT-PCR for viral transcripts in sorted B lymphocyte lineages. (J) At 3
days post-infection, 1 million KSHV-infected B cells from three tonsil specimens were stained for
viability, CD19 and CD138. 187 single cells that were viable, CD19+, CD138+ were sorted into 96well plates and analyzed by nested RT-PCR for viral transcripts. Colors indicate single plasma cells
analyzed with RT-PCR (left) or control reactions including no reverse transcriptase (right) The bottom
panel is a venn diagram quantitating the number of plasma cells in RT-PCR reactions which amplified
for each and both viral transcripts.
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Next, we wanted to determine whether the targeting of individual B cell lineages
by KSHV infection is merely a function of the frequency of that lineage within the
sample or dictated by the virus biology. Pairwise correlations between KSHV
infection of specific lineages and the baseline (pre-infection) frequency of that
lineage within the sample revealed no significant effect of the baseline frequency
of any B cell lineage on the susceptibility of that lineage to KSHV infection, (Fig
3F). Interestingly, there were some significant correlations between baseline
frequencies of specific lineages and infection of other lineages. Infection
of plasmablasts was positively correlated with the baseline number of both CD20
negative B cells in the culture and the number of CD20+ plasma cells, and
infection of CD20+ plasma cells was negatively correlated with the baseline
frequency of memory B cells in the sample. Similarly, given that some populations
shift in their frequency during the infection time course (Fig 2.2B), we wanted to
determine whether KSHV infection of specific lineages was a result of the
frequency of that population within the sample at 3 dpi. Pairwise correlations
between KSHV infection of specific lineages and the frequency of that lineage at 3
dpi similarly revealed no direct correlations between lineage frequencies and
infection frequencies (Fig 2.3G). These comparisons revealed more strong
relationships between lineage frequencies and infection frequencies. Infection of
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CD138+ plasma cells and CD20+ plasma cells (which are the more numerous of
the two-plasma cell sub-populations as shown in Fig 2.1B) was negatively
correlated with the total population of plasma cells and the CD20+ sub-population
of plasma cells. This result may indicate that infection of CD20+ plasma cells
results in significant toxicity for that lineage. Moreover, infection of many B cell
lineages was negatively correlated with germinal center B cells at 3 dpi with MZlike B cell infection being significantly associated. This observation could indicate
that lymphocyte cultures with a microenvironment that favors the survival of
germinal center cells establish a different subset distribution of B lymphocyte
infection. Finally, the 3dpi level of CD20- plasma cells were positively correlated
with infection of both Plasmablast and memory B cell lineages. This data could
indicate that these lineages are differentiating into plasma cells upon infection.
Taken together these data indicate that the B lymphocyte tropism of KSHV is
broad and highly variable from donor to donor. Plasma cells are highly targeted as
a lineage, but transitional, memory and germinal center lineages make up the bulk
of the viral load in tonsil specimens. The distribution of KSHV infection among
lineages is not simply a function of lineage population frequency within the sample
and is likely dictated by cell-intrinsic factors as well as complex immunological
interplay within the sample that remains to be fully characterized.
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2.3.4 Viral gene expression in KSHV infected B lymphocytes
Our observation that KSHV targets diverse B cell lineages for infection is based on
expression of the GFP reporter in the KSHV.219 genome, which is controlled by a
non-viral EF1-alpha promoter. We wanted to validate that the GFP signal we
observe by flow cytometry represents bona fide infection and not simply virus
entry. In order to do this, we first examined total RNA extracted from mock or
KSHV-infected lymphocyte cultures at 3 dpi and analyzed these samples by RTPCR for viral transcripts (LANA and K8.1) as well as GFP as a marker for virus
entry and GAPDH as a housekeeping gene for the efficacy of RNA extraction (Fig
3H). The data show that viral transcripts and GFP are absent in Mock samples but
present in KSHV-infected samples with an average -∆Ct of 6.1 cycles for LANA,
6.6 cycles for K8.1 and 4 cycles for GFP. NRT controls were consistently negative,
confirming that viral DNA was not the source of genetic material for these results.
Both LANA and K8.1 were detected in the majority of samples, suggesting a mix
of lytic and latent infection programs in B lymphocytes. This data
demonstrates bona fide infection, with the production of viral transcripts, is present
in tonsil lymphocyte samples at 3 dpi.
Given that the bulk RT-PCR data showed mixed lytic and latent transcripts present
in our tonsil lymphocyte cultures, we wanted to determine whether B lymphocyte
lineages preferentially undergo a particular viral replication program. To
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accomplish this, we performed large-scale lymphocyte infections, as above, for
three unique tonsil specimens, stained for B cell lineage markers, and sorted
individual lineages using our FACS Aria Fusion cell sorter. We were able to obtain
between 10,000 and 200,000 cells for each lineage from the cell sorting. Total
RNA was extracted from sorted samples and subjected to nested RT-PCR analysis
for GAPDH, LANA and K8.1. These results show that LANA transcripts are
present in all lineages for at least 2/3 tonsil samples analyzed. Transcription of the
K8.1 late lytic gene was observed in memory cells and transitional cells for 1/3
tonsil samples along with LANA transcripts indicating that in this sample there
was a mixture of lytic and latent cells within the lineage populations. NRT
negative controls (red circles) for most lineages were negative or amplified >10
cycles later than the matched RT positive samples indicating that viral DNA was
not the source of genetic material for these results. However, the MZ-like lineage
had positive amplifications in NRT controls for 2/3 tonsil samples. This result may
indicate that in some samples there is a high load of KSHV DNA present in this
lineage so that even the extensive DNase digestion used in our protocol failed to
remove it sufficiently (Fig 2.3I). Because plasma cells are a low abundance cell
type in our tonsil samples, we were uncertain whether bulk sorting would result in
sufficient cells to successfully extract RNA for RT-PCR analysis. Thus, in order to
determine the viral transcription program in plasma cells we gated
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viable/CD19+/CD138+ cells and sorted single cells directly into 96-well plates
containing a hypotonic lysis buffer. We performed single cell nested RT-PCR
analysis without RNA extraction for LANA, K8.1 and GAPDH on 187 plasma
cells from three unique tonsil samples (Fig 2.3J, left panel). NRT controls were
consistently negative confirming that viral DNA was not the source of genetic
material for these results (Fig 2.3J, right panel). We observed 19 plasma cells
expressing LANA transcripts only, 11 plasma cells expressing K8.1 only and 6
plasma cells expressing both viral transcripts (Fig 2.3J, bottom).
Our gene expression data validates the lineage-specific tropism observed in our
flow cytometry data, showing that each lineage identified as susceptible by GFP
expression also contains viral transcripts, indicating bona fide KSHV infection.
Moreover, these results demonstrate that most B cell lineages express latent
transcripts only, with few lineages including plasma cell, memory, transitional and
possibly MZ-like lineages contributing to lytic replication. Given that transitional
and memory cells represent a high proportion of the per-sample viral load in our
analysis (Fig 2.3D & E) it is not surprising to find that they are competent for lytic
replication. However, germinal center cells are uniformly latent in this data, but
were a highly represented cell type in our analysis of lineage contributions to
overall infection. This may indicate that germinal center B cells are another highly
targeted cell type. Finally, differences in this data between tonsil samples indicates
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that lytic replication in our system may be more dependent upon host factors than
lineage-specific factors.
2.3.5 KSHV infection of B lymphocytes does not rely on heparin sulfate
proteoglycans
Previous studies have shown that heparin sulfate proteoglycans (HSPG) of
the syndecan family can serve as an attachment factor facilitating KSHV entry via
interaction with the gH/gL glycoprotein complex (Hahn A, 2009 ). In order to test
whether the high susceptibility of tonsil-derived plasma cells was due to increased
attachment via CD138 (syndecan-1), we attempted to selectively neutralize KSHV
entry by pre-treating cell-free virus particles with soluble recombinant CD138
(srCD138) protein prior to infection. We utilized recombinant CD138 for these
experiments rather than a neutralizing antibody against CD138 because the
biochemistry of the putative interaction between CD138 and gH has not been
established. Thus, the soluble protein will contain all of the protein sequences that
might be bound by gH while an antibody blocks only specific epitopes which may
or may not be part of the interaction domain. Pre-treating KSHV virions with
12.5µg/ml of srCD138 showed a small decrease in overall KSHV infection of B
lymphocytes in 6 of 7 tonsil samples tested (Fig 2.4A). However, the inhibition
was not dose-dependent for any sample. B cell lineage analysis revealed decreased
infection of plasma cell lineages in 3 of 7 samples, but again the effect was
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inconsistent within the data set and was not dose-dependent for any sample. KSHV
infection of other B cell lineages was similarly inconsistently affected by srCD138
treatment of virus particles (Fig 2.4B). Next, we used srCD138 pre-treated virions
to infect human fibroblasts to determine whether srCD138 was able to
neutralize gH on another cell type. In these experiments we observed a slight
decrease in infection in 4 of 6 replicates (Fig 2.4C). Taken together, these results
suggest that, although srCD138 treatment seems to weakly neutralize KSHV viral
particles, the effect is not B cell specific. As a way of confirming these results with
a cell-directed method as opposed to a virus neutralization approach, we used
heparinase treatment to remove all HSPG prior to KSHV infection. Treatment of
human fibroblasts with a heparinase I/III blend resulted in decreased cell surface
heparin sulfate by flow cytometry analysis (Fig 2.4D) and, as demonstrated
previously in human fibroblasts (Akula SM, 2001 ), consistently reduced KSHV
infection of treated target cells compared to untreated controls (Fig
2.4E). Lymphocytes had lower steady-state HSPG levels compared to fibroblasts,
which was further reduced by heparinase treatment (Fig 2.4F). Interestingly,
heparinase treatment of lymphocytes did not result in a reproducible decrease in
KSHV infection (Fig 2.4G). We next wanted to determine whether there was any
effect of heparinase treatment on KSHV infection of particular B cell lineages.
Because the most reliable cell surface marker for plasma cells is the CD138 HSPG,

65

which would be removed by heparinase treatment, we first confirmed that plasma
cells recovered CD138 expression before our 3 dpi analysis timepoint (Fig 2.4H).
Subset analysis revealed no significant differences in KSHV infection between
control and heparinase treated populations for any B lymphocyte lineage (Fig
2.4I). Taken together these data do not support the conclusion that plasma cell
expressed CD138 is used as an attachment factor for KSHV entry and, indeed,
indicates that HSPG are not a significant factor in KSHV attachment to
B primary lymphocytes.
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Figure 2. 4 CD138 and heparin sulfate proteoglycans as attachment factors for KSHV in B
lymphocytes. Purified KSHV virions were pre-treated with srCD138 protein at indicated
concentrations (x-axis) and used for infection of B lymphocytes. Cells were collected at 3dpi, stained
for B cell lineages as shown in S1A Fig and Table 2 and analyzed by flow cytometry for lineage
frequencies and KSHV infection by GFP reporter expression. 8 experimental replicates of 5 unique
tonsil specimens are shown where the average infection rate was 1.8±0.5% in untreated controls. Data
is represented as change in GFP+ cells at each dose of srCD138 compared to untreated control. Colors
denote individual experimental replicates and red diamonds are the mean change at each dose for all
replicates. (B) Data as in (A) for within-subset GFP quantitation. (C) Similar experiments were
performed in E6/E7 transformed fibroblasts derived from human tonsils. 6 experimental replicates are
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shown where the average infection rate was 25.5±16% in untreated controls. Data is represented as
change in GFP+ cells as in (A). (D) 1 million E6/E7 transformed human tonsil fibroblasts were treated
with 4.5 units of heparinase I/III blend for 24 hours and removal of heparin sulfate proteoglycans was
verified by flow cytometry using a heparin sulfate-FITC antibody. Black line indicates no antibody
control. (E) Control (untreated) or heparinase-treated fibroblasts were infected with KSHV.219 and
analyzed for infection by GFP reporter expression at 3 dpi. Student’s T-test was used to compare
control and heparinase-treated cultures for n = 3 experimental replicates p = 0.007. (F) 25 million
human tonsil lymphocytes were treated with 9U of heparinase I/III blend and plated on X-ray
irradiated CDW32 feeder cells for 24 hours. After incubation removal of heparin sulfate proteoglycans
was verified by flow cytometry as in (D). (G) After heparinase treatment lymphocytes were
fractionated and infected as shown in Fig 2A and viable, GFP+ B lymphocytes were quantitated by
flow cytometry at 3 days post-infection. 6 experimental replicates with 6 tonsil specimens were
performed and colors designate unique samples and can be compared between this panel, panel H and
panel I. Student’s t-test was performed to compare infection of control and heparinase treated
lymphocytes p = 0.969. (H) the recovery of cell surface CD138 HSPG after 3 days of culture was
examined by comparing CD138+ cells as a percent of viable B cells in control and heparinase treated
samples for both mock and KSHV-infected conditions. Colors indicate unique tonsil specimens.
Student’s T-test was performed to compare control vs. heparinase conditions for mock p = 0.57, for
KSHV p = 0.52 (I) Data for KSHV-infected cultures at 3dpi with or without heparinase pre-treatment
as in (G) showing the level of KSHV infection for specific B cell lineages. Student’s T-test indicates
no significant difference comparing control and heparinase treated samples for any lineage.
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2.3.6 Immune status alters KSHV infection of B lymphocytes
KSHV lymphoproliferative disorders occur primarily in the context of
immunosuppression, and other studies have shown interactions between T cells
and KSHV infected B cells in tonsil lymphocyte cultures affecting the frequency of
lytic reactivation (Myoung J, 2011 ). Therefore, we wanted to determine whether
the immunological composition of the tonsil lymphocyte environment would affect
the establishment of KSHV infection in B lymphocytes and specifically whether
overall susceptibility or targeting of particular B cell lineages is influenced by the
presence or absence of T cells. Like B cell lineages, levels of CD4+ and CD8+ T
cell lineages vary considerably between tonsil donors (Fig 1D). However, unlike B
lymphocyte subsets, the distribution of T cell subsets are not generally correlated
with donor age (Fig 2.1E). Examination of whether the ratio of CD4/CD8 T cells
in individual tonsil specimens was correlated with the susceptibility of B
lymphocytes to KSHV infection revealed no significant correlation (Fig 2.5A).
Next, we examined correlations between B cell infections and baseline levels of
various CD4 and CD8+ T cell subsets to determine whether any T cell lineages
affected the tropism of KSHV for particular B cell lineages (Fig 2.5B).
Interestingly, levels of naïve and stem cell memory CD4+ T cells was positively
correlated with infection of plasma cells (Fig 2.5B and Fig 2.5C, left panels) with
a greater effect on CD20+ plasma cells than CD20- plasma cells, while overall
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levels of CD45RO+ activated memory T cells were negatively correlated with
KSHV infection of plasma cells (Fig 2.5C, right panel). In addition, although the
correlations were too weak to be significant in this data set, nearly every B cell
lineage and overall KSHV infection was negatively correlated with the presence of
CD4+ T cells expressing a TEMRA phenotype (Fig 2.5B). Baseline levels of
CD8+ T cells had less effect on KSHV infection with only one significant positive
correlation observed in our dataset between CD8+ terminal effector cells and
KSHV infection of naïve B cells (Fig 2.5B).
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Figure 2. 5 The donor specific CD4+ T cell microenvironment influences infection of
CD138+ plasma cells. For each donor, baseline levels of CD4+ T cells/CD8+ T cells is plotted
against the overall susceptibility of the specimen based on the percent of GFP+ B lymphocytes at 3
dpi. Blue line indicates least means linear regression. Correlation analysis reveals no significant linear
or monotonic relationship between the variables. (B) Pairwise linear correlations (Pearson method)
were performed for overall (Total) and lineage specific KSHV infection at 3 dpi (vertical axis) and
baseline T cell subsets as defined in S1 Fig and Table 2. Power analysis reveals that the data set can
predict significant correlations at the level of p>|0.4| with alpha = 0.05 and power = 0.8. (C) Scatter
plots of significant correlations from (B) between the baseline frequency of CD4+ T cell subsets (xaxis) and KSHV infection of CD138+ plasma cells (y-axis). Blue lines indicate least means linear
regression and grey shading is standard error. Colors indicate unique tonsil specimens and can be
compared across panels within the figure.
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To determine whether manipulating the T cell environment would affect KSHV
infection in individual tonsil samples, we performed T cell depletion experiments.
Based on the correlation data shown in Figure 5B, we hypothesized that depletion
of CD4+ T cells would have a greater effect on KSHV infection. We performed
KSHV infections in which total lymphocytes, CD4-depleted total lymphocytes or
CD8-depleted total lymphocytes were added back following infection of sorted
naïve B cells. At 3dpi, we validated T cell depletions (Fig 2.6A) and analyzed
KSHV infection of B lymphocytes. The effect of T cell depletion varied
substantially from sample to sample and neither CD4 nor CD8 depletion
significantly altered overall KSHV infection in tonsil-derived B cells when data
from 11 tonsil samples were aggregated (Fig 2.6 B). However, due to the
heterogeneous nature of our tonsil samples (Fig 2.1B & D), we hypothesized that
the baseline T cell composition of each sample might influence the effect of T cell
depletion on KSHV infection. Indeed, when the change in KSHV infection in
depleted fractions is plotted against the baseline CD4/CD8 T cell ratio, we observe
that KSHV infection increased when depletions were performed in samples with
high baseline levels of CD4+ T cells (Fig 2.6 C). We next analyzed the effect of T
cell depletion on KSHV infection of specific B cell lineages (Fig 2.6 D). These
data reveal that depletion of CD4+ T cells increases infection of plasma cells as
well as MZ-like and Transitional B cell lineages and that the effect is dependent
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upon the baseline CD4/CD8 T cell ratio in the sample with CD4+ T cell-rich
samples showing the greatest effect. Interestingly, CD8 depletions altered infection
of different lineages compared to CD4 depletions but showed a similar dependence
on the baseline level of CD4+ T cells. Power analysis indicates that only the effect
on CD138+ cells and MZ-like lineages in the CD4-depleted condition
and plasmablast lineage in the CD8-depleted condition can be considered
statistically significant based on the sample size. Taken together, these data support
the conclusion that the T cell microenvironment influences the lineages targeted by
KSHV infection in the B lymphocyte compartment.
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Figure 2. 6 Manipulation of T cell microenvironment alters KSHV tropism for B cell
lineages. Naïve B lymphocytes from 11 human tonsil specimens were infected with KSHV.219 as in
Fig 2A, total lymphocytes added back following infection were either untreated or depleted of CD4+
or CD8+ T cells. At 3 days post-infection cells were collected. (A) T cell depletions were validated by
flow cytometry and (B) Cells were stained for B cell lineages as shown in S1A Fig and Table 2 and
analyzed flow cytometry for lineage frequencies and KSHV infection by GFP reporter expression to
determine the change in GFP+ B lymphocytes (viable, CD19+) in CD4 or CD8 depleted samples
compared to non-depleted controls. Colors indicate individual tonsil specimens (n = 11). Student’s T
test reveals no statistically significant change in GFP+ B cell frequency between either CD4-depleted
or CD8-depleted and non-depleted controls. (C) infection data for T cell depletion studies as in (A)
plotted against the baseline (pre-infection) CD4/CD8 T cell ratio in the sample. (D) within-lineage
infection frequency plotted against baseline (pre-infection) CD4/CD8 T cell ratio. For B and C linear
regression of the data is shown as a blue line and Pearson correlation coefficients (r) are shown as red
text within panels only for r with an absolute value ≥ 0.6. Statistical power analysis indicates that this
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dataset can predict correlations at the level of r > |0.7| with alpha = 0.05 and power = 0.8. Thus, r
values ≥ 0.7 can be considered a statistically significant correlation for this data.
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2.4 Discussions
Ex vivo infection of tonsil lymphocytes is emerging as a viable strategy for studying
early infection events for KSHV infection in B lymphocytes. However, the existing
literature on KSHV infection of tonsil lymphocytes is highly varied in both approach
and outcome. Hassman et. al. used cell free wild-type BCBL-1 derived KSHV
virions to infect total CD19+ B lymphocytes from tonsil specimens and used staining
for LANA as the only marker for infection, thus limiting their analysis to latently
infected cells (Hassman LM, 2011 ). Bekerman et. al. also used isolated CD19+ B
cells as infection targets but employed a co-culture infection procedure
using iSLK cells infected with the recombinant KSHV.219 strain employing the
GFP reporter as a marker for infection. Nicol et. al. also employed a co-culture
method to infect tonsil lymphocytes with KSHV.219 but used Vero cells as
producers and did not isolate CD19+ B cells prior to infection. In two
studies, Myoung et. al. used cell free KSHV.219 produced from Vero cells to infect
mixed lymphocyte cultures. With the exception of Bekerman et. al, all of the abovementioned studies employed some kind of activating agent (PHA stimulation or
CD40L stimulation) to manipulate the activation and/or proliferation of cells in
vitro. For our studies, we used cell-free, iSLK-derived KSHV.219 to infect naïve B
lymphocytes followed by reconstitution of the total lymphocyte environment. We
also avoided activation of lymphocytes in both the isolation and culture procedures
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using our previously characterized CDw32 feeder cell system (Totonchy J, 2018
).To date, no consensus has yet emerged on how to perform tonsil lymphocyte
infection studies with KSHV, and how differences in infection and culture procedure
influences the resulting data remains to be established.
Although previous studies in mixed lymphocyte cultures have explored limited
surface markers including immunoglobulins and activation markers (Hassman LM,
2011 ), (Nicol SM, 2016 ) and NK cell ligands (Bekerman E, 2013 ),these studies
essentially treated all B cells as one population. Targeting of specific lineages
including naïve, memory and CD138+ plasma cell-like B lymphocytes was explored
by Knowlton et. al. using B cells derived from peripheral blood, but their detection
method for infected cells was immunostaining for ORF59 protein and thus their
enumeration of infection was biased towards cells undergoing lytic replication
(Knowlton ER, 2014 ). Our current study is the first to use a comprehensive panel
of lineage-defining cell surface markers to carefully explore the lineage-specificity
of KSHV infection in B lymphocytes.
Although previous studies of KSHV infection in tonsil-derived B lymphocytes have
shown the acquisition of plasmablast-like features at later timepoints post-infection
(Hassman LM, 2011 ), (Kang S, 2017), the CD38 high plasmablast lineage is a
minor proportion of our infected cultures at 3 dpi. Based upon these studies, we
might expect to see the emergence of more plasmablast-like cells over time and it
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will

be

interesting

to

determine

whether

this

is

a

result

of

infected plasmablasts expanding or trans-differentiation from other lineages. Our
observation that KSHV-infected B cells are primarily latent in our mixed tonsil
lymphocyte cultures is consistent with previous observations that T lymphocytes
control lytic reactivation of KSHV in tonsil-derived B cells (Myoung J, 2011 ).
For the gamma-herpesviruses EBV and MHV68, the current consensus is that naïve
B cells are the primary infection target and infected cells transit the germinal center
as a way of increasing viral load without resorting to lytic replication and lifelong
latent infection is established in memory B cells while plasma cells are a source of
lytic replication constantly replenishing the viral reservoir by producing virus which
infects more naïve B cells (Johnson KE, 2020 ). Here, we show that multiple
lineages from human tonsils, including terminally differentiated CD138+ plasma
cells, can be targeted by KSHV for de novo infection. In our data, plasma cells are
not primarily lytic as in EBV models, but instead are a mix of lytic and latent
transcription programs with latency slightly predominating (Fig. 2.3J). This result
is not surprising given that KSHV-associated lymphoproliferative diseases are
characterized by primarily latent infection in cells with plasma-like features but PEL
derived cell lines are competent for KSHV replication given the proper stimulus. In
future studies, it will be interesting to examine what factors influence the lytic/latent
balance for KSHV in primary plasma cells. Additionally, our data indicate that
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memory cells are competent for lytic replication (Fig 2.3I), which is also different
from the current model for EBV. However, the studies upon which the EBV models
are based are primarily examination of cells from previously infected human hosts,
representing EBV distribution in an established infection. We are unaware of any
study of EBV infection in human tonsil that recapitulates the early infection
timepoint and the level of detail in characterizing B cell lineages that is used here,
thus it is difficult to place our data in the context of EBV infection. Given that
recombinant EBV molecular genetics systems and ex vivo tonsil lymphocyte culture
systems are now well established, perhaps a second look at the early-stage B
lymphocyte tropism of EBV is warranted.
Our finding that KSHV efficiently targets CD138+ plasma cells early in infection of
tonsil B lymphocytes is particularly intriguing and relevant in the context of KSHVmediated lymphoproliferative diseases, which often have a plasma cell
or plasmablast-like phenotype (Chadburn A, 2008), (Carbone A V. E., 2014 ).
Particularly for PEL, which uniformly presents as a clonal CD138+ neoplasm, these
results suggest that the pathological cells may not be derived from KSHV-driven
differentiation from less mature lineages, but instead could be the result of
modifications of differentiated plasma cells by direct infection. Recent studies have
revealed that XBP-1, a critical cellular mediator of the unfolded protein response
(UPR) which is essential for the differentiation of plasma cells (Iwakoshi NN,
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2003), can activate expression of KSHV vIL-6 without inducing ORF45 or other
lytic genes (Hu D, 2016 ). The fact that the UPR and XBP-1 are uniformly active in
immunoglobulin-producing cells, like plasma cells, suggests that these cells may
provide a unique niche for KSHV persistence where vIL-6 can be produced to
support infected plasma cell survival in the absence of KSHV lytic replication.
Future studies will examine whether vIL-6 is responsible for the survival advantage
we observed for plasma cells in the KSHV-infected conditions in this study (Fig
2.2B).
Current models of human plasma cell maturation suggest that CD20 expression is
lost on plasma cells as they mature and migrate from peripheral lymphoid organs
(such as the tonsil) to the blood and finally the bone marrow (Medina F, 2002).
Thus, CD138+CD20- plasma cells in tonsil that are highly targeted by KSHV in our
analysis may represent a population of cells that is ready to leave the tonsil and
migrate to the bone marrow. A few studies have shown KSHV infection in bone
marrow from patients with MCD (Bacon CM, 2004 ), (Ibrahim HAH, 2016 ) and
HIV positive patients without MCD (Meggetto F, 2001 ), and it would be interesting
to pursue the idea that KSHV uses plasma cells to disseminate to the bone marrow
early in infection. Certainly, our results highlight the virology of KSHV in primary
plasma cells as an area urgently requiring further study.
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In this study, we were unable to establish that targeting of plasma cells was due to
enhanced virion binding via gH/gL interaction with the CD138 HSPG molecule, as
was suggested by a previous study (Hahn A, 2009 ). However, we acknowledge that
selectively blocking virion binding to a specific HSPG in a primary cell system is
technically difficult, and we have no way to directly verify that our neutralization
of gH/gL binding sites using soluble CD138 was effective. Our data using
heparinase treatment to remove HSPG from B lymphocytes prior to infection
supports the conclusion that CD138 is not used as an attachment factor for plasma
cells, and indeed, HSPG are generally dispensable for infection of B cells in our
system (Fig. 2.4G-I). These results are consistent with a previous study that shows
low HSPG levels on the KSHV-susceptible MC116 lymphoma cell line (Dollery
SJ, 2018) and another study showing that ectopic HS expression enhanced binding
but was not sufficient to allow efficient KSHV infection of the BJAB lymphoma cell
line (Jarousse N, 2011 ). Thus, the mechanisms underlying KSHV targeting of
plasma cells and other B lymphocyte lineages for infection remains to be established.
Additional studies in lymphoma cell lines have identified Ephrin receptors as critical
factors in KSHV entry (Großkopf AK, 2019), (Muniraju M, 2019) Thus, our future
studies in this area will and Ephrin family receptors in KSHV infection of tonsillar
B lymphocyte lineages.
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Our characterization of immunological diversity of a large cohort of human tonsil
specimens will be of interest to the general immunology community. Although a few
studies have examined T cell (Petra D, 2015)or B cell (Varon LS, 2017) subsets in
tonsils associated with particular disease states. To our knowledge, only one other
study has used multicolor flow cytometry to examine the immunological
composition of both B cells and T cells in a large cohort of human tonsil samples
(Stanisce L, 2018 ), and this study was focused on comparing the microenvironments
present in matched tonsils and adenoids rather than comparison between donors
based upon demographic data as we have done here.
In this study, we make the observation that manipulating the T cell composition has
a more profound effect on KSHV infection in tonsil specimens that were CD4+ T
cell rich at baseline. Moreover, although the specific B cell lineages affected by
depletion was different depending on whether CD4+ or CD8+ T cells were
experimentally depleted, the greater effect in CD4+ T cell rich samples was
consistent. This data in combination with the viral transcript data shown in Figure
3H-J reveals that KSHV infection of B cells and the lytic/latent balance is sensitive
to the host-specific overall immunological microenvironment and highlight that
there is complexity to this relationship that cannot be adequately understood in the
context of the current study. It will be interesting in future studies to explore the

82

contribution of donor-specific and context-specific immunology to KSHV lytic
reactivation in tonsillar B lymphocyte lineages.
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Abstract

The virion proteins of Kaposi sarcoma-associated herpesvirus (KSHV) were
initially characterized in 2005 in two separate studies that combined the detection
of 24 viral proteins and a few cellular components via LC-MS/MS or MALDITOF. Despite considerable advances in the sensitivity and specificity of mass
spectrometry instrumentation in recent years, leading to significantly higher yields
in detections, the KSHV virion proteome has not been revisited. In this study, we
have re-examined the protein composition of purified KSHV virions via ultra-high
resolution Qq time-of-flight mass spectrometry (UHR-QqTOF). Our results
confirm the detection of all previously reported virion proteins, in addition to 17
other viral proteins, some of which have been characterized as virion-associated
using other methods, and 10 novel proteins identified as virion-associated for the
first time in this study. These results add KSHV ORF9, ORF23, ORF35, ORF48,
ORF58, ORF72/vCyclin, K3, K9/vIRF1, K10/vIRF4, and K10.5/vIRF3 to the list
of KSHV proteins that can be incorporated into virions. The addition of these
proteins to the KSHV virion proteome provides novel and important insight into
early events in KSHV infection mediated by virion-associated proteins. Data are
available via ProteomeXchange with identifier PXD022626.
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3.1 Introduction
Kaposi’s sarcoma herpes virus (KSHV) was first discovered about twenty-five
years ago through the use of representational difference analysis by Chang et al.
(Chang, et al., 1994) and about a year later, Moore et al. (Moore, et al., 1996)looked
into similarities of this novel virus with other known gammaherpesviruses and were
able to identify it as the most similar with herpesvirus saimiri (HVS) through gene
alignment and amino acid sequencing alignments on Open Reading Frames (ORFs)
suitable for phylogenetic analysis; however, they noted that the divergence between
the viruses is ancient. They, furthermore, classified this virus as the first human
gamma-2 herpesvirus. To this day, KSHV is the only viral agent of the rhadinoviral
subfamily capable of infecting human B cells 1. In the context of
immunosuppression, KSHV infection causes Kaposi’s sarcoma, an endothelial cell
neoplasm, the B cell lymphoproliferative disorders primary effusion lymphoma
(PEL) and multicentric Castleman’s disease (MCD), as well as a recently discovered
KSHV inflammatory cytokine syndrome disease (KICS) (Karass M. e., 2017).
As with all herpesviruses, KSHV undergoes either latent or lytic infection
programs. New virions are produced during the lytic phase, and latency is used for
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long-term maintenance of viral genomes as extra-chromosomal episomes (Speck &
Ganem, 2010). Although different environmental and physiological signals, such as
viral coinfections (Vieira, O’Hearn, Kimball, Chandran, & Corey, 2001), hypoxia
(Davis, et al., 2001), oxidative stress (Ye, et al., 2011); cellular factors and cellular
signaling (Yu, et al., 2007), such as histone deacetylases (Shin, Decotiis, Giron,
Palmeri, & Lukac, 2013), and even dietary supplements

(Dyson, Walker,

Whitehouse, Cook, & Akula, 2012) can cause KSHV lytic reactivation, latency is
thought to be the predominant mode of KSHV infection in human hosts. However,
there is convincing evidence that lytic replication plays a significant role in KSHVassociated pathology (Grundhoff & Ganem, 2004 ). Despite the substantial body of
work on KSHV, early infection events in disease-relevant cell types and the role of
individual virion-associated tegument factors in the establishment of infection
remain poorly studied (Naranatt, et al., 2004).
The tegument layer is a dense proteinaceous layer sandwiched between the
nucleocapsid and the virion envelope that can critically affect the host’s cellular and
viral biology immediately following viral entry (Roizman, et al., 1981 ). These
proteins make up a large proportion of the virion’s overall protein composition, and
they serve as prepackaged factors capable of influencing the host cell physiology
immediately upon the fusion of the viral envelope with the host cell membrane. Early
infection functions of tegument proteins include cell cycle modulation (De Oliveira,
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Ballon, & Cesarman, 2010), transcriptional activation of viral genes (Sathish N,
2012 ), inhibition of host gene expression activation (Zhu, Sathish, & Yuan, 2010),
translocation of the virion capsid to the nucleus (Bergson, et al., 2014 ), and evasion
of the innate immune response. Thus, identification and functional analysis of the
virion proteins of KSHV is a critical step in understanding the early stages of KSHV
infection.
In 2005, two research groups independently characterized the virion proteins of
KSHV derived from lytic induction of latently infected BCBL-1 PEL cells. These
studies both utilized a bottom-up proteomics approach to characterize virionassociated proteins by extracting individual protein bands visible on SDS-PAGE
gels of purified virions, using either MALDI-TOF (Bechtel, Winant, & Ganem,
2005) or LC, MS/MS (Zhu, 2005) to identify the individual proteins after tryptic
digestion. These studies together identified 24 viral and a few cellular proteins as
virion associated. Additional proteins have since been detected in KSHV virions via
other methods (Dai, Gong, Wu, Sun, & Zhou, 2014 ), (Wu, et al., 2015), (Gong, et
al., 2014), (Butnaru & Gaglia, 2019), (Dünn-Kittenplon, Kalt, Lellouche, & Sarid,
2019), (Sander, et al., 2007 ), (Majerciak, Yamanegi, & Zheng, 2006 ), (Chow, He,
Snow, Rose-John, & Garcia, 2001 ); however, despite significant advances in
proteomics methods and instrumentation in recent years, the KSHV virion proteome
has not been revisited.
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Advances in proteomics technology have given rise to de novo sequencing in
shotgun proteomics (den Ridder, Daran-Lapujade, & Pabst, 2020 ), which combines
high-resolution spectrum data from modern mass spectrometry instruments with
automated de novo peptide sequencing algorithms. These technological advances,
combined with enhancements in sample preparation, have revolutionized proteomics
in the last ten years.
In this study, we have taken advantage of advanced instrumentation and analysis
methods; to reanalyze the KSHV virion proteome using a bottom-up shotgun method
(Yates, 1998 ), combined with de novo sequencing on highly purified KSHV virions
produced from the iSLK the epithelial cell line as well as dual digestion
with trypsin/lys-c and chymotrypsin. Our method’s improved sensitivity has
allowed us to validate all of the 24 previously reported virion-associated proteins
and add seventeen other proteins to the KSHV virion proteome. Seven of our novel
proteomic hits have been identified as virion-associated by non-proteomic methods,
and we report ten proteins in our analysis that have never previously been identified
as virion-associated.
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3.2 Materials and methods
3.2.1. Purification of Cell-Free KSHV Virions
Latently infected iSLK producer cells stably infected with BAC16 recombinant
KSHV WT were grown to 70–75% confluency in DMEM (Caisson
Labs, Smithfield, UT, United States Catalog#: DML10—500 ML) supplemented
with

10%

cosmic

calf

serum

(Sigma-Aldrich, St.

Louis,

MO, United

States Catalog#: C8056—500 ML), 250 µg/mL geneticin (Goldbio, St. Louis, MO,
United States Catalog#: G-418-1), 1 µM puromycin (Bio Basic, Markham, ON,
Canada Catalog#: PJ593), and 1.2 mg/mL hygromycin B (A.G. Scientific, San
Diego, CA, United States Catalog#: H-1012-PBS). Then induced for 72 h with
3 mM sodium butyrate (Sigma-Aldrich, St. Louis, MO, United States Catalog#:
B5887-1G)

and

States Catalog#:

2 µM doxycycline
4090—50 mg).

(Tocris, Minneapolis,

Culture

supernatants

MN,

were

United

clarified

by

centrifugation at 500 g for 12 min and passed through a 0.45 uM filter placed on ice.
The virus was then pelleted out of clarified supernatants over a 50% Opti-prep
(Iodixanol) (Ford, Graham, & Rickwood, 1994 ) cushion prepared in TNE buffer at
pH 7.40 by ultracentrifugation at 41,000 g for 120 min using an SW28 rotor.
Immediately after (adapting a previously reported purification method used for mass
spectrometry of virions), the concentrated virus particles were centrifuged through
a 10–50% Iodixanol density step gradient prepared in TNE buffer
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(Garrigues,

Rubinchikova, DiPersio, & Rose, 2008 ) at 45,000 g for 2 h. The virus band at the
gradient junctions of 22–24% was collected and kept at −80 °C for further
processing. Iodixanol fractions were also collected and the viral DNA was extracted
from them using the Zymo Quick DNA/RNA Viral kit (Zymo Research, Irvine, CA,
United States Catalog#: D7020). Endpoint RFU qPCR assay was then performed on
DNA fractions using probes and primers against LANA (LANA forward (5′AATGGGAGCCACCGGTAAAG-3′),

LANA

CGCCCTTAACGAGAGGAAGT-3′),

LANA

reverse
probe

ACACAAATGCTGGCAGCCCG-BHQ13′))

(5′(5’ 6FAM-

using TaqProbe 5x

qPCR MasterMix-Multiplex (ABM MasterMix-5PM), 5% DMSO, primers at
900 nM and probes at 250 nM on BioRad(Hercules, CA, United States ) CFX qPCR
machine in 40 cycles.
3.2.2. Trypsin and Detergent Treatment of Purified Virions
The purified virion sample was then divided into two fractions. One fraction was
treated with 0.25% trypsin- 2.21 mM EDTA for 60 min at 37 °C, while shaking at
300 rpm, to cleave and strip external envelope proteins and non-viral proteins and
debris from virion preparations followed by virion lysis. This fraction is herein
referred to as VTT fraction. The second fraction was kept untreated and is herein
referred to as VT fraction. Both fractions were then treated with Pierce protease
inhibitor (Thermo Scientific, Waltham, MA, United States Catalog#: A32963).
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Proteins were extracted and lipids removed using ReadyPrep 2D-Cleanup Kit
(BioRad, Hercules, CA, United States Catalog#: 1632130). Protein concentration
was then quantified using a Qubit 3.0 fluorometer (Invitrogen, Waltham, MA,
United States). The sample concentration was adjusted to a minimum of 0.5
mg/mL and pH as adjusted to (pH 7.5). The purified proteome samples were reduced
and alkylated, using Thermofisher EasyPep™ Mini MS Sample Prep Kit (Thermo
Fisher Scientific, Waltham, MA, United States Catalog#: A40006).
The samples were then either tryptic digested for 6–8 h at 37 °C in Tris-HCl
buffer with final protease to a protein ratio of 1:100 w/w of Pierce Trypsin/Lys-C to
protease mix (Thermo Scientific, Waltham, MA, United States Catalog#:1863467)
or digested with Pierce Chymotrypsin Protease (TLCK-treated) (Thermo Fisher
Scientific, Waltham, MA, United States Catalog#: 90056) with final protease to
protein ratio of 1:100 w/w, for 12–14 h at 37 °C in 1 mM HCl, while shaking at 300
rpm. The digestion was stopped using the digestion stop reagent of the EasyPep™
Mini MS Sample Prep Kit, and the samples were further cleaned and filtered
following the kit’s protocol. The samples were then extracted in 0.1% formic acid
in diH2O and kept at −80°C until analysis.

3.2.3. Mass Spectrometry Analysis
The samples were thawed on ice, and 50 uL of the peptide digest fraction was
then injected onto a reverse-phase C18 Acclaim RSLC 120 column
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(Thermo Scientific, Waltham, MA, United States Catalog#:074812) at 2.2 um and
120°A

2.1 × 250

mm

connected

to

an ultra-high performance

liquid

chromatography (UHPLC) coupled to an electrospray ionization source of an ion
trap mass spectrometer (Bruker Impact II UHR-QqTOF LC/MS). The sample was
separated within 75 min with 0.2 mL/minute flow rate. A gradient method started at
99% buffer A (0.1% Formic acid in water) and 1% buffer B (0.1% Formic acid in
Acetonitrile) and held at 1% B for 5 min. The gradient was changed linearly to 55%
B in 60 min, and then changed to 90% B in 10 min. Finally, it was held for 5 min to
equilibrate back to 1% B initial condition. The column oven set at 37 °C.
QTOF parameters for electrospray capillary at 4.5 V dry gas was set to 8 L/min.
Dry temperature was set to 200 °C. Nebulizer was set to 1.8 Bar. Target mass range
was set from 300 to 1600 m/z. Collision cell energy was set to 8 e (De Oliveira,
Ballon, & Cesarman, NF-κB signaling modulation by EBV and KSHV. , 2010 ) (De
Oliveira, Ballon, & Cesarman, NF-κB signaling modulation by EBV and KSHV. ,
2010) Transfer time was set to 90 µs, and pre-pulse storage was set to 10 µs. Spectra
rate was set to 2 Hz with Auto MS/MS Spectra rate upper limit of 30 and lower limit
of 4 and only the most intense precursor ions were selected for fragmentation and
cycle time of 3 s. Dynamic exclusion duration was 0.3 min and exclude singly
charged m/z. Precursor ions isolation was m/z dependent window of 2–5. The
collision energy was adjusted, as a function of m/z value, between 23–65 eV, the
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system was calibrated using 10 mM sodium formate solution, and the accepted range
was set to 250–1600 m/z.
Utilizing PEAKS DB, PEAKS PTM, and SPIDER search tools from PEAKS
Studio (software version10), the mzxml files were analyzed against a sequence
database with the HHV8 protein database’s customized library pulled
from Uniprot (Swiss-prot)
(https://www.uniprot.org/uniprot/?query=reviewed:yes%20taxonomy:37296#)
downloaded on 07/01/2020 containing 86 sequences. Trypsin (for trypsin digested
samples) and chymotrypsin (for samples digested with chymotrypsin) were selected
with a maximum of three missed cleavages permitted; the search parameters were
set to fixed modification of Carbamidomethyl and variable modification of
methionine oxidation. Additional criteria used in the search were peptide mass
tolerance of ±20.0 ppm, and fragment mass tolerance of ±0.05 Da followed with the
peptide score p-value of less than 0.00316. Using the Spider search feature, a special
feature in PEAKS software, a single amino acid mutation and up to three additional
modifications per peptide were automatically detected with PTM_Ascore of 20 and
mutation ion intensity of 5%. All of reported peptides (Appendix B1.B.6(Tables S1–S6)) have a score (-10lgP) greater than 25 and corresponding to a
statistically significant (p < 0.00316) confident identification; moreover, from our
positive matches, only proteins identified with more than at least 3 peptide
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sequences with a mass tolerance of <0.05 Da were reported. An exception was made
for the two previously reported ORF53 and ORF28, which are exceedingly small in
size and contain a limited number of trypsin cleavage sites when using trypsin.
However, using chymotrypsin, we were able to report more hits for both proteins.
Additionally, we queried a common contaminants database to ensure the overall
quality of the samples. The mass spectrometry proteomics data have been deposited
to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol, et al., 2019 )
partner repository with the dataset identifier PXD022626 and 10.6019/PXD022626
(Deutsch, et al., 2020), (Perez-Riverol, et al., 2016).
3.2.4. Antibodies and Western Blotting
Purified virion proteome equivalent to 1:50 of the final yield was mixed 1:1 with
5× Laemmeli buffer (0.5M Tris-HCl PH6.8, Glycerin, S.D.S., 0.25%Bromophenol
blue, B-mercaptoethanol) boiled for 10 min at 95 °C and then run on Mini-Protean
T.G.X. Stain Free 4–15% Bis-Tris PAGE gels (BioRad, Hercules, CA, United
States, Catalog#:4561081), then transferred to chemiluminescence Polyvinylidene
difluoride(PVDF) membranes

(Amersham, Buckinghamshire,

United

British

Kingdom, Catalog#:88585). The membranes were dry-blocked overnight and
rehydrated with 2% dried milk in T.B.S. buffer and then incubated with diluted
primary antibodies against ORF8 (gB) (Invitrogen, Waltham, MA, United
States, Catalog#:PA5-19852) or B-actin (Cell Signaling technology, Danvers, MA,
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United States, Catalog#8H10D10) as the housekeeping control for four h at room
temperature or 4 °C overnight. Anti-rabbit or anti-mouse immunoglobulin G
antibody conjugated to horseradish peroxidase (Invitrogen, Waltham, MA, United
States) was used as the secondary antibody. The enhanced chemiluminescence
system (BioRad, Hercules, CA, United States, Catalog#: 1705060S) was used to
detect antibody–antigen complexes using the BioRad Universal Hood II gel imager.
For the iodixanol fractions each fraction was collected then mixed 1:1 with 5x
Laemmeli buffer (0.5M Tris-HCl PH6.8, Glycerin, S.D.S., 0.25% Bromophenol
blue, B-mercaptoethanol) boiled for 10 min at 95 °C and then run on two similar
Mini-Protean T.G.X. Stain Free 4–15% Bis-Tris PAGE gels (BioRad, Hercules, CA,
United States, Catalog#:4561081), post run one of the gels were stained with
Coomassie blue (0.05% Coomassie brilliant blue, 50% methanol, 10% acetic acid)
for 1 h, and destained (50% methanol, 10% acetic acid) for 3 h. The second gel was
then transferred

to

chemiluminescence

PVDF

membranes

(Amersham, Buckinghamshire, United British Kingdom, Catalog#:88585). The
membrane was dry-blocked overnight and rehydrated with 2% dried milk in T.B.S.
buffer and then incubated with diluted primary antibody against ORF8 (gB)
(Invitrogen, Waltham, MA, United States, Catalog#:PA5-19852) four hours at room
temperature or 4 °C overnight. Anti-rabbit G antibody conjugated to horseradish
peroxidase (Invitrogen, Waltham, MA, United States) was used as the secondary
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antibody. The enhanced chemiluminescence system (BioRad, Hercules, CA, United
States, Catalog#: 1705060S) was used to detect antibody–antigen complexes using
C-DiGit Blot Scanner (Li Cor Biosciences, Lincoln, NE, United States).
3.3 Results

3.3.1. Purification of Cell Free KSHV Virions and Virion Protein Fractions
One of the significant limitations of the original KSHV proteomics studies was
the production of high-yield purified virions from BCBL1 cells sufficient to obtain
a high protein concentration for analysis. In this study, we employed the more recent
and highly productive iSLK producer cell line to produce KSHV virions from the
recombinant BAC16 KSHV genome for our studies (Myoung & Ganem, 2011 ).
iSLK cells were induced at confluency with doxycycline and sodium butyrate, and
at 72 h post-induction, virions were purified from 2 L of filtered culture supernatants
for further processing. Adopting a method previously reported for KSHV virion
purification for mass spectrometry (Garrigues, Rubinchikova, DiPersio, & Rose,
2008 ), the supernatant was then ultracentrifuged over a 50% Iodixanol (Opti prep)
(Ford, Graham, & Rickwood, 1994 ) cushion, the cell free virions in 50% iodixanol
were collected and further purified by ultracentrifugation on a 10–50% Opti-Prep in
TNE buffer density step gradient to ensure further cleanup of the sample. Virus was
quantitated by real-time qPCR using LANA as a genomic target. A genome peak
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was obtained at the 22–24% Opti-Prep interface (Figure 3.1a). Fractions were then
used in Coomassie blue staining and Western blotting against the ORF8(gB)
antibody to determine the purity and concentration of virions in these fractions
(similar to methodology used in Bechtel et al. (Bechtel, Winant, & Ganem,
2005)), respectively, (Figure 3.1b), and only the fractions around 22–24% iodixanol
were collected and labeled as V fraction and kept at −80 °C for further processing.
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Figure 3. 2 (a) Endpoint RFU qPCR using LANA genome on Iodixanol fractions. (b) Top
Coomassie blue staining of the Iodixanol gradient fractions. (b) Bottom Western blot
using gB/ORF8 antibody on different iodixanol gradient fractions to ensure the quality of
the virion purification, based on the data, only fractions of 22–24% Iodixanol containing
virions was used for further processing. This fraction was labeled as fraction V. (c) Western
blot for gB/ORF8 on proteins from trypsin digested (VTT) and purified (VT) fractions as
well as virions.
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The V fraction was then divided into two equal fractions, one where the proteins
were extracted and then digested with either trypsin/LysC or chymotrypsin, referred
to as VT fraction. The second was exposed to 0.25% trypsin- 2.21 mM EDTA for
60 min at 37 °C, while shaking at 300 rpm to strip the envelope layer and possible
cellular debris before protein extraction and purification using labeled as the VTT
fraction. The quality and purity of these fractions and the efficacy of external trypsin
treatment was validated by Western blotting for ORF8/gB and B-actin (Figure
3.1c).
3..3.2. Mass Spectrometry Quality Control
As the VT fraction contains both glycoproteins as well as envelope contained
proteins, it was used for the initial mass spectrometry analysis of probing for
previously reported virion proteins. PEAKS Studio software (Version 10) (Zhang,
et al., 2012) was used for all of the data analysis presented herein. Using the database
search approach, the raw datafiles were analyzed against a customized library of
HHV8

protein

database

pulled

from Uniprot (Swissprot)((https://www.uniprot.org/uniprot/?query=reviewed:yes%
20taxonomy:37296#) downloaded on 07/01/2020 containing 86 sequences). Trypsin
(for trypsin digested samples) and chymotrypsin (for samples digested with
chymotrypsin) were selected with a maximum of three missed cleavages permitted;
the search parameters were set to fixed modification of carbamidomethyl and
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variable modification of methionine oxidation. Additional criteria used in the search
were peptide mass tolerance of ±20.0 ppm, and fragment mass tolerance of ±0.05
Da followed with the peptide score p-value of less than 0.00316. Using the Spider
search feature, a special feature in PEAKS software, a single amino acid mutation
and up to three additional modifications per peptide were automatically detected
with PTM, a score of above 20 and mutation ion intensity of 5%. All of the reported
peptides (included in Appendix B.1-B.6(Tables S1–S6)) have a score (−10logP)
greater than 25, corresponding to a statistically significant (p < 0.00316) confident
identification. Moreover, from our positive matches, only proteins identified with
more than at least three peptide sequences with a peptide mass tolerance of <20 ppm
detected in triplicate runs were reported. It should be noted that similar to Zhu et
al. (Zhu, 2005), for the previously reported ORFs 28 and 53, due to the smaller size
of the proteins, and limited trypsin cleavage cites, an exception was made
were two and one peptide hits with trypsin were also accepted; however, using
chymotrypsin, we detected three and two unique peptide hits, respectively.
An example of the quality control statistics and our applied methodology is
shown in Figure 3.2. At an false discovery rate (FDR) = 1.0% (Figure 3.2a), 203
peptide matches were accepted following the other criteria including the –log
p, which is set at 25 (Figure 3.2b) corresponding to the p-value of less than
0.01, demonstrating our sacrifice in reduction in the decoy hits in exchange for
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increase in true peptide match score. This decrease of p-value indicating the ppm
peptide error is demonstrated and the blue dots are the high-quality hits (Figure
3.2c). Although the PEAKS DB database search feature was mainly used for our
analysis, the PEAKS de novo sequencing feature was also used and Table S8 shows
a few examples of some of our sequences with the ALC% cut-off of 75%. Figure
2d, e respectively show the distribution of our detected peptide features as well as
the increasing trend in the accuracy of the de novo peptide match sequencing with a
tight error tolerance.

102

Figure 3. 2 Statistical data presented from PEAKS analysis on the 17 proteins found uniquely in
our study, with false discovery rate (FDR) set at 1%. (a) The false discovery rate (FDR) curve.
The X-axis is the number of peptides-spectrum matches (PSM) being kept. The Y-axis is the
corresponding FDR for the unique hits of our study. (b) Peptide-spectrum matches (PSM) score
distribution, showing the distribution of the PEAKS peptide score. (c) The precursor mass error in
ppm vs. −10lgP peptide score for all the PSMs. (d) Distribution of abundance of identified
peptides. (e) The de novo sequencing validation and accuracy level (ALC).
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3.3.3. KSHV Virion Protein Identification
Using the MS methodology mentioned above, we detected all 25 previously
reported virion proteins that were identified by Bechtel et al. (Bechtel, Winant, &
Ganem, 2005) and Zhu et al. (Zhu, 2005) (Table 3.1 Appendix B.1-B.6 (and
Tables S1 and S4)). We detected ORFs 18, 32, 38, 42, 43, 56, and K2, which were
not identified as virion-associated in the first proteomic studies but have since been
identified as virion proteins by other methods 20–27 (Table 3.2 and Appendix B.1B.6 (Tables S2 and S5)). Finally, we detected 10 KSHV proteins that have not been
previously reported as virion associated. These novel virion proteins are ORFs 9, 23,
35, 48, 58, 72, K3, K9, K10, K10.5 (Table 3.3 and Appendix B.1-B.6 (Tables S3
and S6)). Figure 3.3 shows an example of the protein coverage in our study (Figure
3.3) where a detected peptide sequence hit of ORF52 (DRPLTATEK) with –10lgp
of 44.48 with an m/z of 515.7792, z = 2 using Collision-Induced Dissociation
(CID) activation mode on qTOF detected Via PEAKS Studio software.
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Number
Previous Number of Unique
aa
Gene

Protein

of Unique Peptide
Report by Peptide Hits via

Size

Hits via
MS

Trypsin Digest
Chymotrypsin Digest

Major DNA-binding
ORF6

Zhu et al.
1133

protein (MBP)

19

Tripartite terminase

Zhu et

ORF7

695
subunit 1 (TRM1)

7

6

6

3

10

20

9

5

3

3

8

3

7

5

al. 19
Zhu et

Envelope glycoprotein
ORF8

al. 19,
845

B (gB)

Bechtel et
al.18
Zhu et

ORF11

ORF11

407
al. 19

Capsid Scaffolding
ORF17

Zhu et
534

protein

al. 19
Zhu et
al. 19,

ORF21

Thymidine kinase

580
Bechtel et
al.18

Envelope glycoprotein
ORF22

Zhu et
730

H (gH)

al. 19,

105

Bechtel et
al. 18
Bechtel et
ORF24

ORF24

752

4

7

5

6

5

3

6

4

2

3

7

7

6

3

al. 18
Zhu et
Major capsid protein
ORF25

al. 19,
1376

(MCP)

Bechtel et
al.18
Zhu et

Triplex capsid protein
ORF26

al. 19,
305

2 (TRX-2)

Bechtel et
al.18
Zhu et

ORF27

ORF27

290
al. 19
Zhu et

ORF28

ORF28

102
al. 19
Zhu et

Cytoplasmic
al. 19,
ORF33 envelopment protein 2 334
Bechtel et
(CEP-2)
al. 18
Envelope glycoprotein
ORF39

Zhu et
400

M (gM)

al. 19

106

Zhu et
ORF45

ORF45

407

5

4

5

3

9

5

1

2

4

3

7

5

6

12

4

3

3

4

al. 19
Envelope glycoprotein
ORF47

Zhu et
528

L (gL)

al. 19
Zhu et

ORF52

ORF52

131
al. 19

Envelope glycoprotein
ORF53

Zhu et
110

N (gN)

al. 19
Zhu et

Triplex capsid protein
ORF62

al. 19,
331

1 (TRX-1)

Bechtel et
al. 18
Zhu et

Inner tegument
ORF63

al. 19,
927

protein

Bechtel et
al. 18

Large tegument
ORF64

Zhu et
2635

protein deneddylase

al. 19

Small capsomereZhu et
ORF65

interacting protein

170
al. 19

(SCP)
Packaging protein
ORF68

Zhu et
545

UL32 homolog

al. 19

107

Zhu et
al. 19,
ORF75

ORF75

1296

8

6

4

4

Bechtel et
al.18
ORF

Zhu et
gp35/37

K8.1

228
al. 19

Table 3.1. Proteins identified in the VT fraction in our study that were previously reported
by mass spectrometry.
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Proteins identified in VT fraction of our study that were previously reported
by mass spectrometry. All peptides have a score (−10lgP) greater than 25
and correspond to a statistical significance of p < 0.00316; moreover, from
our positive matches, only proteins identified with more than at least 3
peptide sequences with a mass tolerance of <0.05 Da were reported.
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Unique Peptide

Unique Peptide

aa Previous Report
Gene

Protein

Hits via Trypsin Hits via Chymotrypsin
Size

by MS
Digest

Digest

4

4

Dai et al. 20

7

4

Wu et al.21

4

3

3

3

6

5

Protein UL79
ORF18

257 Gong et al. 22
homolog
Capsid vertex

ORF32 component 1 (CVC- 454
1)
Cytoplasmic
ORF38 envelopment protein 61
3 (CEP-3)
Cytoplasmic

ORF42 envelopment protein 278 Butnaru et al. 23
1 (CEP-1)
DünnORF43

Portal Protein

605

Kittenplon et
al.24

ORF48

ORF48

402 Sander et al. 25

6

3

ORF56

DNA primase

843 Majerciak. 26

6

4
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ORF

Viral Interleukin 6

K2

Homolog

Katano, H. et
204

12

7

al.37

Table 3.2. Proteins identified by mass spectrometry in our study that were previously
reported by other methods.
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Proteins identified in VTT fraction of our study that were previously
reported by non-mass spectrometry methods. All peptides have a score
(−10lgP) greater than 25 and correspond to a statistical significance of p <
0.00316; moreover, from our positive matches, only proteins identified
with more than at least 2 peptide sequences with a mass tolerance of <0.05
Da were reported.
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Unique
Unique Peptide
Peptide
aa
Gene

Protein

Hits via
Hits via −10lgP (Trypsin)

Size

−10lgP (Chymotrypsin)
Chymotrypsin

Trypsin
Digest
Digest
ORF9

DPOL

1012

6

45.15

4

34.08

ORF23

ORF23

404

6

26.45

4

32.21

ORF35

ORF35

150

4

26.23

3

37.48

ORF58

ORF58

357

5

42.45

4

41.66

257

4

42.46

4

45.19

333

5

35.01

3

32.7

vIRF-1 like protein 449

5

39.12

4

26.26

7

27.51

3

26.50

viral cyclin
ORF72
homolog
E3
ORF

ubiquitin-

K3

protein
ligase MIR1
Viral IRF-

1
Viral IRFvIRF-3 like protein 566
3
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Viral IRFvIRF-4 like protein 911

11

37.95

5

30.02

0

N/A

5

35.06

4
DNA
ORF44 Replication 788
helicase
Table 3.3 Virion-associated proteins identified that have not previously been reported by
any method.
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Novel proteins identified in VTT fraction. All peptides have a score (-10lgP)
greater than 25 and correspond to a statistical significance of p <
0.00316; moreover, from our positive matches, only proteins identified with
more than at least 2 peptide sequences with a mass tolerance of <0.05 Da were
reported.
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Figure 3. 3 CID spectrum of the precursor ion at m/z7792 (z = 2) corresponding to the peptide
sequence (DRPLTATEK) of an ORF52 (–10lgP 0f 44.48 and –1.6ppm), from F10:1136 detected
by using the Bruker Impact II UHR-QqTOF 125 LC/MS system identified with PEAKS Studio
software.
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For some of the previously reported hits like ORF6 and ORF7, we were able to
detect more unique peptide fragments than were reported initially; however, for
some other proteins such as ORF25, the number of peptide hits we found was less
than what was previously reported; Bechtel et al. (Bechtel, Winant, & Ganem,
2005) explain that one reason for having so many peptides for ORF25 in their
study could be that virions were damaged during the purification and processing of
their sample. Our reduced detection of ORF25 peptides could indicate that our
altered sample preparation approach resulted in less damage to virions prior to
protein extraction.

Figure 3. 4 Example of post-translational modifications (PTMs) detected via PEAKS DB
analysis for ORF52.

117

Additionally, we detected ORF44 peptides only with chymotrypsin digestion and
not with trypsin digestion, the peptide hits for this protein also followed our tight
criteria of peptide mass tolerance of 20 ppm and fragment mass tolerance of 0.01;
in addition to that, they all have −10lgP > 25. The identified peptides are included
in Table S7.
It is important to note that we analyzed our dataset using a database containing
only KSHV protein sequences, so our analysis does not include any host proteins
associated with the virion. Next, we wanted to confirm that our novel hits (Table 3)
were actually encapsulated within the virions and not due to debris that might have
been coincidentally co-purified with the virion fraction. To accomplish this, we
pre-treated intact, purified virions with 0.25% trypsin-EDTA to eliminate any
proteins not being protected by the virion envelope before performing protein
extraction and MS analysis (VTT protein fraction). We used a Western blot for gB
to validate the trypsin pre-treatment’s efficacy in stripping the envelope layer
(Figure 3.1c). Both original virion proteomic studies (Bechtel, Winant, & Ganem,
2005), (Zhu, 2005) identified beta-actin as a cellular protein incorporated into
KSHV virions, so we utilized this marker as a loading control for this analysis. As
expected, MS analysis of the digested pre-treated (VTT) protein fractions included
all of the protein hits shown in Tables 3.1–3.3 except for 10 proteins, including the
eight known glycoproteins ORFs 8, 22, 28, 39, 47, 53, 68, and K8.1, as well as
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ORF27 and one of our novel detected proteins, ORF58. Thus, we can conclude
confidently that nine of our novel virion proteins, ORFs 9, 23, 35, 48, 72, K3, K9,
K10, K10.5, are contained within the virion envelope and are not present in the
sample due to contamination of the virion preparation with free proteins that are
not indeed virion encapsulated. These results also support the prevailing hypothesis
that ORFs 27 and 58 are glycoproteins (Russo, et al., 1996 ), (Chandran, et al.,
1998), (Quiceno, 2010).
Moreover, these data reconfirm Zhu et al.’s (Zhu, 2005) speculation that ORF28 is
an envelope glycoprotein, based on only its similarity in homology to EBV BDLF3
protein. Of the proteins mentioned in Table 3.2, that have been introduced as
tegument proteins of KSHV, ORF18 was reported by Gong et al. (Gong, et al.,
2014) to be essential for de novo lytic activity and viral reactivation, which is in
line with our observation of this protein within the newly formed virions. Dai et al.
(Dai, Gong, Wu, Sun, & Zhou, 2014 ) in 2014 reported ORF32 as a tegument
assembly mediator. ORF42 has been reported to be an essential post-translational
regulator, and the loss of it would result in the formation of fewer virion particles.
ORF43 has been shown to function as a gate for the packaging of viral DNA into
procapsids and a further injection of it to the host nucleus (Sander, et al., 2007 ).
ORF56 plays a vital role in DNA replication and viral DNA synthesis and is
reported to be a primary lytic gene. Interestingly, its protein expression levels have
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been reported to be dependent on ORF57 (Majerciak, Yamanegi, & Zheng, Gene
structure and expression of Kaposi’s sarcoma-associated herpesvirus ORF56,
ORF57, ORF58, and ORF59. , 2006 ), (Jenner, Albà, Boshoff, & Kellam, 2001 ),
(Majerciak, Pripuzova, McCoy, Gao, & Zheng, 2007 ). In our analysis, we also
observed post-translational modifications including, but not limited to, oxidation,
carbamidomethylation, deamidation, and acetylation. These modifications, where
present, are indicated in the peptide sequences reported in Supplemental Tables
S1–S6(Appendix B.1-B.6). An example of some PTMs observed in the ORF52
protein are shown in Figure 4. It should be noted that, although our analysis was
able to detect some PTMs and they are reported in our data, sample preparation for
bottom-up proteomics often introduces modifications during sample preparation.
Observation of the true spectrum of PTMs in KSHV virion proteins would require
further studies using specialized methodologies that were not employed here.
3.4 Discussion
Since the emergence of system-wide protein analysis three decades ago, a common
approach to proteomics has been the 2D separation of proteins followed by in-gel
trypsinization of individual bands before sequencing and identification
(Shevchenko, Tomas, Havlis, Olsen, & Mann, 2006 ). Despite its ease of use and
flexibility, this technique has some significant drawbacks, including incomplete
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digestion, loss of sample, failure to detect low abundance proteins, and limited
dynamic range for proteins. These limitations have resulted in a recent shift
towards in-solution, gel-free, or “shotgun” proteomics (Zhang, Fonslow, Shan,
Baek, & Yates, 2013 ). Moreover, the development of ultra-high-pressure LC
systems in conjunction with smaller inner diameter columns and particle size and
development of algorithms and software for de novo sequencing has enabled the
detection of thousands of proteins in single LC-MS runs (den Ridder, DaranLapujade, & Pabst, 2020 ), (Thakur, et al., 2011). Our study has taken advantage of
these advances in proteomics technology to take a fresh look at the KSHV virion
proteome.
The current study benefits majorly from a few advancements in KSHV research,
some of which were not accessible at the time of the original studies done by
Bechtel et al. (Bechtel, Winant, & Ganem, 2005) and Zhu et al. (Zhu, 2005). In
particular, the iSLK cell producer cell line has greatly improved KSHV virion
yields compared to previous systems isolating WT KSHV from PEL cell lines
(Brulois, et al., 2012), (Myoung & Ganem, 2011 ). We believe this increased virion
yield, combined with modern instrumentation and analysis software, contributed
substantially to the increased sensitivity of our analysis.
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EBV systems have shown that gamma-herpesvirus virions can have altered protein
composition based upon the producer cell type (Borza & Hutt-Fletcher, 2002 ).
However, differences in KSHV virion protein composition from different cell
types have not been examined. Given that both original mass spectrometry studies
analyzed KSHV virions from PEL cell lines, we cannot determine whether our
novel proteins are a result of the increased sensitivity of our methods or the fact
that these proteins are only incorporated into virions when they are produced in
iSLK or possibly generally from cells of epithelial origin. Since the iSLK system
has become increasingly prevalent in the field for the production of KSHV, these
results provide critical insight into the protein composition of the iSLK-derived
virions, which are commonly used for both in vitro and in vivo experimental
studies of KSHV virology.
In addition to validating all of the previously reported proteins packaged within
KSHV virions, we report 10 novel virion-associated proteins. ORF58 encodes a
homolog of EBV BMRF2 protein with unknown functions (Nishimura, Watanabe,
Yagi, Yamanaka, & Fujimuro, 2017 ), but together with ORF27, it has long been
speculated to be a glycoprotein (Russo, et al., 1996 ), (Chandran, et al., 1998),
(Quiceno, 2010). Our data that ORF58 is removed from the virion by pre-treatment
of intact viral particles with trypsin support the conclusion that this ORF58 is a
glycoprotein. Similarly, although ORF27 was not novel in our study, we showed
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that trypsin pre-treatment removed ORF27 from our virion proteome, thus
confirming Zhu et al. (Zhu, 2005) primary classification of ORF27 as a
glycoprotein.
Three additional novel virion proteins detected here are highly conserved among
gamma herpesviruses (ORF 23, 35, and 48). ORF23 binds to ORF34, and its
specific function is still unknown (Ohno, Steer, Sattler, & Adler, 2012). However,
a study in MHV68 has shown that its ortholog is not essential for in vitro and in
vivo infection (Bergson, et al., 2016). ORF35 encodes a poorly characterized
protein that is essential for viral reactivation (Hikita, Yanagi, & Ohno, 2015). A
study of MHV68 ORF35 has shown that it is essential for efficient lytic replication
and latency (Qi, et al., 2015 ). ORF48 is also poorly studied in KSHV, but a study
on the homologous protein in MHV68 has determined that this gammaherpesvirus-conserved ORF is RTA-responsive and functions in both viral lytic
replication and latency during in vivo infections (Wu, et al., 2001). Future studies
into the functions of these proteins are needed to establish the implications of their
presence in the virus particle.
ORF9 encodes the viral DNA polymerase (Holzerlandt, Orengo, Kellam, & Albà,
2002) and interacts with K10/vIRF4 (Sander, et al., 2007 ). There is evidence of
ORF9 gene expression as early as 0–10 hours post-infection (Jenner, Albà,
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Boshoff, & Kellam, 2001 ), implying that genome replication is an importanta
crucial stepe establishment of infection. ORF72 is the viral cyclin homolog, which
shares 54% sequence homology with the cellular Cyclin D2 (Holzerlandt, Orengo,
Kellam, & Albà, 2002), (Chang, et al., 1996 ), (Li, et al., 1997 ), (Moore, Boshoff,
Weiss, & Chang, 1996 ), (Jones, et al., 2014 ) and binds to a number of cellular
cyclin-dependent kinases to promote proliferation of KSHV-infected cells
(Godden-Kent, et al., 1997 ), (Swanton, et al., 1997 ), (Chang & Li, 2008 )
Packaging ORF9 and ORF72 into the virus particle implies that early genome
replication and manipulation of the host cell cycle are critically important for the
initial establishment of KSHV infection in a new host cell.
Our remaining novel virion proteins can broadly be classified as
immunomodulatory and immune evasion genes. K2 expresses the viral IL-6
homolog (Neipel, et al., 1997 ), which has significant immunomodulatory effects
during KSHV infection and KSHV-associated disease (Sakakibara S. &., 2011).
Although vIL-6 is known to signal intracellularly in the endoplasmic reticulum to
manipulate host cell processes in an autocrine manner (Meads & Medveczky,
2004 ), (Giffin, West, & Damania, 2015 ), we are unsure of the specific
implications of the protein being contained in the virus particle where it would
presumably be released into the cytoplasm upon infection. K3 is a membraneassociated ubiquitin ligase, which, along with K5, inhibits antigen presentation on
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Major Histocompatibility Complex Class I ( MHC Class I) (Lorenzo, Jung, &
Ploegh, 2002 ) and cell surface expression of receptors such as DC-SIGN (Lang,
Bynoe, Karki, Tartell, & Means, 2013 ). Despite clear data from overexpression
studies showing that K3 can reduce MHC-I expression at the cell surface (Coscoy
& Ganem, 2000 ), previous studies using K3 knockout viruses have led to the
prevailing theory that K3 does not function in this way during lytic reactivation or
early infection (Brulois, et al., 2012), (Brulois, et al., 2014 ). Importantly,
however, the earliest timepoint examined by Brulois et al. in their 2012 study of de
novo infection with a K3 knockout virus was 36 h post-infection, which is well
past the window we would expect to see an effect of K3 as a virion-incorporated
factor. Our data that K3 is virion incorporated establish a new context in which K3
may function very early in the viral life cycle (exceedingly earlyrs of infection) and
may provide an explanation for the previous negative data for K3 function in the
context of viral infection.
Finally, we observed three viral interferon regulatory factor (vIRF) proteins as
novel virion-associated proteins in our analysis. K9/vIRF-1 suppresses both type I
and type II interferon responses (Pozharskaya, et al., 2004 ), (Gao, et al., 1997).
Similarly, K10.5/vIRF-3 interferes with both type I and type II interferon responses
and additionally can alter CIITA and MHC II expression (Wies, et al., 2008 ),
(Schmidt, Wies, & Neipel, 2011 ). In 2014, Lee et al. reported that K10/vIRF4 is a
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lytic protein capable of suppression of c-IRF4 and c-Myc, thus manipulating the
host gene expression profiles to facilitate viral lytic replication (Lee, et al., 2014 ).
In 2017, the same group characterized novel immune evasion strategies of vIRF4
to inhibit the IRF7-mediated IFN-α production (Hwang, Kim, Jung, & Lee, 2017
), (Zhu, King, Smith, Levy, & Yuan, 2002). It is not the first time that an
immunomodulatory protein has been reported to be prepackaged within KSHV
virion in order to have a quick response against immune recognition; ORF45, as
reported by Zhu et al. (Zhu, 2005), (Paulose-Murphy, et al., 2001 ), is not only
packaged within the virion but is also known to interact with IRF7. Our data that
three additional vIRFs are encapsulated within the virion necessitate further study
into how these proteins may participate in immune evasion very early in KSHV
infection.
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Abstract
KSHV is the etiologic agent of the lymphoproliferative disorder Multicentric
Castleman Disease (MCD). However, not much is known about how KSHV
establishes infection in B lymphocytes. KSHV infected cells with plasmablast
characteristics are frequently found in the lymph nodes and spleens of MDC
patients. Reports have shown that these plasmablasts increase in number and
coalescence to form variably sized cellular aggregates both within and outside of
the germinal centers of infected lymph nodes and spleens. Thus, it is possible that
KSHV gene products contribute directly to plasmablast proliferation and/or
differentiation during early infection in B lymphocytes.
The majority of virion proteins reside within the tegument layer of herpesviruses.
Some of these proteins play a crucial role in virus life cycle and early stages of
infection. ORF11 is one of the few tegument proteins that is only found in the
gamma-herpesvirus family. This conservation has lead us to hypothesize that
ORF11 has B cell-specific functions, which have not been characterized. Here, we
utilize both gain-of-function and loss-of-function approaches to determine the role
of ORF11 in early KSHV Infection of B lymphocytes. For loss of function studies,
we have made a recombinant virus lacking ORF11 tegument factor and used it to
perform de novo infections on primary B cells. We show that ORF11 affects the
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proliferation of plasmablasts during early KSHV infection. Our gain of function
studies also reveals that, ORF11 has a transmembrane domain. Taken together our
results demonstrate that ORF11 participates in the establishment or maintenance of
KSHV latency in B lymphocytes. And further suggests that plasmablast
differentiation during KSHV infection is regulated both positively and negatively
by KSHV gene products, and these gene products may alternately influence
disease progression in KSHV-associated lymphoproliferative disorders.
4.1 Introduction
KSHV is a rhadinoviral gamma herpesvirus, capable of both lytic and latent life
cycles (G. Miller L. H., 1997). However, in in vivo endothelial and B cell infection
with KSHV, infection is primarily latent, accompanied by the expression of a few
viral genes including LANA, viral cyclin, vFLIP and vIRF3 (Chen, 2007), (K.A.
Staskus, 1997 ), (B. Lubyova, 2000 ). This state of infection is very dynamic and
can shift towards lytic reactivation, via poorly-characterized processes which lead
to RTA (replication and transcription activator) protein expression (R. Renne,
1996 ), (R. Sun, 1998 ). In the lytic phase, a significant level of viral gene
expression through a cascade of signaling occurs (R. Sarid, 1998 ) leading to
structural protein production and packaging of the virion.
KSHV shares a series of highly conserved genes, some of which have been known
to have enzymatic regulatory roles in different host interactions such as nucleic
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acid metabolism, DNA production, and protein expression and modification (K.
Borchers, 1994 ). One of these genes is KSHV open reading frame 11 (ORF11), a
highly conserved gene common to majority of the gamma herpesviruses subfamily
(M.M. Alba, 2001).
In the KSHV genome, the ORF11 gene is located adjacent and in the opposite
orientation to the significantly characterized ORFK2 (vIL-6) (H. Deng, 2002 ),
and it was detected for the first time by Russo et al. (Russo, et al., 1996 ) using
BC-1 genomic libraries for its mapping. Later, two other groups were able to
demonstrate detection of ORF11’s activity post chemical stimulation, or RTA
expression, thus establishing it as a lytic gene (R.G. Jenner, 2001), (H. Nakamura,
2003). Davidson and Stow later applied computational analysis to ORF11’s
sequence and speculated that the ORF11 coding sequence contains a dUTPase
domain (A.J. Davison, 2005). Two years later, Chen and Lagunoff reported that
ORF11 is not significantly involved in the regulation of other viral genes in BJAB
cells (Chen, 2007). The ORF11 protein is associated with purified KSHV virions
(Zhu, 2005), (Nabiee R., 2020). Investigations on virion-wide protein–protein
interactions have revealed that ORF11 interacts with other tegument proteins such
as ORF45, ORF64 and ORF63, suggesting a potential role in primary KSHV
infection (R. Rozen, 2008). This association suggests that ORF11 may function in
KSHV virion morphology, latency establishment, or host interactions (Zhu, 2005).
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Chen et al., in two consecutive studies (Chen L., 2009), (Chen L. M. S., 2011),
further explored how ORF11 gene transcription is regulated in KSHV lytic
replication. They showed that ORF11 expression is not directly regulated by RTA,
which indicates other viral or cellular factors may be involved in the regulation of
ORF11 gene expression. They also detected a silencer region within the ORF11
sequence, suggesting a novel mechanism of gene regulation utilized by KSHV to
precisely control ORF11 gene expression.
Due to its conservation exclusively in gamma-herpesviruses, we hypothesized that
ORF11 may have a B cell-specific function. In the current manuscript, we have
utilized gain of function and loss of function assays to reveal previously
uncharacterized functions of ORF11. Our gain of function studies demonstrate that
ORF11 localizes to the plasma membrane in HEK293 cells we also show that
ORF11 has a transmembrane domain. In our loss of function studies, we
demonstrate that ORF11 is not an essential protein for viral production, but has a
suppressive role in proliferation and differentiation of particular subsets of B
lymphocytes.
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4.2 Materials and Methods
4.2.1 Tissue Culture
Different tissue culture techniques were used in this study, details have been
highlighted in the proper sections of methodology. Overall maintenance
immortalized cell flasks were always maintained up to 80-85% confluency and
passaged weekly; primary cells were cryopreserved and thawed before seeding for
specific experiments, with an emphasis on passage number consistency between
samples and/or replicates.

4.2.2 X-ray Irradiation
CDw32 L cells (CRL-10680) were obtained from ATCC and were cultured in
DMEM supplemented with 20% FBS (Sigma Aldrich) and
Penicillin/Streptomycin/L-glutamine (PSG/Corning). For preparation of feeder
cells, CDw32 L cells were trypsinized and resuspended in 15 ml of media in a petri
dish and irradiated with 45 Gy of X-ray radiation using a Rad-Source (RS200)
irradiator. Irradiated cells were then counted and cryopreserved until needed for
experiments.
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4.2.3 Tonsil Tissue Dissociation and Isolation of Primary Lymphocytes
De-identified human tonsil specimens were obtained after routine tonsillectomy by
NDRI and shipped overnight on wet ice in DMEM+PSG. All specimens were
received in the laboratory less than 24 hours post-surgery and were kept on ice,
throughout the collection and transportation process. Lymphocytes were extracted
by dissection and maceration of the tissue in RPMI media. Lymphocyte-containing
media was passed through a 40µm filter and pelleted at 1700rpm (Heraeus
Megafuge Centrifuge by Thermo Fisher Scientific) for 5 minutes. RBC were lysed
for 5 minutes in sterile RBC lysing solution (0.15M ammonium chloride, 10mM
potassium bicarbonate, 0.1M EDTA). After dilution to 50ml with PBS,
lymphocytes were counted, and pelleted. Aliquots of 5E7 to 1E8 cells were
resuspended in 1ml of freezing media containing 90% Serum (FBS or CCS) and
10% DMSO and cryopreserved until needed for experiments.

4.2.4 Generation of KSHV-∆ORF11 using BAC16
KSHV-∆ORF11 was constructed by seamless two-step Red recombination
(Tischer et al., 2010) in GS1783 E. coli containing the BAC16 KSHV genome
(Brulois et al., 2012). Primers containing sequences from the N-terminal coding
region of ORF11 containing two consecutive stop codons (Fig 4.2) were used to
amplify the Kanamycin selection cassette from pepKanS plasmid and en passant
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mutagenesis was performed to introduce the stop codons seamlessly into the
ORF11 gene. Mutant strains were verified by Sanger sequencing of the region of
interest, pulse field electrophoresis to validate maintenance of the LTR packaging
sequences and next generation sequencing of the entire genome using an Illumina
miSeq to verify that mutagenesis did not produce any second site mutations.
BAC16 contains a constitutive GFP reporter under an EF1alpha promoter and
hygromycin resistance for selection of infected cells in mammalian culture. iSLK
producer cell lines were made by first transfecting BAC16 genomic DNA into
293T and selecting 293T for 2 days with 50 µg/ml hygromycin B. Thereafter,
infected 293T lines were co-cultured with iSLK. The selective media for iSLK
(detailed below) was used to remove 293T from these cultures once the infection
was transferred to the iSLK. Pure iSLK producer lines were made by selection
with hygromycin B at 1.2 mg/ml.
4.2.5 Preparation of Cell Free Recombinant KSHV Particles
iSLK (Brulois, et al., 2012) stably infected with BAC16 (Plancoulaine S, 2000)
recombinant KSHV were grown in DMEM supplemented with 10% CCS, 50µg/ml
gentamicin, 250µg/ml G418, 1µM Puromycin, and 1.2mg/ml Hygromycin
B. Twelve confluent T175 flasks were induced at 70% confluency for 72 hours
with 3mM Sodium Butyrate and 2µM Doxycycline. Culture supernatants were
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clarified by centrifugation at 1500rpm for 12 minutes and passed through a 0.45
uM filter placed on ice. Virus was pelleted out of clarified supernatants over a 25%
sucrose cushion prepared in TNE buffer at PH 7.40 by ultracentrifugation at
22,000 rpm for 120 minutes. Virus pellets were resuspended in a total of 2mL TNE
buffer and stored in smaller quantities to avoid freeze thaw at -80˚C.
4.2.6 Viral Titering
To determine the Multiplicity of Infection (MOI), Human fibroblasts were derived
from primary human tonsil tissue and immortalized using HPV E6/E7 lentivirus
derived from PA317 LXSN 16E6E7 cells (ATCC CRL-2203). These E6/E7
transformed fibroblasts were seeded at 100,000 cell/well in 6-well culture plates.
24 hours post-seeding increasing doses of cell free KSHV was added in serum free
DMEM. Infected cultures were spinoculated at 1000rpm, 4˚C, 30 minutes followed
by incubation for 1 hour at 37˚C. Cultures were then fed with complete media
(DMDM+10% FBS+ PSG) and maintained at 37˚C for 3 days. At 72 hours post
infection, viral titers were assessed using flow cytometry with eGFP expression as
a marker for virus-positive cells, using a FACSVERSE flow cytometer (BD
Biosciences, San Jose, CA), and data were analyzed using FlowJo cytometry
analysis software (FlowJo, LLC, Ashland, OR). as well as quantitative PCR
(qPCR) of genomic DNA copy number in virus stock. For qPCR, DNA was
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extracted from the virus stock (pretreated with DNase) using zymo viral
DNA/RNA extraction kit (Zymo Research, Inc., Irvine, CA). Viral genomes were
quantified using TaqMan Fast advanced master mix (Applied Biosystems, Foster
City, CA) utilizing thermo fisher scientific primers and probes targeting the
BAC16 eGFP cassette (Thermo Fisher Scientific, Waltham, MA)(Fwd:
TGACCCTGAAGTTCATCTGC, Rev: GAAGTCGTGCTGCTTCATGT, Probe:
CCCACCCTCGTGACCACCCT). Samples were analyzed in duplicates. An eightseries of 10-fold dilutions of plasmid pCAGGS-eGFP(17) was used as a standard
for absolute quantification of viral genome copies.
The data was then compared to make sure that in primary infections we are
reaching TCID20 as well as ensuring that for different viruses the genome copy
number of virus compared to cells (gCPC) were similar.

4.2.7 Infection of Primary Lymphocytes with KSHV
Lymphocytes were thawed rapidly at 37˚C, diluted dropwise to 5ml with RPMI
and pelted at 1500 rpm for 5 minutes. Pellets were resuspended in 1ml
RPMI+20%FBS+100µg/ml DNase I+ Primocin 100µg/ml and allowed to recover
in a low-binding 24 well plate for 2 hours at 37˚C, 5% CO2. After recovery, total
lymphocytes were counted, and Naïve B cells were isolated using Mojosort™
Naïve B cell isolation beads (Biolegend 480068) or Naïve B cell Isolation Kit II
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(Miltenyi 130-091-150) according to manufacturer’s instructions. Bound cell
fraction (non-naïve B and other lymphocytes) were retained and kept at 37˚C in
RPMI+20% FBS+ Primocin 100µg/ml during the initial infection process. 1E6
Isolated naïve B lymphocyte were infected with iSLK-derived Bac16-KSHV (WT
and/or mutant) (dose equivalent to the ID20 at 3dpi on human fibroblasts) or Mock
infected; in 400ul of total of virus + serum free RPMI in 12x75mm round bottom
tubes via spinoculation at 1000rpm (Eppendorf centrifuge 5840r) for 30 minutes at
4˚C followed by incubation at 37˚C for an additional 30 minutes. Following
infection, cells were plated on irradiated CDW32 feeder cells in a 48 well plate,
reserved bound cell fractions were added back to the infected cell cultures at the
density of 1E6, and FBS and Primocin (Invivogen) were added to final
concentrations of 20% and 100µg/ml, respectively. Cultures were incubated at
37˚C, 5% CO2 for the duration of the experiment. Followed by intermittent
feeding every 72 hours by replacing 200uL of the media with fresh media.

4.2.8 Multicolor Flow cytometry
A proportion of lymphocyte cultures equivalent to ~500,000 cells were acquired by
aseptic technique at certain time points such as: at baseline, 3,6, and10 days post
infection(dpi) these representing cells were pelleted at 1500 rpm (using Eppendorf
centrifuge 5840 (Eppendorf AG, Hamburg, Germany) for 5 minutes into 96-well
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round bottom plates. The supernatant for some experiments’ would be collected
and frozen at -80°C (Eppendorf AG, Hamburg, Germany) for further analysis and
cells were then resuspended in 100µl PBS (calcium and magnesium free)
containing (0.4ng/ml) fixable viability stain (BD Biosciences, Franklin Lakes, NJ)
light protected and incubated on ice for 15 minutes. Cells were pelleted and
resuspended in 100µl cold PBS (without calcium and magnesium) containing 2%
FBS,0.5% BSA and 0.1% Sodium Azide (FACS Block) and incubated on ice for
10 minutes after which 100µl cold PBS (without calcium and magnesium)
containing 0.5% BSA and 0.1% Sodium Azide (FACS Wash) was added. Cells
were pelleted and resuspended in FACS Wash containing B lymphocyte and T
lymphocyte specific phenotype panel (including but not limited to, and depending
on the time point and purpose of analysis) as follows for 15 minutes on ice:
(volumes indicated were routinely used for up to 0.5(10)^6 cells and were based on
titration of the individual antibodies on primary tonsil lymphocyte
specimens(FMO)) CD19-PerCPCy5.5 (2.5µl, BD 561295), CD20-PE-Cy7 (2.5ul,
BD 560735), CD38-APC (10µl, BD 555462), IgD-APC-H7 (2.5µl, BD 561305),
CD138-v450 (2.5µl, BD 562098), CD27-PE (10µl BD 555441). After incubation,
150µl FACS Wash was added and pellet lymphocytes were washed with a further
200µl of FACS Wash prior to being resuspended in 200µl FACS Wash for
analysis. Data was acquired on a BD FACSVERSE Flow Cytometer or a BD
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Fortessa X20 Special Order Flow Cytometer, and analyzed using FlowJo software.
Table 4.1 shows which B cell subset express particular surface markers.

B Lymphocytes

Subset

Molecular Markers

Plasma

CD19+, CD20+/-, CD138+(Mid to High), CD38-

Transitional

CD19+, CD138-, CD38Mid, IgD+ (Mid to High)

Plasmablast

CD19+, CD138-, CD38High, IgD+ /- (mostly -)

Germinal Center

CD19+, CD138-, CD38Mid, IgD-

Naïve

CD19+, CD138-, CD38Low, CD27-, IgD+ (Mid to High)

Marginal Zone Like (MZ-Like)

CD19+, CD138-, CD38Low, CD27+ (Mid to High), IgD+ (Mid to High)

Memory

CD19+, CD138-, CD38Low, CD27+ (Mid to High), IgD-

Double Negative

CD19+, CD138-, CD38Low, CD27-, IgD-
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Table 4.1 B cell lineages used in this study

4.2.9 RT-PCR for Viral Gene Expression
For viral gene expression assays, primary naïve lymphocytes 1E6 cells were
harvested at indicated time points and total RNA was extracted using DirectZol
RNA Miniprep Kit (Zymo Research, Inc., Irvine, CA) according to manufacturer
instructions. A second DNase step was performed using Ambion DNA free Kit
(Cat #AM1906) and cDNA was synthesized from 50ng total RNA using Thermo
High-Capacity cDNA synthesis kit. 3µl of cDNA was used for duplicate RT-PCR
reactions with TaqMan Fast Advanced Mastermix (Cat #: 4444556). Primer and
probe (FAM/BGH) sequences were as follows (5’ to 3’) in the Table 4.2.

Primer / Probe

Primer / Probe Sequence

Name
LANA Forward GCCTATACCAGGAAGTCCCA
LANA Reverse

GAGCCACCGGTAAAGTAGGA

LANA Probe

ACACAAATGCTGGCAGCCCG
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K8.1 Forward

TGCTAGTAACCGTGTGCCAT

K8.1 Reverse

AGATGGGTCCGTATTTCTGC

K8.1 Probe

TGCGCGTCTCTTCCTCTAGTCGTTG

ORF59 Forward TTAAGTAGGAATGCACCCGTT
ORF59 Reverse GGAAGCCGGTGGTAGGAT
ORF59 Probe

CCAGGCTTCTCCTCTGTGGCAA

Table 4.2 : Primer and Probe Sequences used for qPCR Assays.

4.2.10 Immunofluorescence assays (IFA)
Cells were fixed for 15 minutes at RT using 4% formaldehyde, washed with Sterile
PBS, and labeled using traditional IFA methods incorporating 4% PFA solution in
PBS for fixation followed by incubation at RT for 15 minutes, 3X PBS washes,
and permeabilization using Perm Buffer (BD Catalog#: 554723). These steps were
then followed by 1 hour RT incubation with Primary Antibody (Anti- C-MYC
Antibody, Catalog#: 626801 Biolegend) and 3X PBS washes. Finally the
secondary Antibody ( Alexa flour 488, Thermofisher Catalog#: A1134) and DAPI
(ThermoFisher Scientific Catalog #: 28718-90-3) were added for 30 minutes at RT,
the samples were washed 3X times with PBS and covered with PBS for further
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analysis. For high intensity signaling the Tyramide IFA kit ( ThermoFisher
Scientific, Catalog#: B40922) was used following its protocol, ( (Scintific, 2020)).
Cells were washed and then fixed on the slides or kept in the vessels depending on
whether they are adherent or non-adherent cells, until examined using a Nikon
A1R high-definition resonant scanning confocal microscope and a NIS- Elements
software (AR 4.30.02, 64bit).
It is worth mentioning that for some procedures the methanol fixation method will
be used as the antibody and protein reaction post fixation might vary. For which
the cells will be washed and then pure (100%) methanol that has been chilled prior
at -20°C will be added on top of them and incubated at -20°C for 5 minutes and
from there the rest of the procedure was similar to 4%PFA IFA method.
4.2.11 Construction of ORF11-myc-pCDNA
Utilizing a C-myc tag for the studies and the following primers (ORF11_P1:
AGTGTGGTGGAATTCTGCatggcgcaggagtcagagc, ORF11_VR:
tctgactcctgcgccatGCAGAATTCCACCACACTGG ; and ORF11_P3:
ttgccaccggacgcagtGAACAAAAACTCATCTCAGAAGAGG) in a pCDNA
plasmid backbone, DNA was produced, and verified via running on agarose gel as
well as PCR, then purified via ZYMO DNA purification kits, and HEK293T cells
were then transiently transfected with the DNA using 0.1mM MgCL2 and HEPES
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1x for DNA delivery, cells were then antibiotic screened using Zeocin. The cells
were also kept under antibiotic selection for the duration of studies, the cells were
treated with 10ug of MG132, in order to increase the stability of expressed protein
upon inhibition of proteasomal degradation for 3 hours before IFA staining for
confocal microscopy. For the codon optimized studies the following P1, P3 and
VR primers were used in the same pCDNA (ORF11CO_P1:
AGTGTGGTGGAATTCTGCatggcccaagagtccgagcagtgc , ORF11CO11_P2:
TGAGATGAGTTTTTGTTCGCTTCTGCCGGTGGCCACG, ORF11CO_VR:
tcggactcttgggccatGCAGAATTCCACCACACTGG).

4.2.12 Cell Proliferation assays
BrdU tagging kit in APC channel was obtained from BD(Catalog #:557892 BrdU
APC Staining Kit Component A) and cells were treated and plated with 7.5 uL of
10mM BrdU post infection and on 3- and 6-days post infection they were stained
and analyzed on BD LSR-Fortessa II with a panel consisting of 15 markers as
described above.
4.2.13 UV inactivation studies
Purified cell free virions were freshly tawed on ice and the UV inactivated for 10
minutes prior to B cell infection, BrdU was added to the wells post infection and
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cells were similarly analyzed on 3- and 6-days post infection they were stained and
analyzed on BD LSR-Fortessa II with a channel consisting of 15 markers.

4.3 Results
4.3.1 ORF11 Protein Localizes to Plasma Membrane and has a Transmembrane
Domain.
Cloning the ORF11 open reading frame from the KSHV genome into pCDNA2.1myc resulted in very low expression levels upon transfection that were not
improved by inhibiting proteasomal degradation with MG132 (data not shown).
However, codon optimization of ORF11 significantly improved the expression
level. Our microscopy analysis reveals that ORF11 is localized within the plasma
membrane (Fig.4.1). To investigate whether ORF11 resides fully within the plasma
membrane and determine its topology, cells were induced and stained for the Cterminal myc tag either unpermeablized or permeabilized with Triton X-100 at
0.1%. We observed the signal in both fractions, demonstrating that the C-terminus
of ORF11 is outside the cell. We further verified this observation through
topology prediction modeling utilizing TMHMM topology prediction modeler
.
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from university of Denmark (A. Krogh, 2001), which predicts an 18 amino acid
transmembrane helix domain in the ORF11 protein. Based on these results we are
proposing a schematic model for ORF11 localization within the plasma membrane
(Fig 4.2).
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Figure 4. 1 ORF11 expression is localized to plasma membrane and the expression level is
significantly improved by codon optimization.the top panels show HEK293T cells transfected with
ORF11 pCDNA constructs, post 24 hours of induction using Doxycycline, the nuclei are stained
using DAPI and the green signal is from the C-myc tagged ORF11 protein expressing GFP marker.
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Figure 4. 2 ORF11protein Has A Transmembrane Domain. (A)The top panel is confocal microscopy analysis of the
HEK293T cells expressing ORF11 pCDNA, samples on the left are permeabilized using 0.1% Tritonx-100 while the samples
on the right are not permeabilized, demonstrating the transmembrane domain. (B) demonstrates the results of TMHMM
topology prediction for KSHV ORF11. (C) shows our proposed scheme for the localization of ORF11 protein within the
cells.
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4.3.2 KSHV ORF11KO, Mutant Development, And Preliminary Studies
Confirm That ORF11 Is Not Essential for Viral Production
Next, we designed loss of function approaches to study the events occurring in de
novo infection of B lymphocytes with a knockout ORF11 mutant (KSHV∆ORF11) compared to KSHV-WT. A BAC16 mutant was produced through the
introduction of two sequential stop codons within the ORF11 sequence, the entire
BAC genome was further sequenced, and no other alterations were observed
within the genome. (Fig4.3)
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Figure 4. 2 KSHV ORF11 Mutant development. As demonstrated two amino acids genetic
codons (11 and12) have been mutated to DNA stop codons thus rendering a an ORF11 Knockout
construct. The bottom panel is the sequencing results confirming that the only change introduced
in the backbone has been the insertion of the stop codons
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KSHV-∆ORF11 virions were efficiently produced from iSLK producer cell lines,
demonstrating that ORF11 is not essential for viral production and packaging.
Once cell free virions were prepared, we used E6/E7 fibroblast cells for viral
titering, higher GFP expression within the ∆ORF11 infected samples is observed
with similar number of viral particles (based on qPCR genome titering). (Fig4.4)
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Figure 4. 4 Higher GFP Expression Within The ∆ORF11 Infected Samples Is Observed Within
Similar Doses, With Similar Number of Viral Particles (Based On (PCR genome Titering) in
E6/E7 Fibroblasts, results are acquired at 3 days post infection.
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4.3.3 Increased Infection with ORF11KO Is Observed in B lymphocytes
However, There Is No Significant Viral Particle Production Change.
Equivalent TCID20 doses of WT and ∆ORF11 virus were used for de novo
infections of tonsil derived B lymphocytes as explained in methodology. We
observed significantly increased numbers of GFP positive B lymphocytes within
the ∆ORF11 infected samples (Fig 4.5). We hypothesized that this increase in
infected cells could be due to (1) increased spread of KSHV-∆ORF11 virus within
the cultures or (2) increased proliferation of KSHV-∆ORF11 infected cells. To test
the first hypothesis, we analyzed KSHV genomes in the culture supernatant of
infected B lymphocytes at 6 days post infection. Interestingly, this data did not
show any changes in the viral production level between WT and ∆ORF11 culture
supernatants (Fig.4.5).
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Figure 4. 3 Increased Infection with ORF11KO Is Observed However There Is No Significant
Viral Particle Production Change. (A) Shows a comparison between different conditions over the
course of time and how GFP is constantly higher in Delta11 samples. (B) shows statistical
analysis of the GFP levels between WT and Delta11 where with P value of 0.065 Delta11 is
showing higher levels of GFP. (C) Comparison of Viral DNA production between different
samples from the viral DNA extracted from supernatant of infected B cells at 6 days post
infection. (D) statistical analysis of GFP positive double negative B cells, with P value of
0.042.(E) statistical analysis of GFP positive Plasmablast B cells, with P value of 0.064.
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4.3.4 Increased Proliferation In △ORF11 Mutant Virus Infected Cells, Is Linked
to Increased Proliferation of Plasmablasts and Plasma Cells.
Since the previous experiments had demonstrated that the increased infection we
observe with KSHV-∆ORF11 is not due to higher viral production, we speculated
that the increase might be due to increased proliferation of B lymphocytes infected
with KSHV-∆ORF11. In order to examine whether B cell populations differed
between KSHV-WT and KSHV-∆ORF11, we employed a multicolor flow
cytometry panel that we reported previously (Aalam F, 2020) and analyzed total B
cell lineages and the distribution of infection within B cell lineages at 3, 6 and 10
days post-infection. As observed in (Fig.4.6), the total plasmablast population and
the infected plasmablast population are both increased in KSHV-∆ORF11 infected
cultures compared to the KSHV-WT infected samples.
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Figure 4. 6 Observed changes in total population of B cells, as well as changes in GFP(Infected)
only population of B cells. All B cells are shown as frequency of viable, CD19+ B cells. the GFP
subsets are shown as the frequency of infected subsets of the particular parent subset. Na stands
for Naïve B cell, Mem stands for Memory B cells, MZ stands for Marginal Zone B cells, Trans
stands for transitional B cells, GC stands for Germinal Center B cells, PB stands for Plasmablasts,
and finally DN stands for Double negative cells based on negative expression of CD27 and IgD
observed in our gating scheme (Appendix A.1) similar to Fig4.5, the elevated levels of GFP in the
infected Plasmablast and infected Double negative cells are statistically significant (P values are
respectively 0.064 and 0.041 based on Wilcoxon test). A more detailed look into the surface
markers each of the subsets express is available in Table 4.1.
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In order to determine whether the increased plasmablast numbers observed with
KSHV-∆ORF11 were due to proliferation, we added BrdU at 100mM
concentration to cultures at infection. At 3 and 6 dpi cells were stained with surface
markers for B cell immunophenotypes and then fixed, permeabilized, treated with
DNase to liberate BrdU epitopes and incubated overnight with Anti-BrdU
antibody. These results show a statistically significant increase in total B cell
proliferation with KSHV-∆ORF11 (Fig 4.9). More importantly it can be observed
that the higher proliferation in the samples is associated with significantly
increased proliferation of plasmablasts and plasma cells (Fig4.9), these two B cell
subsets are biologically/pathologically important cell types as plasmablasts are
precursors of short- and long-lived plasma cells and they both are a proliferating
fraction of antibody-secreting cells, which play complex roles in humoral
immunity and host protection.
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Figure 4. 7 BrdU analysis shows increased proliferation in total B cell population and individual
subset proliferation. All B cells are shown as frequency of viable, CD19+ B cells. the
Proliferating (Prolif) subsets are shown as the frequency of infected subsets of the particular
parent subset. Na stands for Naïve B cell, Mem stands for Memory B cells, MZ stands for
Marginal Zone B cells, Trans stands for transitional B cells, GC stands for Germinal Center B
cells, PB stands for Plasmablasts, and finally DN stands for Double negative cells based on
negative expression of CD27 and IgD observed in our gating scheme (Appendix A.1) similar to
Fig4.9, the elevated levels of proliferation in the Plasmablasts and plasma cells, as well as overall
proliferation are statistically significant (P values are respectively 0.0067 and 0.00024, and
0.0052). A more detailed look into the surface markers each of the subsets express is available in
Table 4.1.
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Figure 4.8 Total B Cell Proliferation, Plasmablasts and, Plasma Cell Proliferation Increases
Significantly Post Infection with ORF11KO, statistical analysis has been done using ggplot
ggpaired statistical tests.
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4.3.5 Increased proliferation phenotype is not linked to ORF11 protein packaged
within the viral particles.
A possible explanation for the increased levels of proliferation could be the ORF11
protein packaged within the virion and its interaction with the host in early stages
of infection. In order test whether virion-associated ORF11 was responsible for
suppressing B cell proliferation, we UV-inactivated the virion for 10 minutes prior
to infection (Appendix C.2, shows our optimization experiments of UVInactivation exposure time effects on viral infectivity) to prevent any de novo gene
expression, thus providing a chance to study the effects of proteins carried by the
virion in absence of new proteins being produced from virion DNA after infection.
The UV virus was then used in side-by-side infections of B cell lymphocytes using
BrdU to assess proliferation. We observed that the UV inactivated KSHV-∆ORF11
did not display the increased proliferation seen in non-UV treated infections, and
more importantly it behaves similar to WT UV inactivated virion (Fig.4.10), these
results suggest that it is ORF11 produced in the cells after infection and not ORF11
packaged into the virus particles that is affecting proliferation of plasmablasts and
plasma cells in our experiments.
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Figure 4. 9 UV inactivated ∆ORF11 infection of B cells does not yield any proliferation,
indicating that it is not the ORF11 packaged within the virus that has an effect in the suppression
of B cell proliferation but the role of newly expressed ORF11 within the infected cells, analysis is
done by ggplot.
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4.4 Discussion and Future Directions
The ORF11 tegument protein, although highly conserved within gamma
herpesviruses, is still a poorly characterized protein. This protein has been detected
within the virion of KSHV (Zhu, 2005), (Bechtel, Winant, & Ganem, 2005) ,
(Nabiee R., 2020). Furthermore, investigations on have revealed that ORF11
interacts with other tegument proteins such as ORF45, ORF64 and ORF63
suggesting a potential role in primary KSHV infection, such as virion morphology,
latency establishment, or host interaction. (R. Rozen, 2008), (Zhu, 2005). Later
with the discovery of a dUTPase like domain in ORF11 coding sequence, it was
suggested that ORF11 protein may function as a dUTPase (A.J. Davison, 2005),
yet as of now it is still not confirmed whether ORF11 is capable of such functions,
due to lack of evidence (Ramirez CN, 2009.) later Chen et al. (Chen L. M. S.,
2009) suggested that ORF11 promotor is not directly controlled by RTA and there
might be an indirect regulation involved, however later on they also reported of
identification of a silencer within ORF11 concluding that KSHV might be using a
particularly novel gene regulation mechanism to precisely control ORF11 (Chen L.
M. S., 2011) .
In our studies we have found that ORF11 is plasma membrane-localized and has a
transmembrane domain with C-out topology.
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More importantly it has been established that in MCD patients’, the flare-ups
episodes are closely linked to higher vIL6-expression (Sakakibara S. &., 2011), it
had also been reported previously that deletion of vIL6 lead to increased
expression of ORF11 (Chen L. M. L., 2006). In the current study, we report that an
ORF11 knockout virus, causes selective proliferation of plasmablasts and plasma
cells. Higher proliferation these two biologically/pathologically important cell
types, combined with the prior knowledge of vIL6’s role and contribution to lytic
phase may indicate that ORF11 participates in persistence of latency through antiproliferative effect on CD138+ B cells; a cell type which we have shown is highly
targeted early in KSHV infection of tonsil lymphocyte samples (Aalam F, 2020).
One possible mechanism for this observation is that ORF11 can inhibit
proliferation by inhibiting toll like receptor (TLR) signaling. TLRs are
differentially expressed in various immune cells, moreover TLR ligands, such as
bacterial and viral components, found at sites of infection or inflammation, affect
the expression of their cognate TLRs. (Hornung V, 2002 ). It has also been
reported that tonsillar B cells exhibit a constitutively high level of several TLRs. In
particular, TLR1 and TLR10 (Månsson, 2006), further emphasizing the unique
ability of B cells to respond directly, via TLRs, to a certain range of microbial
patterns. During latency, KSHV inhibits TLR3-mediated IFN induction via vIRFs
(Jacobs SR, 2013 ). In 2008 West et al. (West J, 2008 ) first reported that KSHV
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upregulates the TLR3 pathway during infection to induce TLR3-specific cytokines
and chemokines. More importantly it has been reported that TLR9 is the major
pattern recognition receptor for KSHV infection (West JA, 2011 ). Lagos et al.
found that KSHV suppresses TLR4 for immune escape during KSHV infection in
endothelial cells (Lagos D, 2008 ), (Zheng, 2020). Thus, KSHV uses two
mechanisms to avoid attack by the host immune system, leading to repeated
infection in the host (Lagos D, 2008 ).
Such evidence strongly indicates the need for further investigation in the potential
regulatory role of ORF11 in B lymphocytes KSHV infection.
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5 Chapter V: Conclusions and Future Directions

5.1 Conclusions
Despite the vast body of research in the KSHV field, there are still major gaps in
our basic understanding of KSHV host-pathogen interactions, such as the route of
transmission, cellular tropism, and, more importantly, early infection events
leading to establishment and persistence of KSHV in B lymphocytes. In the studies
presented in this dissertation, we have aimed to address some of these gaps, by
utilizing our laboratory’s model system (Totonchy J, 2018 ) that benefits from the
use of primary tonsil derived B cells, as well as the versatile BAC16 KSHV virion
backbone and iSLK virion production cell line (Brulois, et al., 2012), (Myoung &
Ganem, 2011 ). What follows is a summary of our important findings for each of
our 3 aims, and their contribution towards a better understanding of KSHV
virology.
5.1.1 In Chapter 2:
We examined KSHV infection of tonsillar B lymphocytes from 40 human donors
in order to determine whether KSHV has a particular B cell subtype tropism, as
well as addressing how the presence or absence of certain immune cells influences
the initial stages of KSHV infection. We observed that susceptibility to KSHV
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infection does not rely on demographic factors, such as age, sex, or race.
Additionally, we observed that, although a variety of B cell subtypes derived from
tonsils are susceptible to infection, KSHV has a significant tropism towards plasma
cells (mature antibody-secreting B cells) in early infection events. This finding is
particularly intriguing in the context of KSHV-mediated lymphoproliferative
diseases, which often have a plasma cell or plasmablast-like phenotype, suggesting
that the pathological cells observed in KSHV related diseases such as PEL may not
be derived from KSHV-driven differentiation from less mature lineages, but
instead could be the result of modifications of differentiated plasma cells by direct
infection. We also studied the microenvironments present in these experiments and
observed that T cell composition manipulation has a more profound effect on
KSHV infection in tonsil specimens that were CD4+ T cell rich at baseline. These
results lay the foundation for further studies into the specific biology of KSHV in
different types of B cells, an effort that may help us ultimately discover how to
prevent the establishment of infection in these cells or reveal new ways to halt the
progression of B cell cancers associated with KSHV infection.
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5.1.2 In Chapter 3:
We revisited the KSHV virion proteome, which has not been re-examined since the
early 2000’s, even with substantial advances in both proteomics technology and
the introduction of new KSHV cellular and molecular tools and cell models. Given
the vital role virion packaged proteins play in early KSHV infection events, it was
an unfilled gap in our basic understanding of KSHV. We re-examined the protein
composition of purified KSHV virions via ultra-high resolution Qq time-of-flight
mass spectrometry (UHR-QqTOF). Our results confirm the detection of all 24
previously reported virion proteins, in addition to 17 other viral proteins, some of
which have been characterized as virion-associated using other methods, and 10
novel proteins identified as virion-associated for the first time in this study. These
results add KSHV ORF9, ORF23, ORF35, ORF48, ORF58, ORF72/vCyclin, K3,
K9/vIRF1, K10/vIRF4, and K10.5/vIRF3 to the list of KSHV proteins that can be
incorporated into virions. The addition of these proteins to the KSHV virion
proteome provides novel and important insight into early events in KSHV infection
mediated by virion-associated proteins.
5.1.3 In Chapter 4:
We looked at a poorly characterized yet highly conserved tegument protein of
KSHV called ORF11. As we had shown in the previous chapters of this thesis,
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KSHV is the only known rhadinoviral capable of infecting B cells, and the highly
conserved genes are likely to play roles specifically in B cell infection (Chapter I).
In Chapter II, we were able to show that KSHV has a particular tropism for plasma
cells, finally in Chapter III we demonstrated that ORF11 is abundantly present in
the KSHV virion. Thus, we decided to utilize gain and loss of function approaches
to further study the contribution of ORF11 to KSHV early infection events. Our
studies reveal that KSHV-∆ORF11 targets similar lineages at higher frequency
compared to WT (increased number of GFP+ cells with similar viral dose),
indicating that ORF11 has regulatory roles in infection. In addition, KSHV∆ORF11 increases the frequency of specific B cell subsets (plasmablasts, and
plasma cells) by increasing cellular proliferation of these cell types. These results
indicate that ORF11 has a suppressive role in plasmablast proliferation and
contributing to the establishment of latency. We also demonstrated that ORF11,
localizes to the plasma membrane and has a transmembrane domain.

5.2 In Summary
We aimed to study early KSHV infection events, in order to provide a better
understanding of the less studied and poorly understood aspects of KSHV hostpathogen interactions. Our results demonstrated that KSHV has broad
lymphotropism and favors infection of plasma cells. This information can further
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be used to facilitate the study of KSHV transmission and conceptualize new
therapeutics. Our results open doors to many other questions that could be asked
within the same context, which will ultimately increase our understanding of the
human immune system as well as KSHV’s basic virology.
Moreover, our proteomics studies have introduced 10 new virion associated
proteins, especially detection of vIRFs provides unique opportunities to study and
understanding of the earliest stages of KSHV infection in new ways and how these
proteins may participate in immune evasion early in KSHV infection, and how
KSHV can utilize these packaged proteins to affect the environment of host cells
before de novo transcription is started.
In chapter 4, we combined our newly found knowledge of KSHV’s B cell subtype
tropism and our findings of KSHV’s virion proteome to further look into dynamics
of KSHV-B cell interactions, and not only we were able to provide much needed
information about the poorly characterized ORF11 protein but more importantly to
provide information that suggests how KSHV uses its vast protein repertoire for
the maintenance of latency and essentially using B cells as a viral reservoir before
reactivation and infection of other human cells.
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5.3 Future Directions
It is important to note that upon viral entry and during reactivation, the host mounts
immune responses against KSHV infection mostly via innate immune receptors,
especially toll-like receptor (TLR) responses, which have been shown to act as the
first responders in many viral infections (Lester SN, 2014). It has also been
reported that KSHV activates TLR3 (West, 2008), TLR4 (Lagos D, 2008 ), and
TLR9 (West JA, 2011 ). In addition, we know that certain B cell subsets rely
heavily on TLRs for regulation of proliferation and cytokine secretion (Hou,
2013). Specifically, in tonsils, they primarily rely on TLR9 (Månsson, 2006).
Finally, it is worth noting that in most clinical studies, especially studies focused
on MCD disease, high levels of plasmablast proliferation is consistently detected
(Hassman LM, 2011 ). Moreover, elevated levels of particular viral proteins are
reported, most notably vIL6 protein (Sakakibara & Tosato, 2011). Chen et al.
(Chen, 2007) observed high levels of ORF11 post knockout of vIL6.
Taken together with our observations in the previous chapters, these results suggest
that plasmablast differentiation during KSHV infection is regulated both positively
and negatively by KSHV gene products, and these gene products may alternately
influence disease progression in KSHV-associated lymphoproliferative disorders.
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One way they could interact and influence these cellular responses could be via
interactions with TLRs, particularly TLRs3, 4 and 9.
However, further studies are needed to more effectively shine light on host cellular
signaling profile changes, especially in early infection events. Given the significant
breakthroughs in deep gene sequencing, as well as cell-based small-molecule
screening campaigns (Calderon, 2020), it might be beneficial to invest in
utilization of these technologies combined with tools developed in our studies to be
able to further analyze and study host-pathogen interactions in early KSHV events.

170

References
A. Krogh, B. L. (2001). Predicting transmembrane protein topology with a hidden Markov
model: Application to complete genomes. . Journal of Molecular Biology, , 567-580.
A.J. Davison, N. S. (2005). New genes from old: redeployment of dUTPase by herpesviruses . J.
Virol., , 12880-12892.
Aalam F, Nabiee. R. (2020). Analysis of KSHV B lymphocyte lineage tropism in human tonsil
reveals efficient infection of CD138+ plasma cells. . PLOS Pathogens , 16(10):
e1008968.
Akula SM, W. F. (2001 ). Human herpesvirus 8 interaction with target cells involves heparan
sulfate. . Virology. , 245–255.
Alkharsah KR, S. V. ( 2011 ). Deletion of Kaposi's sarcoma-associated herpesvirus FLICE
inhibitory protein, vFLIP, from the viral genome comprises the activation of STAT1responsive cellular genes and spindle cell formation in endothelial cells. J Virol., 10375–
10388.
B. Lubyova, P. P. (2000 ). Characterization of a novel human herpesvirus 8-encoded protein,
vIRF-3, that shows homology to viral and cellular interferon regulatory factors . J.
Virol.,, 8194-8201.
Bacon CM, M. R.-Q. (2004 ). Pathology of bone marrow in human herpes virus-8 (HHV8)associated multicentric Castleman disease. . Br J Haematol. John Wiley & Sons, Ltd; ,
585–591.
Bai Z, H. Y. (2014). Genomewide mapping and screening of Kaposi's sarcoma-associated
herpesvirus (KSHV) 3' untranslated regions identify bicistronic and polycistronic viral
transcripts as frequent targets of KSHV microRNAs. . J Virol. , 377-392.
Barasa A, Y. P. (2017). BALB/c mice immunized with a combination of virus-like particles
incorporating Kaposi sarcoma associated herpesvirus (KSHV) envelope glycoproteins
gpK8.1, gB, and gH/gL Induced comparable serum neutralizing antibody activity to UVinactivated KSHV. . Oncotarget , 34481–34497.
Bechtel, J. ,., Winant, R., & Ganem, D. (2005). Host and Viral Proteins in the Virion of Kaposi’s
Sarcoma-Associated Herpesvirus. journal of virology, 4952-4964.
Bekerman E, J. D. (2013 ). A role for host activation-induced cytidine deaminase in innate
immune defense against KSHV. Gao S-J, editor. PLoS Pathog. Public Library of Science,
e1003748.
Bergson, S., Itzhak, I., Wasserman, T., Gelgor, A., Kalt, I., & Sarid, R. (2016). The Kaposi’ssarcoma-associated herpesvirus orf35 gene product is required for efficient lytic virus
reactivation. . Virology , 499, 91–98.

171

Bergson, S., Kalt, I., Itzhak, I., Brulois, K., Jung, J., & Sarid, R. (2014 ). Fluorescent Tagging
and Cellular Distribution of the Kaposi’s Sarcoma-Associated Herpesvirus ORF45
Tegument Protein. . J. Virol. , 12839–12852.
Bhutani M, P. M. (2015 ). Kaposi Sarcoma–Associated Herpesvirus-Associated Malignancies_
Epidemiology, Pathogenesis, and Advances in Treatment. Seminars in Oncology. .
Elsevier, 223–246.
Borza, C., & Hutt-Fletcher, L. (2002 ). Alternate replication in B cells and epithelial cells
switches tropism of Epstein-Barr virus. . Nat. Med. , 594–599.
Brulois, K., Chang, H., Lee, A.-Y., Ensser, A., Wong, L.-Y., Toth, Z., . . . al., e. (2012).
Construction and manipulation of a new Kaposi’s sarcoma-associated herpesvirus
bacterial artificial chromosome clone. J. Virol., 9708–9720.
Brulois, K., Toth, Z., Wong, L.-Y., Feng, P., Gao, S.-J., Ensser, A., & Jung, J. (2014 ). Kaposi’s
sarcoma-associated herpesvirus K3 and K5 ubiquitin E3 ligases have stage-specific
immune evasion roles during lytic replication. . J. Virol. , 9335–9349.
Butnaru, M., & Gaglia, M. (2019). The Kaposi’s Sarcoma-Associated Herpesvirus Protein
ORF42 Is Required for Efficient Virion Production and Expression of Viral Proteins. .
Viruses , 711.
Carbone A, C. E. ( 2010 ). Understanding pathogenetic aspects and clinical presentation of
primary effusion lymphoma through its derived cell lines. . AIDS., 479–490.
Carbone A, V. E. (2014 ). Diagnosis and management of lymphomas and other cancers in HIVinfected patients. Nat Rev Clin Oncol. . Nature Publishing Group, 223–238.
Casper C, K. E.-L. (2007 ). Frequent and asymptomatic oropharyngeal shedding of human
herpesvirus 8 among immunocompetent men. J Infect Dis. , 30–36.
Casper C, R. M.-L. (2004). HIV infection and human herpesvirus-8 oral shedding among men
who have sex with men. . J Acquir Immune Defic Syndr. , 233–238.
Cesarman E, C. Y. ( 1995). Kaposi's sarcoma-associated herpesvirus-like DNA sequences in
AIDS-related body-cavity-based lymphomas. . N Engl J Med., 1186–1191.
Chadburn A, H. E. (2008). Immunophenotypic analysis of the Kaposi sarcoma herpesvirus
(KSHV; HHV-8)-infected B cells in HIV+ multicentric Castleman disease (MCD).
Histopathology. Blackwell Publishing Ltd; , 513-524.
Chandran, B., Bloomer, C., Chan, S., Zhu, L., Goldstein, E., & Horvat, R. (1998). Human
herpesvirus-8 ORF K8.1 gene encodes immunogenic glycoproteins generated by spliced
transcripts. . Virology , 140–149.

172

Chang, P., & Li, M. (2008 ). Kaposi’s sarcoma-associated herpesvirus K-cyclin interacts with
Cdk9 and stimulates Cdk9-mediated phosphorylation of p53 tumor suppressor. . J. Virol.
, 278–290.
Chang, Y., Cesarman, E., Pessin, M., Lee, F., Culpepper, J., Knowles, D., & Moore, P. (1994).
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma.
Science ( 266), 1865–1869.
Chang, Y., Moore, P., Talbot, S., Boshoff, C., Zarkowska, T., Godden-Kent, D., . . . Mittnacht,
S. (1996 ). Cyclin encoded by KS herpesvirus. . Nature , 382, 410.
Chaturvedi AK, M. S. (2008). Underestimation of relative risks by standardized incidence ratios
for AIDS-related cancers. . Ann. Epidemiol. , 230–234.
Chen L., M. L. (2006). The KSHV viral interleukin-6 is not essential for latency or lytic
replication in BJAB cells. J virology, 425-435.
Chen L., M. S. (2009). Identification and characterization of the promoter region of Kaposi's
sarcoma-associated herpesvirus ORF11. Virus Res., 160-168.
Chen L., M. S. (2011). A silence element involved in Kaposi ́s sarcoma-associated herpesvirus
ORF11 gene expression. Acta viruses.
Chen, L. &. (2007). Establishment and maintenance of Kaposi's sarcoma-associated herpesvirus
latency in B cells. Journal of virology, 14383–14391.
Chow, D.-C., He, X., Snow, A., Rose-John, S., & Garcia, K. (2001 ). Structure of an
Extracellular gp130 Cytokine Receptor Signaling Complex. . Science , 2150–2155.
Coscoy, L., & Ganem, D. ( 2000 ). Kaposi’s sarcoma-associated herpesvirus encodes two
proteins that block cell surface display of MHC class I chains by enhancing their
endocytosis. Proc. Natl. Acad. Sci. USA, 8051–8056.
Dünn-Kittenplon, D., Kalt, I., Lellouche, J., & Sarid, R. (2019). The KSHV portal protein
ORF43 is essential for the production of infectious viral particles. . Virology , 205–215.
Dai, X., Gong, D., Wu, T.-T., Sun, R., & Zhou, Z. ( 2014 ). Organization of Capsid-Associated
Tegument Components in Kaposi’s Sarcoma-Associated Herpesvirus. . J. Virol., 12694–
12702.
Davis, D., Rinderknecht, A., Zoeteweij, J., Aoki, Y., Read-Connole, E., Tosato, G., . . .
Yarchoan, R. (2001). Hypoxia induces lytic replication of Kaposi sarcoma–associated
herpesvirus. . Blood , 3244–3250.
De Oliveira, D., Ballon, G., & Cesarman, E. (2010 ). NF-κB signaling modulation by EBV and
KSHV. . Trends Microbiol. , 248–257.

173

De Oliveira, D., Ballon, G., & Cesarman, E. (2010). NF-κB signaling modulation by EBV and
KSHV. . Trends Microbiol. , 248–257.
den Ridder, M., Daran-Lapujade, P., & Pabst, M. (2020 ). Shot-gun proteomics: Why thousands
of unidentified signals matter. . FEMS Yeast Res. , foz088.
Deutsch, E., Bandeira, N., Sharma, V., Perez-Riverol, Y., Carver, J., Kundu, D., . . . al., e.
(2020). The ProteomeXchange consortium in 2020: Enabling ‘big data’ approaches in
proteomics. Nucleic Acids Res. , 1145–1152.
Dollery SJ, S.-C. R. (2018). Glycoprotein K8.1A of Kaposi's sarcoma-associated herpesvirus is a
critical B cell tropism determinant, independent of its heparan sulfate binding activity. . J
Virol. , 1–38.
Drexler, H. e. (1998 ). “Lymphoma cell lines: in vitro models for the study of HHV-8+ primary
effusion lymphomas (body cavity-based lymphomas).”. Leukemia , 1507-1517.
Dyson, O., Walker, L., Whitehouse, A., Cook, P., & Akula, S. (2012). Resveratrol Inhibits
KSHV Reactivation by Lowering the Levels of Cellular EGR-1. . PLoS ONE , e33364.
Ford, T., Graham, J., & Rickwood, D. (1994 ). Iodixanol: A Nonionic Iso-osmotic Centrifugation
Medium for the Formation of Self-Generated Gradients. . Anal. Biochem. , 360–366.
Friborg J Jr, K. W. (1998 ). Distinct biology of Kaposi's sarcoma-associated herpesvirus from
primary lesions and body cavity lymphomas. . J Virol. , 10073–10082.
G. Miller, L. H. (1997). Chang Selective switch between latency and lytic replication of Kaposi's
sarcoma herpesvirus and Epstein–Barr virus in dually infected body cavity. J.Virol, 314324.
G. Miller, L. H. (1997 ). Selective switch between latency and lytic replication of Kaposi's
sarcoma herpesvirus and Epstein–Barr virus in dually infected body cavity lymphoma
cells. J. Virol.,, 314-324.
Gao, S., Boshoff, C., Jayachandra, S., Weiss, R., Chang, Y., & Moore, P. (1997). KSHV ORF
K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. . Oncogene ,
1979–1985.
Garrigues, H., Rubinchikova, Y., DiPersio, C., & Rose, T. (2008 ). Integrin αVβ3 Binds to the
RGD Motif of Glycoprotein B of Kaposi’s Sarcoma-Associated Herpesvirus and
Functions as an RGD-Dependent Entry Receptor. . J. Virol. , 1570–1580.
Giffin, L., West, J., & Damania, B. (2015 ). Kaposi’s Sarcoma-Associated Herpesvirus
Interleukin-6 Modulates Endothelial Cell Movement by Upregulating Cellular Genes
Involved in Migration. . mBio , e01499-15.

174

Godden-Kent, D., Talbot, S., Boshoff, C., Chang, Y., Moore, P., Weiss, R., & Mittnacht, S.
(1997 ). The cyclin encoded by Kaposi’s sarcoma-associated herpesvirus stimulates cdk6
to phosphorylate the retinoblastoma protein and histone H1. . J. Virol. , 4193.
Gonçalves PH, U. T. (2017 ). HIV-associated Kaposi sarcoma and related diseases. . AIDS. ,
1903–1916.
Gong, D., Wu, N., Xie, Y., Feng, J., Tong, L., Brulois, K., . . . al., e. (2014). Kaposi’s SarcomaAssociated Herpesvirus ORF18 and ORF30 Are Essential for Late Gene Expression
during Lytic Replication. . J. Virol. , 11369–11382.
Großkopf AK, S. S. (2019). EphA7 Functions as Receptor on BJAB Cells for Cell-to-Cell
Transmission of the Kaposi's Sarcoma-Associated Herpesvirus and for Cell-Free
Infection by the Related Rhesus Monkey Rhadi Rhadinovirus. . Jung JU, editor. J Virol,
1029.
Grundhoff, A., & Ganem, D. (2004 ). Inefficient establishment of KSHV latency suggests an
additional role for continued lytic replication in Kaposi sarcoma pathogenesis. . J. Clin.
Investig. , 124–136.
H. Deng, M. S. (2002 ). Transcriptional regulation of the interleukin-6 gene of human
herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) . J. Virol., 8252-8264.
H. Nakamura, M. L. (2003). Global changes in Kaposi's sarcoma-associated virus gene
expression patterns following expression of a tetracycline-inducible Rta transactivator . J.
Virol. , 4205-4220.
Hahn A, B. A. (2009 ). Kaposi's sarcoma-associated herpesvirus gH/gL: glycoprotein export and
interaction with cellular receptors. J Virol. American Society for Microbiology Journals,
396–407.
Hassman LM, E. T. (2011 ). KSHV infects a subset of human tonsillar B cells, driving
proliferation and plasmablast differentiation. J Clin Invest. , 752–768.
Hikita, S., Yanagi, Y., & Ohno, S. (2015). Murine gammaherpesvirus 68 ORF35 is required for
efficient lytic replication and latency. J. Gen. Virol. , 96, 3624–3634.
Holzerlandt, R., Orengo, C., Kellam, P., & Albà, M. ( 2002). Identification of new herpesvirus
gene homologs in the human genome. . Genome Res., 12, 1739–1748.
Hornung V, R. S. (2002 ). Quantitative expression of toll-like receptor 1-10 mRNA in cellular
subsets of human peripheral blood mononuclear cells and sensitivity to CpG
oligodeoxynucleotides. J Immunol., 68(9):4531-7.
Hu D, W. V. (2016 ). Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral
Interleukin-6 by X-Box Binding Protein 1. . Frueh K, editor. J Virol. American Society
for Microbiology Journals; , 368–378.

175

Hwang, S., Kim, D., Jung, J., & Lee, H. (2017 ). KSHV-encoded viral interferon regulatory
factor 4 (vIRF4) interacts with IRF7 and inhibits interferon alpha production. Biochem.
Biophys. Res. Commun. , 700–705.
Ibrahim HAH, B. K. (2016 ). Bone marrow manifestations in multicentric Castleman disease. .
Br J Haematol. John Wiley & Sons, Ltd; , 923–929.
Iwakoshi NN, L. A.-H. (2003). Plasma cell differentiation and the unfolded protein response
intersect at the transcription factor XBP-1. . Nat Immunol. Nature Publishing Group; ,
321–329.
Jacobs SR, G. S. (2013 ). The viral interferon regulatory factors of kaposi's sarcoma-associated
herpesvirus differ in their inhibition of interferon activation mediated by toll-like receptor
3. . J Virol. , 87(2):798-806.
Jarousse N, T. D.-A. (2011 ). Virally-induced upregulation of heparan sulfate on B cells via the
action of type I IFN. . J Immunol. American Association of Immunologists, 5540–5547.
Jenner, R., Albà, M., Boshoff, C., & Kellam, P. (2001 ). Kaposi’s sarcoma-associated
herpesvirus latent and lytic gene expression as revealed by DNA arrays. . J. Virol. , 891–
902.
JN., M. (2007. ). The epidemiology of KSHV and its association with malignant disease. In:
Arvin A, Campadelli-Fiume G, Mocarski E, et al., editors. Human Herpesviruses:
Biology, Therapy, and Immunoprophylaxis. . Cambridge: Cambridge University Press; ,
Chapter 54.
Johnson KE, T. V. (2020 ). Gammaherpesviruses and B Cells: A Relationship That Lasts a
Lifetime. . Viral Immunol. , 316–326.
Jones, T., Ramos da Silva, S., Bedolla, R., Ye, F., Zhou, F., & Gao, S. ( 2014 ). Viral cyclin
promotes KSHV-induced cellular transformation and tumorigenesis by overriding contact
inhibition. Cell Cycle, 845–858.
K. Borchers, M. G. (1994 ). Genome organization of the herpesviruses: minireview . Acta Vet.
Hung, 217-225.
K.A. Staskus, W. Z. (1997 ). Haase Kaposi's sarcoma-associated herpesvirus gene expression in
endothelial (spindle) tumor cells. J. Virol., , 715-71.
Kang S, M. J. (2017). Primary lymphocyte infection models for KSHV and its putative
tumorigenesis mechanisms in B cell lymphomas. . J Microbiol. The Microbiological
Society of Korea, 319–329.
Karass, M. e. (2017). “Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS): A Rare but
Potentially Treatable Condition..”.”The oncologist vol. 22,5, 623-625.

176

Karass, M., Grossniklaus, E., Seoud, T., Jain, S., & Goldstein, D. (2017 ). Kaposi Sarcoma
Inflammatory Cytokine Syndrome (KICS): A Rare but Potentially Treatable Condition.
Oncologist , 623–625.
Katano, H., Sato, Y., Kurata, T., Mori, S., & Sata, T. (2000). Expression and localization of
human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi’s sarcoma,
and multicentric Castleman’s disease. Virology , 335–344.
Knowlton ER, R. G. (2014 ). Human herpesvirus 8 induces polyfunctional B lymphocytes that
drive Kaposi's sarcoma. . MBio. , e01277–14.
Lagos D, V. R. (2008 ). Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma
herpesvirus. . Cell Host Microbe. , 470-83.
Lagunoff, L. C. (2007). The KSHV viral interleukin-6 is not essential for latency or lytic
replication in BJAB cells. J. Virology, 425-435.
Lang, S., Bynoe, M., Karki, R., Tartell, M., & Means, R. (2013 ). Kaposi’s sarcoma-associated
herpesvirus K3 and K5 proteins down regulate both DC-SIGN and DC-SIGNR. . PLoS
ONE , e58056.
Lee, H.-R., Doğanay, S., Chung, B., Toth, Z., Brulois, K., Lee, S., . . . Jung, J. (2014 ). Kaposi’s
sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4) targets
expression of cellular IRF4 and the Myc gene to facilitate lytic replication. . J. Virol. ,
2183–2194.
Li, M., Lee, H., Yoon, D., Albrecht, J., Fleckenstein, B., Neipel, F., & Jung, J. (1997 ). Kaposi’s
sarcoma-associated herpesvirus encodes a functional cyclin. . J. Virol. , 1984–1991.
Longnecker R, N. F. (2007. ). Introduction to the human γ-herpesviruses. In: Arvin A,
Campadelli-Fiume G, Mocarski E, et al., editors. Human Herpesviruses: Biology,
Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; , Chapter
22.
Lorenzo, M., Jung, J., & Ploegh, H. (2002 ). Kaposi’s sarcoma-associated herpesvirus K3 utilizes
the ubiquitin-proteasome system in routing class major histocompatibility complexes to
late endocytic compartments. J. Virol. , 5522–5531.
Lukac DM, Y. Y.-F. (2007. ). Human Herpesviruses: Biology, Therapy, and
Immunoprophylaxis. . Cambridge: Cambridge University Press; , Chapter 26.
M.M. Alba, D. L. (2001). VIDA: a virus database system for the organization of animal virus
genome open reading frames . Nucleic Acids Res., 133-136.
Mahnke YD, B. T. (2013 ). The who's who of T-cell differentiation: human memory T-cell
subsets. . EurJ Immunol. John Wiley & Sons, Ltd; , 2797–2809.

177

Majerciak, V., Pripuzova, N., McCoy, J., Gao, S., & Zheng, Z. (2007 ). Targeted disruption of
Kaposi’s sarcoma-associated herpesvirus ORF57 in the viral genome is detrimental for
the expression of ORF59, K8alpha, and K8.1 and the production of infectious virus. J.
Virol. , 1062–1071.
Majerciak, V., Yamanegi, K., & Zheng, Z. G.-a.–1. (2006 ). Gene structure and expression of
Kaposi’s sarcoma-associated herpesvirus ORF56, ORF57, ORF58, and ORF59. . J. Virol.
, 11968–11981.
Månsson, A. A. (2006). A distinct Toll-like receptor repertoire in human tonsillar B cells,
directly activated by PamCSK, R-837 and CpG-2006 stimulation. . Immunology, , 118(4),
539–548. .
Meads, M., & Medveczky, P. (2004 ). Kaposi’s sarcoma-associated herpesvirus-encoded viral
interleukin-6 is secreted and modified differently than human interleukin-6: Evidence for
a unique autocrine signaling mechanism. . J. Biol. Chem. , 51793–51803.
Medina F, S. C.-C.-G. (2002). The heterogeneity shown by human plasma cells from tonsil,
blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of
adhesion molecule expression. . Blood. , 2154-2161.
Meggetto F, C. E. (2001 ). Detection and characterization of human herpesvirus-8—Infected
cells in bone marrow biopsies of human immunodeficiency virus—Positive patients. .
Human Pathology. , 288–291.
Mesri EA, C. E. (2010 ). Kaposi's sarcoma and its associated herpesvirus. . Nat Rev Cancer. ,
707–719.
Minhas, V. &. (2014). Epidemiology and transmission of Kaposi's sarcoma-associated
herpesvirus. . Viruses, 4178–4194.
Moore, P., Boshoff, C., Weiss, R., & Chang, Y. (1996 ). Molecular mimicry of human cytokine
and cytokine response pathway genes by KSHV. . Science , 1739–1744.
Moore, P., Gao, S., Dominguez, G., Cesarman, E., Lungu, O., Knowles, D., . . . Chang, Y.
(1996). Primary characterization of a herpesvirus agent associated with Kaposi’s
sarcomae. . J. Virol. , 549–558.
Muniraju M, M. L. (2019). Kaposi Sarcoma-Associated Herpesvirus Glycoprotein H Is
Indispensable for Infection of Epithelial, Endothelial, and Fibroblast Cell Types.
Longnecker RM, editor. J Virol. , 140.
Myoung J, G. D. (2011 ). Active lytic infection of human primary tonsillar B cells by KSHV and
its noncytolytic control by activated CD4+ T cells. . J Clin Invest. , 1130–1140.
Myoung J, G. D. (2011). Infection of primary human tonsillar lymphoid cells by KSHV reveals
frequent but abortive infection of T cells. . Virology. , 1–11.

178

Myoung, J., & Ganem, D. (2011 ). Generation of a doxycycline-inducible KSHV producer cell
line of endothelial origin: Maintenance of tight latency with efficient reactivation upon
induction. . J. Virol. Methods , 12–21.
Nabiee R., B. S. (2020). An Update of the Virion Proteome of Kaposi Sarcoma-Associated
Herpesvirus. Viruses, 1382.
Naranatt, P., Krishnan, H., Svojanovsky, S., Bloomer, C., Mathur, S., & Chandran, B. (2004).
Host Gene Induction and Transcriptional Reprogramming in Kaposi’s SarcomaAssociated Herpesvirus (KSHV/HHV-8)-Infected Endothelial, Fibroblast, and B Cells. .
Cancer Res, 72-84.
Neipel, F., Albrecht, J., Ensser, A., Huang, Y., Li, J., Friedman-Kien, A., & Fleckenstein, B.
(1997 ). Human herpesvirus 8 encodes a homolog of interleukin-6. . J. Virol. , 839–842.
Neuwirth E. RColorBrewer: ColorBrewer Palettes [Internet]. Available: https://CRAN.Rproject.org/package=RColorBrewer.
Newton, R., Labo, N., Wakeham, K., Marshall, V., Roshan, R., Nalwoga, A., . . . al., e. (2018).
Determinants of Gammaherpesvirus Shedding in Saliva Among Ugandan Children and
Their Mothers. . J. Infect. Dis. , 892–9.
Nicol SM, S. S. (2016 ). Primary B Lymphocytes Infected with Kaposi's Sarcoma-Associated
Herpesvirus Can Be Expanded In Vitro and Are Recognized by LANA-Specific CD4+ T
Cells. . Frueh K, editor. J Virol. American Society for Microbiology , 3849–3859.
Nishimura, M., Watanabe, T., Yagi, S., Yamanaka, T., & Fujimuro, M. (2017 ). Kaposi’s
sarcoma-associated herpesvirus ORF34 is essential for late gene expression and virus
production. . Sci. Rep. , 329.
Ohno, S., Steer, B., Sattler, C., & Adler, H. (2012). ORF23 of murine gammaherpesvirus 68 is
non-essential for in vitro and in vivo infection. . J. Gen. Virol. , 93 Pt 5, 1076–1080.
Pauk J, H. M. (2000 ). Mucosal shedding of human herpesvirus 8 in men. . N Engl J Med.
Massachusetts Medical Society , 1369–1377.
Paulose-Murphy, M., Ha, N.-K., Xiang, C., Chen, Y., Gillim, L., Yarchoan, R., . . . Zeichner, S.
(2001 ). Transcription Program of Human Herpesvirus 8 (Kaposi’s Sarcoma-Associated
Herpesvirus). . J. Virol. , 4843–4853.
Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S., Kundu, D., . . .
al., e. (2019 ). The PRIDE database and related tools and resources in 2019: Improving
support for quantification data. Nucleic Acids Res. , 442–450.
Perez-Riverol, Y., Xu, Q., Wang, R., Uszkoreit, J., Griss, J., Sanchez, A., . . . al, e. (2016).
PRIDE Inspector Toolsuite: Moving towards a universal visualization tool for proteomics
data standard formats and quality assessment of ProteomeXchange datasets. Mol. Cell.
Proteom. , 305–317.
179

Petra D, P. K. (2015). Polyclonal, newly derived T cells with low expression of inhibitory
molecule PD-1 in tonsils define the phenotype of lymphocytes in children with Periodic
Fever, Aphtous Stomatitis, Pharyngitis and Adenitis (PFAPA) syndrome. . Molecular
Immunology. Elsevier, 139-147.
Powles T, R. D. (2009 ). Highly Active Antiretroviral Therapy and the Incidence of Non-AIDSDefining Cancers in People With HIV Infection. . Journal of Clinical Oncology. , 884–
890.
Pozharskaya, V., Weakland, L., Zimring, J., Krug, L., Unger, E., Neisch, A., . . . Offermann, M.
(2004 ). Short duration of elevated vIRF-1 expression during lytic replication of human
herpesvirus 8 limits its ability to block antiviral responses induced by alpha interferon in
BCBL-1 cells. J. Virol. , 6621–6635.
Qi, J., Han, C., Gong, D., Liu, P., Zhou, S., & Deng, H. (2015 ). Murine Gammaherpesvirus 68
ORF48 Is an RTA-Responsive Gene Product and Functions in both Viral Lytic
Replication and Latency during In Vivo Infection. J. Virol. , 5788–5800.
Quiceno, J. (2010). Characterization of Kaposi’s Sarcoma-Associated Herpesvirus Open
Reading Frames 58 and 27. Thesis. South Orange, NJ, USA, : Seton Hall University, .
R. Renne, W. Z. (1996 ). Lytic growth of Kaposi's sarcoma-associated herpesvirus (human
herpesvirus 8) in culture . Nat. Med., 342-346.
R. Rozen, N. S. (2008). Virion-wide protein interactions of Kaposi's sarcoma-associated
herpesvirus. J. Virol. , 4742-4750.
R. Sarid, O. F. (1998 ). Transcription mapping of the Kaposi's sarcoma-associated herpesvirus
(human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1) . J.
Virol. , 1005-1012.
R. Sun, S. L. (1998 ). A viral gene that activates lytic cycle expression of Kaposi's sarcomaassociated herpesvirus . Proc. Natl. Acad. Sci. U.S.A., , 10866-10871.
R.G. Jenner, M. A. (2001). Kaposi's sarcoma-associated herpesvirus latent and lytic gene
expression as revealed by DNA arrays . J. Virol. , 891-902.
R: A language and environment for statistical computing [Internet]. Vienna, Austria: R
Foundation for Statistical Computing. Available: https://www.R-project.org.
Rabkin CS, B. R. (1991 ). Increasing incidence of cancers associated with the human
immunodeficiency virus epidemic. . Int J Cancer. , 692–696.
Ramirez CN, C. S. (2009.). KSHV 12th International Workshop. KSHV 12th International
Workshop.

180

Rappocciolo G, H. H. (2008 ). Human herpesvirus 8 infects and replicates in primary cultures of
activated B lymphocytes through DC-SIGN. . J Virol. American Society for Microbiology
Journals, 4793–4806.
Roizman, B., Carmichael, L., Deinhardt, F., De-The, G., Nahmias, A., Plowright, W., . . . Wolf,
K. (1981 ). Herpesviridae. Definition, provisional nomenclature, and taxonomy. The
Herpesvirus Study Group, the International Committee on Taxonomy of Viruses.
Intervirology , 201–217.
Russo, J., Bohenzky, R., Chien, M.-C., Chen, J., Yan, M., Maddalena, D., . . . al., e. (1996 ).
Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). . Proc. Natl.
Acad. Sci. USA , 14862–148.
Sakakibara, S. &. (2011). Viral interleukin-6: role in Kaposi's sarcoma-associated herpesvirus:
associated malignancies. Journal of interferon & cytokine research : the official journal of
the International Society for Interferon and Cytokine R. journal of interferon & cytokine
research : the official journal of the International Society for Interferon and Cytokine
Research, 791-801.
Sakakibara, S., & Tosato, G. (2011). Viral interleukin-6: Role in Kaposi’s sarcoma-associated
herpesvirus: Associated malignancies. . J. Interferon Cytokine Res. , 791–801.
Sander, G., Konrad, A., Thurau, M., Wies, E., Leubert, R., Kremmer, E., . . . Stürzl, M. (2007 ).
Intracellular Localization Map of Human Herpesvirus 8 Proteins. . J. Virol. , 1908–1922.
Sathish N, W. X. (2012 ). Tegument Proteins of Kaposi's Sarcoma-Associated Herpesvirus and
Related Gamma-Herpesviruses. . Front Microbiol. , 98.
Schmidt, K., Wies, E., & Neipel, F. (2011 ). Kaposi’s sarcoma-associated herpesvirus viral
interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility
complex class II expression. . J. Virol. , 4530–4537.
Shevchenko, A., Tomas, H., Havlis, J., Olsen, J., & Mann, M. (2006 ). In-gel digestion for mass
spectrometric characterization of proteins and proteomes. . Nat. Protoc. , 2856–2860.
Shin, H., Decotiis, J., Giron, M., Palmeri, D., & Lukac, D. (2013). Histone Deacetylase Classes I
and II Regulate Kaposi’s Sarcoma-Associated Herpesvirus Reactivation. . J. Virol. ,
1281–1292.
Soulier J, G. L.-H. (1995). Kaposi“s sarcoma-associated herpesvirus-like DNA sequences in
multicentric Castleman”s disease. . Blood, 1276–1280.
Speck, S., & Ganem, D. (2010). Viral Latency and Its Regulation: Lessons from the γHerpesviruses. . Cell Host Microbe, 100–115.
Stanisce L, S. E. ( 2018 ). Differential cellular composition of human palatine and pharyngeal
tonsils. . Archives of Oral Biology., 80–86.

181

Swanton, C., Mann, D., Fleckenstein, B., Neipel, F., Peters, G., & Jones, N. (1997 ). Herpes viral
cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. . Nature , 184–187.
Thakur, S., Geiger, T., Chatterjee, B., Bandilla, P., Fröhlich, F., Cox, J., & Mann, M. (2011).
Deep and hoverly sensitiveproteome coverage by LC-MS/MS without prefractionation. .
Mol Cell Proteom. , 10.
Totonchy J, O. J. (2018 ). KSHV induces immunoglobulin rearrangements in mature B
lymphocytes. . Coscoy L, editor. PLoS Pathog. , e1006967.
Trus BL, H. J. (2001). Capsid structure of Kaposi's sarcoma-associated herpesvirus, a
gammaherpesvirus, compared to those of an alphaherpesvirus, herpes simplex virus type
1, and a betaherpesvirus, cytomegalovirus. . J Virol. , 2879-2890.
Tsirigos KD, P. C. (2015 ). The TOPCONS web server for consensus prediction of membrane
protein topology and signal peptides. Nucleic Acids Res. , 43.
Uldrick TS, W. V. (2010 ). An interleukin-6-related systemic inflammatory syndrome in patients
co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without
Multicentric Castleman disease. . CLIN INFECT DIS. , 350–358.
van Zelm MC, S. T. (2007 ). Replication history of B lymphocytes reveals homeostatic
proliferation and extensive antigen-induced B cell expansion. . J Exp Med. Rockefeller
Univ Press; , 645–655.
Varon LS, D. R. (2017). Characterization of tonsillar IL10 secreting B cells and their role in the
pathophysiology of tonsillar hypertrophy. Sci Rep. Springer US; , 1–9.
Vieira J, H. M. (1997 ). Transmissible Kaposi“s sarcoma-associated herpesvirus (human
herpesvirus 8) in saliva of men with a history of Kaposi”s sarcoma. . J Virol. American
Society for Microbiology (ASM), 7083–7087.
Vieira, J., O’Hearn, P., Kimball, L., Chandran, B., & Corey, L. (2001). Activation of Kaposi’s
Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Lytic Replication by Human
Cytomegalovirus. . J. Virol. , 1378–1386.
Wabinga HR, P. D.-M. (1993 ). Cancer in Kampala, Uganda, in 1989–1991: changes in
incidence in the era of AIDS. Int J Cancer. , 26–36.
West J, D. B. (2008 ). Upregulation of the TLR3 pathway by Kaposi's sarcoma-associated
herpesvirus during primary infection. J Virol. , 5440-9.
West JA, G. S. ( 2011 ). Activation of plasmacytoid dendritic cells by Kaposi's sarcomaassociated herpesvirus. J Virol., 895-904.
Wickham H. ggplot2: Elegant Graphics for Data Analysis [Internet]. New York: SpringerVerlag. Available: http://ggplot2.orgyear.

182

Wies, E., Mori, Y., Hahn, A., Kremmer, E., Stürzl, M., Fleckenstein, B., & Neipel, F. (2008 ).
The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected
primary effusion lymphoma cells. . Blood J. Am. Soc. Hematol. , 320–327.
Wu, F., Ahn, J.-H., Alcendor, D., Jang, W.-J., Xiao, J., Hayward, S., & Hayward, G. (2001).
Origin-independent assembly of Kaposi’s sarcoma-associated herpesvirus DNA
replication compartments in transient cotransfection assays and association with the
ORF-K8 protein and cellular PML. J. Virol. , 75, 1487–1506.
Wu, J., Avey, D., Li, W., Gillen, J., Fu, B., Miley, W., . . . Zhu, F. (2015). ORF33 and ORF38 of
Kaposi’s Sarcoma-Associated Herpesvirus Interact and Are Required for Optimal
Production of Infectious Progeny Viruses. . J. Virol. , 1741–1756.
Yates, J. 3. (1998 ). Mass spectrometry and the age of the proteome. . J. Mass Spectrom. , 1–19.
Ye, F., Zhou, F., Bedolla, R., Jones, T., Lei, X., Kang, T., . . . Gao, S.-J. (2011). Reactive
Oxygen Species Hydrogen Peroxide Mediates Kaposi’s Sarcoma-Associated Herpesvirus
Reactivation from Latency. . PLoS Pathog. , e1002054.
Yu, F., Harada, J., Brown, H., Deng, H., Song, M., Wu, T.-T., . . . al., e. (2007). Systematic
Identification of Cellular Signals Reactivating Kaposi Sarcoma–Associated Herpesvirus. .
PLoS Pathog. .
Zhang, J., Xin, L., Shan, B., Chen, W., Xie, M., Yuen, D., . . . Ma, B. (2012). PEAKS DB:De
NovoSequencing Assisted Database Search for Sensitive and Accurate Peptide
Identification. . Mol. Cell. Proteom. , 11.
Zhang, Y., Fonslow, B., Shan, B., Baek, M.-C., & Yates, J. (2013 ). Protein Analysis by
Shotgun/Bottom-up Proteomics. . Chem. Rev. , 2343–2394.
Zheng, W. X. (2020). Toll-like receptor-mediated innate immunity against herpesviridae
infection: a current perspective on viral infection signaling pathways. . J Virology , 192.
Zhou, F.-C. e. (2002). “Efficient infection by a recombinant Kaposi's sarcoma-associated
herpesvirus cloned in a bacterial artificial chromosome: application for genetic
analysis..”.”Journal of virology vol. 76,12, 6185-96.
Zhu, F. (2005). Virion Proteins of Kaposi’s Sarcoma-Associated Herpesvirus. . J. Virol. , 800811.
Zhu, F., King, S., Smith, E., Levy, D., & Yuan, Y. A. (2002). Kaposi’s sarcoma-associated
herpesviral protein inhibits virus-mediated induction of type I interferon by blocking
IRF-7 phosphorylation and nuclear accumulation. Proc. Natl. Acad. Sci. USA , 5573–
5578.
Zhu, F., Sathish, N., & Yuan, Y. (2010). Antagonism of Host Antiviral Responses by Kaposi’s
Sarcoma-Associated Herpesvirus Tegument Protein ORF45. . PLoS ONE , e10573.

183

Appendix A. Supplementary data from
Chapter 2
A.1

Gating schemes for tonsil lymphocyte lineages.

184

185

Flow cytometry data for a baseline uninfected sample from a 2-year-old male
donor showing representative gating and lineage definitions used in the study for
(A) B cell lineages based on vanZelm et. al. 2007 (van Zelm MC, 2007 ) and (B)
T cell lineages based on Mahnke et. al. 2013 (Mahnke YD, 2013 ).
A.2

Analyzed flow cytometry data.

Values derived from flow cytometry analysis for baseline B cell and T cell lineage
frequencies, overall infection frequency at 3dpi and lineage-specific infection
frequencies for B cells. Comments associated with column headers contain detailed
definitions for each subset. https://doi.org/10.1371/journal.ppat.1008968.s002 (XLSX)
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Donor Age
4
4
12
12
15
18
19
20
31
32
33
35
36
37
38
39
39
40
40
41
41
42
42
43
44
45
46
46
47
48
48
50
50
51
51
52
53
54
55
585756596261606564
66

2
2
8
8
5
2
2
3
18
36
18
36
31
2
41
30
30
57
57
26
26
21
21
2
29
46
20
20
30
21
21
31
31
30
30
55
18
7
48
442829214220281936
65

Sex

2
2
2
2
2
1
1
2
1
1
1
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
2
2
2
1
1
2
2
2
2
1
1
1
1
21211
2

Race

1
1
2
2
1
1
1
1
1
0
0
2
3
1
1
2
2
0
0
2
2
2
2
1
2
2
1
1
1
0
0
1
1
5
5
5
4
1
2
212001
1

19pos_B 20neg_PC all_B
1.02 8.39
1.02 8.39
0.66 8.58
0.66 8.58
0.96 14.8
0.77 4.96
0.31 5.6
0.58 4.21
0.85 14
0.96 15.5
0.21 4.92
0.81 17.6
1.66 4.4
5.99 5.25
1.02 6.56
2.75 11.1
2.75 11.1
3.91 4.23
3.91 4.23
10.5 3.25
10.5 3.25
3.87 7.9
3.87 7.9
1.11 21.4
6.87 11.3
6.41 17.7
1.87 18.2
1.87 18.2
2.28 12.8
1.77 7.54
1.77 7.54
1.91 7.39
1.91 7.39
1.71 10.5
1.71 10.5
2.11 6.62
1.84 5.99
0.58 23.5
0.88 5.91
0.1.4.10.0.52717429237619 4.2.19.3.3.6.20515386180948
1.59 1.87

83.8
83.8
83.7
83.7
88
86.3
86
87.2
81.7
64
79
80.1
78.9
72.4
82.7
77.6
77.6
69.4
69.4
73.9
73.9
59.8
59.8
83.8
55.1
57.8
85.2
85.2
81.2
76.3
76.3
84.3
84.3
74.8
74.8
62.8
83.1
90.7
85.2
67.82.65.69.54.61.76.74698688571
60.3

all_PC DN
2.38
2.38
1.51
1.51
1.25
1.89
0.91
1.29
0.96
0.98
1.3
1.17
0.55
1.1
1.63
1.27
1.27
1.39
1.39
1.21
1.21
1.54
1.54
2.41
2.17
3.68
8.77
8.77
1.74
1.31
1.31
1.84
1.84
0.81
0.81
1.43
1.07
2.71
1.93
1.0.2.1.1.4739163865145
0.55
2.18
2.18
2.79
2.79
1.1
3.85
4.01
1.97
4.65
2.69
4.51
2.66
2.48
2.12
1.98
2.55
2.55
3.48
3.48
1.24
1.24
4.19
4.19
2.16
4.43
2.42
3.64
3.64
1.67
2.02
2.02
4.38
4.38
1.51
1.51
2.59
3.37
2.38
2.59
2.4.2.5.4.4.4595083170352
2.41

Mem Na
14.1
14.1
8.58
8.58
17.3
11.1
5.13
7.88
33.4
27.6
21.2
22.6
19.6
34.2
14.4
15.3
15.3
13.9
13.9
28.2
28.2
18.7
18.7
9.09
28.5
22.9
10.8
10.8
32.3
33.4
33.4
18.7
18.7
24.5
24.5
31.2
16.3
11.9
27
17.19.24.20.21.16.19159645
30.3
19.5
19.5
38.9
38.9
35.2
29.1
50.5
27.3
38
56
40.5
53.8
45.2
45.9
36
40.2
40.2
58.6
58.6
40.6
40.6
35.2
35.2
33.7
31
41.6
42.3
42.3
14.3
22.1
22.1
38.8
38.8
49.6
49.6
35.1
45.1
27
38.1
50.55.38.14.34.32.20308367257
31.7

NE
6.75
6.75
7.9
7.9
13.5
12.9
6.07
7.16
7.59
3.82
7.73
10.3
14.9
7.97
10.9
11.3
11.3
8.17
8.17
20.2
20.2
9.08
9.08
8.85
10
15.7
8.19
8.19
10.4
9.53
9.53
19.4
19.4
13.9
13.9
18.3
5.65
17
13.6
11.8.15.4.17.16.14.9.032555498341
9.86

GC
42.6
42.6
17.6
17.6
20.4
28.5
18.7
36.4
11.9
6.77
15.2
6.67
11.1
6.06
23.3
24
24
11.2
11.2
6.62
6.62
25.8
25.8
26.9
15.1
8.24
15.3
15.3
29.9
26
26
6.99
6.99
6.27
6.27
7.98
18.6
25.9
8.4
7.9.41.11.14.6.4.49209465138
6.8

PB
3.03
3.03
2.04
2.04
2.19
1.59
1.52
2.93
0.87
0.59
3.61
0.11
0.61
0.61
1.53
1.51
1.51
0.82
0.82
0.32
0.32
1.18
1.18
1.86
2.35
1.28
4.93
4.93
2.62
1.48
1.48
0.27
0.27
0.39
0.39
0.65
1.33
1.64
0.44
0.6.1.583296980965
0.68

Trans dp_B
9.76
9.76
20.9
20.9
9.18
11.2
13.4
15.2
2.48
1.49
5.39
2.46
4.68
1.62
9.49
3.69
3.69
2.22
2.22
1.43
1.43
3.96
3.96
15.3
6.46
4.19
6.06
6.06
7.11
4.32
4.32
9.18
9.18
3.04
3.04
2.88
8.67
11.7
7.88
10.5.7.14.5.12.3.4615284368592
17.7
82.8
82.8
83
83
87
85.5
85.7
86.6
80.9
62.8
78.9
79.2
77
66.4
81.4
74.5
74.5
65.1
65.1
63.2
63.2
55.6
55.6
82.8
48.2
51.4
83.4
83.4
78.9
74.5
74.5
82.4
82.4
73.2
73.2
60.7
81.2
90.1
84.3
67.72.80.61.58.69.53.75.613786196
58.7

20pos_PC CD4
2.34
2.34
1.48
1.48
1.13
1.88
0.9
1.28
0.83
0.77
1.3
1
0.47
0.72
1.57
0.91
0.91
1.22
1.22
0.87
0.87
1.1
1.1
2.26
0.87
1.92
8.56
8.56
1.42
1.21
1.21
1.74
1.74
0.65
0.65
1.33
0.98
2.61
1.9
1.0.2.1.5.1.1.4718156163189184
0.52
68.2
68.2
47.8
47.8
70.9
70.4
63.4
61.7
71.7
83.7
66.1
75.2
80
71.4
68
70.4
70.4
72.8
72.8
69.8
69.8
57.6
57.6
76.6
58.6
63.5
72.1
72.1
71
66.5
66.5
78.5
78.5
77.9
77.9
79.6
66.1
62.5
63
66.71.62.51.56.63.72.73.7492362393
68.1

CD4_CM CD4_Na CD4_SCM CD4_EM CD4_TM CD4_TE CD4_TEMRA CD4_RA CD4_RO CD8
5.24 5.18 1.34 0.78 81.4 0.39 3.01 10.9 85.6
5.24 5.18 1.34 0.78 81.4 0.39 3.01 10.9 85.6
16.7 11.4 2.58 0.98 63 0.49 1.23 15.9 81
16.7 11.4 2.58 0.98 63 0.49 1.23 15.9 81
9.48 18.5 1.02 0.61 66.1 0.14 0.55 21.9 74.7
15.7 12 2.26 0.75 64.6 0.21 1 16 80.6
15.5 17.8 1.57 0.63 58.1 0.78 0.31 19.9 74.7
9.6 12.5 2.4 0.41 69.7 0.21 1.23 17.1 79.6
5.18 4.98 1 1.99 79.1 0 0.4 8.76 87.8
20.2 10 1.2 0.23 63.7 0.028 0.97 13 85.9
14.7 18 1.95 0.8 61.3 0.069 0.66 21 77
19.3 4.25 0.6 0.37 70.2 0 0.75 7.69 89
11.5 25.5 0.86 1.03 50.8 0 0.56 32.6 64
22.4 19.9 2.48 0.37 49.5 0 0.64 22.8 73.7
13.1 8.35 2.06 0.72 71.2 0.36 0.45 12.7 84.6
7.26 8.71 1.7 0.5 73.8 0.19 1.51 16.3 81.8
7.26 8.71 1.7 0.5 73.8 0.19 1.51 16.3 81.8
9.23 27 6.39 0.26 40.4 0.58 0.84 45.3 48.1
9.23 27 6.39 0.26 40.4 0.58 0.84 45.3 48.1
7.54 13.5 2.69 0.91 64 0 0.69 25 70.3
7.54 13.5 2.69 0.91 64 0 0.69 25 70.3
18.1 10.4 1.95 1.15 55.8 1.72 1.03 18.5 73.6
18.1 10.4 1.95 1.15 55.8 1.72 1.03 18.5 73.6
4.06 2.17 1.17 0.38 89 0.069 1.07 5.54 93
10.4 23.7 0.68 1.07 54.8 0 3.22 31.3 67.4
8.52 11.5 0.26 0.92 74.3 0.26 0.79 14 83.5
5.3 8.65 0.093 1.49 78.7 0.19 0.93 12.2 86.5
5.3 8.65 0.093 1.49 78.7 0.19 0.93 12.2 86.5
5.64 8.54 0.96 0.6 72.6 0.14 3.63 18.4 79.5
9.59 9.57 0.76 0.37 69.3 0.022 2.19 19 78.7
9.59 9.57 0.76 0.37 69.3 0.022 2.19 19 78.7
15.1 8.92 1.52 0.84 67.1 0.04 3.8 15.2 82.7
15.1 8.92 1.52 0.84 67.1 0.04 3.8 15.2 82.7
12.8 5.25 2.97 0.48 72.3 0.13 1.46 10.6 87.1
12.8 5.25 2.97 0.48 72.3 0.13 1.46 10.6 87.1
17.7 24.4 2.46 0.75 48.5 0.032 1 30 65.7
8.94 12.8 1.35 0.34 70.2 0 0.62 17.8 78.7
7.87 3.42 0.16 1.27 81.5 0.079 2.62 6.6 89.1
21.7 4.23 1.14 0.69 62.8 0.13 2.27 9.34 85.2
29.38.20.3.32.37.41.36.19.798127282 14.9.1.18.8.7.9.26.7.212718249215 4.1.0.5.2.0.1.31481548526137 0.1.0.0.2158316358349 47.48.54.91.38.47.49.44.5986264 0.049114800 0.3.0.1.0.84892546373419 8.19.3.13.7.5.10.32.19916953871841 88.77.94.68.89.86.65.7861843651
36.6 13.5 2.98 0.15 42.8 0.11 0.95 19.4 76
15.5
15.5
40.8
40.8
14.3
17.7
19.9
23.1
19.9
11.4
24
16.3
12.2
21.2
13.2
22.9
22.9
19.6
19.6
21.9
21.9
31.7
31.7
10.8
29.7
28.5
18.7
18.7
15.4
20.5
20.5
8.32
8.32
8.61
8.61
14
25.7
20.2
26.9
17.20.27.22.18.14.35291629257
26.1

CD8_CM CD8_Na CD8_SCM CD8_EM CD8_TM CD8_TE CD8_TEMRA CD8_RA CD8_RO GFP
0.25 11 1.96 19.1 33.8 5.88 12.7 41.4 44.9
0.25 11 1.96 19.1 33.8 5.88 12.7 41.4 44.9
1.58 7.63 1.66 10.8 56.6 1.58 8.93 26.3 62.3
1.58 7.63 1.66 10.8 56.6 1.58 8.93 26.3 62.3
0.68 20.7 2.71 2.03 23.7 2.37 24.4 70.8 20.7
1.67 31.3 6 3.33 18.7 0.83 11.3 72.8 21.5
3.17 20 1.67 7.5 45.2 3.33 3.83 38.8 52.3
0.91 17 2.74 10.1 14.6 1.83 31.3 70 19.6
0 11.5 0 10.1 40.3 3.6 15.1 43.2 51.8
0.31 22.2 0.84 3.55 48.1 0.52 7.93 45.2 52.4
0.96 10.4 0.29 2.2 75.7 1.53 1.63 17.2 78
0.69 4.48 0.34 11.4 56.6 0.34 8.97 27.9 61.4
1.41 21.7 0 4.23 38.6 1.41 10.7 49.9 46.5
1.85 12.3 0.93 11.1 55.9 0.62 2.78 26.5 69.1
0.46 34.3 0.93 1.39 29.6 0.93 13 67.1 31
0.39 6.16 0.13 5.25 62.2 1.04 7.39 29.9 68.1
0.39 6.16 0.13 5.25 62.2 1.04 7.39 29.9 68.1
0.48 12.4 2.87 3.35 53.1 0 7.66 40.7 49
0.48 12.4 2.87 3.35 53.1 0 7.66 40.7 49
0 22.1 1.09 7.12 40.3 0.36 10.8 49.1 39.6
0 22.1 1.09 7.12 40.3 0.36 10.8 49.1 39.6
0.83 11.7 1.25 5.42 45 1.25 8.75 44.8 45.8
0.83 11.7 1.25 5.42 45 1.25 8.75 44.8 45.8
0.49 11.4 2.43 7.3 23.8 3.16 17.3 62 29.2
1.54 24.7 0.39 4.63 38.8 1.16 11 52.7 45.4
0.87 2.04 0.58 2.62 71.4 0.58 6.71 21.6 72
0.36 10.8 0.36 2.52 52.2 3.24 11.5 37.8 56.5
0.36 10.8 0.36 2.52 52.2 3.24 11.5 37.8 56.5
0.42 10.4 0.42 4.86 40.4 2.75 16.7 48.4 45
0.78 15.5 0.71 4.81 41.5 1.06 15.2 50 42.9
0.78 15.5 0.71 4.81 41.5 1.06 15.2 50 42.9
3.4 23 2.64 9.06 25.7 2.26 15.5 55.1 34.7
3.4 23 2.64 9.06 25.7 2.26 15.5 55.1 34.7
0 5.04 0.96 9.59 67.9 2.16 4.56 18.2 77.9
0 5.04 0.96 9.59 67.9 2.16 4.56 18.2 77.9
1.48 19.4 0.37 1.29 36 2.03 17 57.4 34.9
0.58 26.4 1.59 6.79 31.1 0.29 7.8 60.1 34.1
3.45 3.45 0.25 23.6 54.7 0 9.36 16.3 55.9
4.14 5.47 1.33 2.66 65.7 1.04 4.44 22.2 66.9
2.3.1.4.2.4.1.8508243885324 18.20.10.3.35.19.20.46.517354423 3.1.0.6.3.1.2.4.0857783893758762 22.15.8.38.43.41.39.21.21078547 40.42.46.67.7.20.26.27.1126418467 1.0.0.4737536152481259 11.5.2.3.4.3.2.716024162897 29.31.21.37.22.25.24.60.29912148 62.66.58.48.50.66.70.33.749585461
3.07 6.11 0.74 70.1 14.4 1.24 0.69 5.16 82.4
2.58
1.65
1.15
1.21
1.52
1.39
2.63
1.62
3.27
2.24
1.77
1.04
1.33
1.29
2.43
1.15
1.12
2.66
2.18
2.23
2.43
1.51
1.65
1.1
1.12
1.23
2.09
1.78
1.58
1.11
1.04
1.24
1.01
1.4
1.59
1.65
1.5
1.43
1.5
1.0.2.3.2.2.274002936289658
1.64

19PC_GFP 20PC_GFP PC_GFP DN_GFP Mem_GFP Na_GFP NE_GFP GC_GFP PB_GFP Trans_GFP
57.1 25.6 27.1 0 2.16 2.23 3.45 2.59 2.61 2.05
40 19 20.9 3.64 2.15 0.39 1.14 1.87 1.49 1.12
100 7.14 16.7 1.76 2.51 1.03 2.23 1.81 1.2 0.68
75 3.33 11.8 2.16 2.22 1.03 1.62 1.91 0.62 0.89
60 23.3 28.6 5.88 1.87 1.44 1.32 2.02 3.95 1.13
66.7 7.69 10.9 0.64 1.51 0.31 1.2 1.86 1.85 1.07
81.8 23.5 46.4 0 10.7 2 2.68 3.2 2.17 2.01
100 17.5 21.4 3.08 2.51 0.44 2.71 2.67 2.35 1.17
0 22.2 22.2 7.5 3.47 3.12 1.75 3.62 0 2.59
25 33.3 34 2.12 1.43 1.01 4.31 2.8 7.04 2.02
0 35.7 35.1 3.14 2.76 0.96 3.28 2.18 1.83 1.37
63.6 8.4 12.7 0.71 1.33 0.21 2.05 1.12 2.82 0.64
50 20 21.1 1.04 2.32 0.18 2.42 1.18 2.94 0.71
77.3 14.3 32.1 0.46 1.9 0.16 2.73 0.99 6.25 0.48
57.1 11.8 13.7 0.5 1.05 0.66 7.14 3.51 2.32 2.02
30 12.1 14 2.06 1.58 0.6 1.17 2.54 1 0.75
0 12.9 12.6 2.58 1.62 0.52 1.71 2.43 1.79 0.63
100 44.4 79.2 2.52 5.86 0.62 6.01 3.19 0 1.63
100 35.3 47.6 0.52 2.84 0.87 2.96 2.46 0 1.96
100 30.1 32.7 2.55 2.97 0.59 4.42 2.71 6.78 1.67
83.3 14.2 17.7 1.38 2.3 0.35 3.46 2.78 4.66 1.66
100 7.41 24.2 2.56 3.24 0 1.95 1.21 0 1.05
85.7 7.81 15.5 1.28 2.58 0.35 3.79 1.72 3.97 0.81
66.7 12.2 18.2 1.31 0.97 0.23 1.85 2 0 0.96
41.7 13.3 21.4 0 0.95 0.3 1.81 1.03 1.89 0.83
0 14.3 13.5 0.71 1.04 0 1.65 1.41 2.04 0
66.7 10.7 14.5 2.49 3.01 0.59 3.85 3.66 6.25 1.48
55.6 9.26 12.8 2.33 3 0.53 4.16 2.57 5 1.28
30.8 13.5 14.2 0.22 1.39 0.3 1.83 1.41 1.45 1.16
12.5 3.68 3.91 1.46 1.29 0.57 0.74 1.44 1 0.59
8.82 2.48 2.93 1.04 1.09 0.13 1.27 1.38 0.58 0.64
33.3 3.93 4.95 1.4 0.81 0.6 1.36 1.17 0 0.86
28.6 3.52 4.26 2.3 0.97 1 1.12 1.74 0 1.08
33.3 10.4 11.2 2.15 1.34 0.41 1.63 3.07 1.68 1.01
0 8.7 9.29 3.34 1.71 0.5 1.86 2.83 0.56 0.73
33.3 3.89 4.56 3.34 0.79 1.37 1.11 2.69 1.58 0.82
44.4 14.1 16.8 2.67 1.45 0.45 2.15 2.04 2.83 1.17
75 5.38 9.18 1.53 2.67 0.69 4.26 2.02 2.7 1.03
80 4.03 7.69 1.92 3.4 0 1.67 2.59 1.5 0.76
33.57.12.7525315 6.5.10.7.13.11.363682921 7.6.15.9.14.12.11.901899 0.1.2.1.79028590761 1.3.4.2.2.3.19085751842 0.0.0.62510120 0.1.4.1.98641792341 2.1.0.2.3.1296876958 1.3.5.3.1.71845607869 0.1.2.1.0.502248136274
33.1003 16.29.73 33.29.34 0 5.1.69 1.190 0.90 2.7545 6.1059 1.494
80 11.2 12.3 0.86 3.71 0.33 4.37 2.33 1.65 1.1

A.3

Analyzed flow cytometry data for B cell lineages at 3 days post infection.

Values derived from flow cytometry analysis for overall B cell lineage frequencies in Mock and KSHVinfected cultures at 3 days post-infection. Abbreviations and lineage definitions are as in S1 Table
comments. https://doi.org/10.1371/journal.ppat.1008968.s003 (XLSX)
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CD19B
1.74
1.2
1.45
0.98
1.11
1.23
1.14
1.39
1.38
0.76
2.53
2.38
1.63
1.05
0.47
0.61
0.27
0.43
8.19
5.55
0.91
1.02
0.58
0.77
0.69
0.74
0.23
0.14
0.2
0.38
1.76
2.14
2.73
3.92
2.57
2.25
1.9
1.63
3.56
3.65
1.15
1.06
1.23
1.15
0.37
0.44
0.54
0.72
7.34
9.29
6.11
6.76
3.68
5.12
5.98
6.63
1.18
0.84
1.13
1.06
0.72
1.13
6.24
6.96
2.07
1.22
1.73
2.38
2.89
2.84
5.69
5.1
2.9
3.13
2.04
1.66
4.98
4.89
3.28
3.19
3.3
2.13
8.16
10.1
6.54
8.36
1.15
1.64
1.38
1.15
3.48
3.77
7.05
6.23
1.7
1.88
2.58
3.22
0.74
1.28
0.21
0.35
0.18
0.23
0.2
0.17
0.099
0.094
0.23
0.26
0.41
0.58
0.22
0.18
0.51
1.11

CD19_PC
AllB
4.64
2.02
5.51
6.98
0.35
0.37
3.23
2.35
0
0
0
1.02
0
1.23
1.67
16.7
3.12
3.64
0.82
0
0
1.41
3.12
2.44
2.74
0
0
0
0
0
0.37
0
0
0
1.36
1.6
1.5
1.25
0.24
0.16
0.72
0.6
1.05
1.98
3.51
5.38
7.45
8.26
0
0
0.84
2.42
0.42
0.19
0.092
0.5
3.66
1.39
8.86
9.43
0
3.57
0.96
1.87
0.81
4.35
1.96
1.28
2.14
2.79
0.63
1.62
0.62
1.11
4.82
1.7
1.56
14.1
0.57
1.39
1.43
1.05
0.24
0.049
0.37
0.045
3.77
1.68
0.88
4.52
0.39
0.74
0.52
0.91
3.06
4.35
0
3.6
2.27
0.89
8.89
4.65
10.7
2.04
11.7
15.4
12.1
0
11
6.42
8.82
3.33
37.5
0
2.6
1.54

All_PC
49.6
53.7
49.6
57
84.1
85.8
86.5
85.4
55
57.2
87.7
85.7
80.7
82.9
88.2
86
84
83.5
85.4
82.9
54.4
57.3
41.8
48.3
53.2
56
54.1
56.3
57.8
49.5
80.5
70.4
85.8
85.6
83.3
83.5
88.2
87.9
91.2
94.1
93.1
94.2
93.1
92.9
69.9
67.4
70.4
69.3
82.1
78.5
80.4
84.1
83.4
81.6
85.1
88
69.3
70.1
71.2
66.3
89.2
93.4
52.2
54.3
50.3
44.4
90.7
90.4
91.4
89.6
83.4
89.1
84.3
84.4
84.6
79.7
41.6
68.8
92
92.2
92
91.7
94.6
94.2
96.2
96.6
60.6
80.5
94.8
93.9
92.7
91.8
90.7
92.2
53
53.1
82.2
82.6
82.4
82.8
67
70.9
72.2
74.8
69
67.4
68.4
74.7
86.6
84.7
81.8
79.7
91.5
89
74.8
77.6

DN
0.95
0.45
1.95
1.81
0.37
0.39
0.36
0.43
0.25
0.56
0.16
0.28
0.21
0.29
0.12
0.3
0.21
0.39
1.13
1.89
0.36
0.4
0.79
0.39
1.19
0.23
1.03
0.65
0.7
1.25
0.29
0.49
0.56
0.84
0.36
0.47
0.22
0.31
0.39
0.36
0.24
0.32
0.53
0.35
0.62
0.83
1.15
0.94
0.14
0.17
0.34
0.39
0.2
0.39
0.35
0.82
0.89
0.65
1.43
1
0.45
0.4
0.78
0.84
1.47
2.06
0.84
0.95
0.88
1.56
1.51
2.32
1.48
1.47
1.64
1.36
1.69
2.66
0.8
1.11
1.72
1.47
0.35
0.31
0.8
0.54
2.14
1.5
0.31
0.62
0.14
0.75
0.76
1.59
2.29
2.26
0.78
1.86
0.97
0.62
1.23
0.78
0.71
0.52
1.3
0.81
1.59
0.63
0.79
0.55
1.26
0.54
0.44
0.52
1.18
0.63

Mem
5.88
4.61
4.96
4.15
10.5
10.2
9.86
9.88
4.27
3.67
1.61
1.94
8.77
10.3
5.2
4.18
6.94
6.14
1.84
1.76
1.56
1.4
1.7
1.36
4.11
4.53
1.2
0.76
1.13
1.68
1.5
2.47
4.03
3.74
3.25
2.78
2.99
2.72
2.56
2.21
1.93
1.89
1.79
2.38
5.6
4.42
4.02
3.96
1.61
1.49
3.07
1.93
1.68
2.9
2.8
2.3
1.43
1.86
1.57
1.18
1.74
1.65
3.97
2.83
6.23
5.6
2.1
1.93
1.94
2.37
2.11
3.25
2.63
2.72
2.31
2.43
5.62
4.22
2.72
2.89
3.19
2.88
1.27
1.22
0.99
1.16
2
2.39
1.38
1.38
0.82
1
1.85
1.91
3.86
3.74
2.58
2.42
1.07
1.14
2.67
2
0.93
0.92
0.76
0.85
4.52
4.45
1.18
1.31
0.95
0.94
0.41
0.24
2.85
3.13

Na
7.95
5.96
8.45
6.18
40.9
41.2
43.1
44
5.65
7.13
57.4
58
32.1
35
23
29.4
30.8
33.9
9.28
9.73
3.36
2.96
4.28
3.85
4.52
2.94
1.33
0.97
1.48
1.64
1.69
2.61
26
24.2
7.43
7.14
6.98
7.28
6.73
5.25
6.65
6.41
6.83
6.36
54
54.9
52.3
55.2
9.52
11.7
10.1
9.42
22.8
24.1
21.2
22.1
11.2
10.6
10.9
10.3
9.42
8.19
23.2
23
20.7
19
10.5
10.8
10.5
11.4
30
26.1
15
14.8
14.1
13
44.9
33.2
21.5
22.6
22.7
20.9
8.93
9.73
8.84
9.5
21
15.2
6.05
6.34
7.01
8.56
11.3
9.72
28.7
28.3
17.8
19.7
7.13
7.35
3.88
4.36
4.47
4.34
5.3
5.27
10.5
10.7
5.92
6.72
9.4
9.87
7.24
8.56
6.35
5.6

NE
2.4
2.39
1.52
2.23
20.1
21.2
20.7
22.6
2.89
1.67
8.73
9.89
25.8
21.6
39
31.3
24
21.6
1.08
1.29
3.4
2.93
2.31
2.6
3.94
7.31
1.11
1.59
1.3
1.73
2.73
2.13
8.8
8.97
4.33
4.35
4.12
4.01
4
4.61
16.6
13.7
13
12.3
10.8
10.1
11.9
9.32
12.8
14
11
15.7
12.4
8.92
12
11.9
5.49
5.89
5.68
4.48
26.3
25
7.31
6.61
5.63
4.09
27.7
27
28.5
23.4
3.38
4.68
3.62
3.28
2.63
2.33
25.3
27.6
17.2
20
17.7
14.8
8.4
9.32
7.2
8.5
3.75
2.92
15.5
12.4
9.83
15.4
3.05
3.35
4.58
4.31
14.4
14
2.57
2.81
1.07
1.04
1.53
1.73
0.76
0.71
4.17
4.98
1.1
0.99
0.95
1.05
2.47
1.86
1.05
1.45

189

GC
2.7
2.43
2.73
3.51
28.5
27.3
26.4
23.5
2.26
3.23
32.3
30.2
33.4
33.1
32.8
35.1
38.2
38.4
5.3
4.74
2.2
2.13
2.27
2.53
2.27
1.73
0.6
0.76
1
1.06
1.04
1.5
7.68
5.33
0.62
1.03
1.02
1.21
1.96
1.92
7.18
6.89
6.9
7.13
29.5
30.6
31.8
31.5
6.76
5.85
4.87
7.57
8.5
8.29
7.92
7.31
3.95
5.44
5.32
4.66
17.3
16
7.54
5.52
5.83
4.8
10.9
11.4
11.7
11
8.82
7.4
6
5.8
5.68
4.8
12.9
14.8
18.1
19.4
17
14.9
5.04
5.29
5.2
5.82
12.5
6.66
18
17.1
4.85
5.38
6.08
5.12
7.96
9.28
13.3
13.7
1.12
1.11
0.7
0.6
0.76
0.95
0.83
0.73
3.46
3.94
0.22
0.24
1.08
1.02
3.26
3.13
0.89
0.79

PB
42.6
33.3
45
34.8
19.9
19.6
20.5
21.8
47.8
48.4
19.2
18.8
31.5
33.6
16.1
16.8
16.4
16.9
38.4
37.5
34.1
32.7
38.6
36.5
43.9
40.5
24.7
20.8
34
31.4
36.6
53.7
10.6
12.9
16.6
15.8
16.5
16.9
19.7
16.5
11.9
12.7
14.1
14
25.3
26.2
23.1
25.5
9.84
11.8
14.3
8.14
17.3
24.7
23.3
25.8
23.6
21.2
22.2
22.4
8.43
10.5
31.1
36.8
35.6
42.3
5.92
5.51
5.27
7.24
31
28.3
37.3
36.8
37.2
40.4
3.56
3.77
13.7
11.4
13.5
18
21.9
23.2
22
21.8
21.3
33.2
8.21
9.6
7
7.19
17.1
17.5
21.6
23.2
8.69
10.7
14.2
13.4
19.3
18.9
19.4
18.1
28.2
27.2
30.3
25.9
10.9
11.4
33.2
30.4
12.9
14.7
16.4
14.4

Trans
13.7
22.4
15.1
20.9
7.11
5.76
5.99
5.92
8.41
8.8
0.7
0.86
1.78
2.82
0.8
0.99
0.76
0.8
6.01
6.48
13.5
18.2
16.5
17.2
16.2
11.3
27.5
30.1
20.7
24.1
9.3
6.61
0
0
0.54
0.73
0.79
0.82
1.27
1.03
0.89
1.07
1.16
1.47
3.02
3.19
1.91
2.33
0.45
0.36
0.54
0.097
0.39
0.62
0.57
1.02
3
1.48
3.04
3.72
0.19
0.22
1.83
2.11
1.54
1.94
0.09
0.13
0.15
0.16
1.51
1.48
2.09
1.9
3.54
3.99
0.19
0
0.21
0.14
0.25
0.33
1.15
1.03
2.02
1.38
4.21
7.58
1.18
1.51
0.38
0.28
3.17
2.45
1.11
1.38
0.14
0.07
1.21
1.09
3.18
3.7
1.79
1.45
4.61
4.88
3.35
3
6.9
9
2.48
1.95
0.29
0.28
3.63
2.58

DP
23.8
28.5
20.4
26.5
64
65
63.5
62.8
28.6
26.5
62.8
60.4
56.8
55.7
74.9
71.7
74
72.2
37.1
36.5
41.5
39.2
33.4
35.5
23.8
31.4
42.6
44.3
39.8
37.2
46.9
30.4
41.3
43.3
66
67
66.6
66.1
62.8
67.5
54.8
57.2
55.9
56.2
51.5
49.2
49.9
48.1
59
54.8
55.6
56.9
36.2
29.6
31.3
28.1
50.4
52.7
49.8
52
35.8
37.5
23.8
21.6
22
19.5
42.3
42.6
41.2
43.1
21.5
26.5
31.8
33.1
32.8
31.6
5.62
13.7
25.4
22.3
23.7
26.4
52
49
52.1
50.6
33
30.5
49.4
51.1
70.1
61.6
56.6
58.3
29.8
27.2
42.3
37.4
71.7
72.5
67.9
68.6
70.4
72
58.2
59.6
42.1
46.4
73
69.8
50.7
54.2
72.9
70.7
67.6
71.4

DPPC
47.6
52.4
48.1
55.9
83
84.6
85.3
84
53.4
56.3
85.2
83.3
79.1
81.8
87.7
85.3
83.7
83.1
76.5
77
53.3
56.1
41.1
47.5
52.5
55.2
53.9
56.1
57.6
49.1
78.6
68
84
82.3
80.4
80.9
86
86
87.5
90.5
91.9
93.2
91.9
91.7
69.5
66.9
69.8
68.5
74.7
69.2
74.2
77.3
79.5
76.2
78.8
81
68.1
69.3
70.1
65.2
88.5
92.1
45.7
46.9
48.1
43.2
89
88
88.5
86.7
77.7
84
81.4
81.2
82.5
78.1
36.4
63.7
88.6
88.8
88.4
89.5
86
83.6
89.1
87.8
59.5
78.9
93.4
92.8
89.2
88
83.6
86
51.3
51.2
79.6
79.4
81.6
81.6
66.8
70.6
72.1
74.6
68.8
67.3
68.3
74.6
86.3
84.5
81.4
79.2
91.3
88.8
74.3
76.5

0.82
0.42
1.82
1.73
0.37
0.39
0.32
0.39
0.26
0.57
0.16
0.25
0.21
0.27
0.12
0.18
0.2
0.38
1.18
2.03
0.37
0.38
0.75
0.36
1.17
0.23
1.03
0.65
0.7
1.26
0.29
0.51
0.57
0.87
0.33
0.44
0.19
0.28
0.39
0.37
0.24
0.32
0.52
0.33
0.61
0.8
1.1
0.87
0.16
0.19
0.29
0.16
0.19
0.4
0.36
0.85
0.84
0.64
1.31
0.83
0.46
0.36
0.76
0.69
1.51
2
0.82
0.94
0.84
1.51
1.57
2.36
1.52
1.49
1.56
1.35
1.71
1.8
0.81
1.1
1.73
1.47
0.36
0.35
0.83
0.59
2.11
1.49
0.3
0.57
0.13
0.74
0.78
1.63
2.27
2.18
0.81
1.79
0.96
0.61
1.21
0.76
0.68
0.52
1.27
0.77
1.58
0.63
0.76
0.53
1.22
0.52
0.35
0.52
1.17
0.61

Sample
ND11
ND11
ND11
ND11
ND12
ND12
ND12
ND12
ND14
ND14
ND15
ND15
ND18
ND18
ND19
ND19
ND20
ND20
ND21
ND21
ND23
ND23
ND23
ND23
ND25
ND25
ND26
ND26
ND26
ND26
ND27
ND27
ND31
ND31
ND32
ND32
ND32
ND32
ND33
ND33
ND39
ND39
ND39
ND39
ND4
ND4
ND4
ND4
ND40
ND40
ND40
ND40
ND41
ND41
ND41
ND41
ND42
ND42
ND42
ND42
ND43
ND43
ND44
ND44
ND45
ND45
ND46
ND46
ND46
ND46
ND47
ND47
ND48
ND48
ND48
ND48
ND49
ND49
ND50
ND50
ND50
ND50
ND51
ND51
ND51
ND51
ND52
ND52
ND53
ND53
ND54
ND54
ND55
ND55
ND56
ND56
ND57
ND57
ND58
ND58
ND59
ND59
ND60
ND60
ND61
ND61
ND62
ND62
ND63
ND63
ND64
ND64
ND65
ND65
ND66
ND66

Cond
Mock
Mock
KSHV
KSHV
Mock
Mock
KSHV
KSHV
Mock
KSHV
Mock
KSHV
Mock
KSHV
Mock
KSHV
Mock
KSHV
Mock
KSHV
Mock
Mock
KSHV
KSHV
Mock
KSHV
Mock
Mock
KSHV
KSHV
Mock
KSHV
Mock
KSHV
Mock
Mock
KSHV
KSHV
Mock
KSHV
Mock
Mock
KSHV
KSHV
Mock
Mock
KSHV
KSHV
Mock
Mock
KSHV
KSHV
Mock
Mock
KSHV
KSHV
Mock
Mock
KSHV
KSHV
Mock
KSHV
Mock
KSHV
Mock
KSHV
Mock
Mock
KSHV
KSHV
Mock
KSHV
Mock
Mock
KSHV
KSHV
Mock
KSHV
Mock
Mock
KSHV
KSHV
Mock
Mock
KSHV
KSHV
Mock
KSHV
Mock
KSHV
Mock
KSHV
Mock
KSHV
Mock
KSHV
Mock
KSHV
KSHV
Mock
KSHV
Mock
KSHV
Mock
KSHV
Mock
KSHV
Mock
KSHV
Mock
KSHV
Mock
KSHV
Mock
KSHV
Mock

Appendix B. Supplementary data from
Chapter 3
B.1 Supplementary Table1: Hits reported previously by other labs through MassSpectrometry and detected in our analysis as well using Trypsin as digesting enzyme.
Gene

ORF6

ORF7

ORF8

ORF11

ORF17

ORF21

Number
of
AminoUnique Sequences of Correspondence detected
Acid
Peptide
Hits
244-251: R.QFVHDQYK.I
569-587: K.GIDSTVEAELLKFINC(+57.02)M(+15.99)IK.N
Major DNA691-712: F.C(+57.02)DLFDTDAAIGGMFAPARMQVR.I
binding
1133
7
43-49: G.NGYPEAK.V
protein (MBP)
574-580: T.VEAELLK.F
740-752: E.SIQAGFMKPASQR.D
1012-1031: R.DNPNLPKTVVLELVKHLGSS.C
327-355: R.GTPKHFFDC(+57.02)FRPDSLETLFC(+57.02)GGLFSSVED.T
Tripartite
546-568: L.FPSPPNVTLAQC(+57.02)FEAAGMLPHQK.M
terminase
23-33: L.SYADPATLDTK.S
695
6
subunit 1
414-426: R.QLVGGDKPEEVLR.D
(TRM1)
355-362: L.TPESC(+57.02)VKA.C
454-470: A.SAGLFTFQPLLSNSTHR.K
650-662: R.LASSVFDLETMFR.E
834-845: L.TQSLDISPETGE
197-215: R.YFSQPVIYAEPGWFPGIYR.V
692-705: R.DLSEIVADLGGIGK.T
Envelope
163-173: K.VNVNGVENTFT.D
glycoprotein
845
10
778-788: P.SGGAPTREEIK.N
B (gB)
581-588: T.NNQVETC(+57.02)K.D
70-78: S.ASITGELFR.F
674-686: G.LREDLDNTIDMNK.E
165-175: N.VNGVENTFTDR.D
24-42: R.GEPVWDSVIHPSHIVISNR.V
67-78: R.AYPNFTFDNTHR.K
118-147: R.ASVSANIAVGGLKIIILALTLVHAQGVYLR.C
151-164: K.DLSTPHC(+57.02)APAIVQR.E
ORF11
407
9
165-195: R.EVLSSGFEPQFTVTGIPVTSSNLNQC(+57.02)YFLVR.K
230-261: R.ISVTAPAQETPVWGLVTTSFSLTPTAPLAFDR.N
275-285: R.HYIPVIYSGPK.I
294-309: R.QVVWHNNSYTSSLPC(+57.02)K.V
310-339: K.VTAIVSNHC(+57.02)C(+57.02)NC(+57.02)DIFLEDSEWRPNKPAPLK.L
Protein

Capsid
Scaffolding
Protein (CSP)

Thymidine
kinase

534

580

3

386-397: W.HAGPPPSSSAAA.A
421-433: K.EHGGTYVHPPIYV.Q
264-285: F.LSMLQSSIDGMKTTAAKMSHTL.S

8

382-395:
486-504:
364-373:
252-264:
274-294:
328-354:
382-392:
244-251:

R.LSFDHFFQLLSIFR.A
K.NLHEQSMLPMITGVLDPVR.H
R.HLLSPAVVFP.L
R.NVYLLYLEGVM(+15.99)GV.G
V.C(+57.02)GILPQERVTSFPEPMVYWTR.A
K.FSLPFRTNATAILRMMQPWNVGGGSGR.G
R.LSFDHFFQLLS.I
R.TPVTVDYR.N

565-597:
154-163:
164-184:
661-668:
629-636:
158-169:
165-210:

K.IIATVPLPHVTYIISSEALSNAVVYEVSEIFLK.S
I.FASKWSLFAR.D
R.DTPEYRVFYPMNVM(+15.99)AVKFSIS.I
R.VQTNLFLD.K
S.TPRRGC(+57.02)PL.C
K.WSLFARDTPEYR.V
D.TPEYRVFYPMNVM(+15.99)AVKFSISIGNNESGVALYGVVSEDFVVVTLHNR.S

ORF22

Envelope
glycoprotein
H (gH)

730

7

ORF24

ORF24

752

4

ORF25

Major capsid
protein (MCP)

1376

5

395-412: T.DARTLGSSTVSDMLEPTK.H
86-96: Q.EGTLLGKVGRR.Y
422-444: I.TIFNTNM(+15.99)VINTKISC(+57.02)HVPNTLQK.T
372-391: Y.APKDRRAAMKGNLQAC(+57.02)FQRY.A
123-143: HHIGAEIELAAADIELLFAEK
158-172: TITSALQFGMDALER
1057-1070: ASTSMFVGLPSVVR
1243-1255: R.GSLGDVLYNITFR.Q
1293-1335: R.LAGAPATSTTDLQYVVVNGTDVFLDQPC(+57.02)HMLQEAYPTLAASHR.V

190

ORF26

Triplex capsid
protein 2
(TRX-2)

305

5

ORF27

ORF27

290

6

ORF28

ORF28

102

2

ORF33

Cytoplasmic
envelopment
protein 2
(CEP-2)

334

7

ORF39

Envelope
glycoprotein
M (gM)

400

6

203-220: R.VLDDLSMYLC(+57.02)ILSALVPR.G
268-285: R.VMFSYLQSLSSIFNLGPR.L
90-96: P.SDN(+.98)LQIK.N
232-251: R.HDRHPLTEVFEGVVPDEVTR.I
175-189: L.DLYTTNVSFM(+15.99)GRTYR.L
1-26: M(+15.99)ASSDILSVARTDDGSVC(+57.02)EVSLRGGR.K
169-189: Y.SM(+15.99)ALRRAFAVMVNTSC(+57.02)AGVTL.C
104-110: V.TPSSIEF.A
44-60: T.DAIKDAFLSDGIVDMAR.K
35-60: P.DTEPWVVETDAIKDAFLSDGIVDM(+15.99)AR.K
179-191: V.MVNTSC(+57.02)AGVTLC(+57.02)R.G
63-73:
ATVAYQVLR
74-96:
TLGPQAGSHAPPTVGIATQEPYR
117-126: R.FPYIAPPPSR.E
117-145: R.FPYIAPPPSREHVPDLTRQELVHTSQVVR.R
135-145: R.QELVHTSQVVR.R
160-196: R.NVNPFVWLGGGSVWLLFLGVDYMAFC(+57.02)PGVDGMPSLAR.V
257-270: R.NFLGLLFDPIVQSR.V
276-303: K.ITSHPTPTHVENVLTGVLDDGTLVPSSK.A
318-324: R.LLIYEC(+57.02)K.K
6- 16:
SDRFLMSSWVK
105-149:
AKHVHATTMMSM(+15.99)QSWIALLGSHSVLYVAILRM(+15.99)WSM(+15.99)QLFIHVLSYK
136-149:
M(+15.99)WSMQLFIHVLSYK
270-290:
QVGFYVGVFVGYLILLLPVIR
370-379:
VKDISTPAPR
380-400:
TQYQSDHESDSEIDETQMIFI
266-288: HFSHQPPSSEEDGEDQGEVLSQR
356-381: GHLPTQSPSTSAHSISSGSTTTAGSR
17-25: R.MLPIEGAPR.R
201-218: Y.GLSPASRNSVPGTQSSPY.S
50-68: R.GYAGPTVIDMSAPDDVFAE.D

ORF45

ORF45

407

5

ORF47

Envelope
glycoprotein L
(gL)

528

5

ORF52

ORF52

131

9

ORF53

Envelope
glycoprotein
N (gN)

110

1

ORF62

Triplex capsid
protein 1
(TRX-1)

331

4

ORF63

Inner
tegument
protein

927

7

ORF64

Large
tegument
protein
deneddylase

2635

6

ORF65

Small
capsomereinteracting
protein (SCP)

170

4

8-14: DPVIQER
28-45: M(+15.99)NTLDQGNM(+15.99)SQAEYLVQK
28-46: M(+15.99)NTLDQGNMSQAEYLVQKR
47-64:HYLVFLIAHHYYETYLRR

ORF68

Packaging
protein UL32
homolog

545

3

290-324: K.NGTASVC(+57.02)LLC(+57.02)EC(+57.02)LAAHPEAPKALQTLQC(+57.02)EVMGHIE.N
454- 467:
LDLAHPSQTSHLYA
5-15: K.EPSAVHPDAPR.I

ORF75

ORF75

1296
8

17-25:
MLPIEGAPR
121-137: AMAMFVRTSSSTHDEER
121-146: AM(+15.99)AM(+15.99)FVRTSSSTHDEERM(+15.99)LPIEGAPR
387-409: HFSHQPPSSEEDGEDQGEVLSQR
477-503: GHLPTQSPSTSAHSISSGSTTTAGSR
98-117: R.IDVC(+57.02)MSDGGTAKPPPGANNR.R
47-78: L.TATEKEAQLTATVGALSAAAAKKIEARVRTIF.S
52-68: K.EAQLTATVGALSAAAAK.K
43-51: R.DRPLTATEK.E
21-29: K.ISQLTVENR.E
99-117: I.D(+57.02)(+57.02)VC(+57.02)MSDGGTAKPPPGANNR.R
98-117: R.IDVC(+57.02)MSDGGTAKPPPGAN(+.98)NR.R
98-118: R.IDVC(+57.02)MSDGGTAK(+42.01)PPPGANNRR.R
52-68: K.EAQ(+.98)LTATVGALSAAAAK.K
103-110:

FVDEVVHA

45-53: K.YAASTRPTV.G
211-217: S.C(+57.02)PMVQRR.E
4-10: V.QAENAAR.L
68-73: R.QPTYGDFLVYSQTFSPQ.E
445-452: R.ALAFFVPP.A
480-491: K.TTWGGAVPANLA.R
501-512: T.QHISSTPPPTLK.D
604-624: R.HSQDALYNLLDC(+57.02)IQELFTHIR.Q
725-741: R.EATVAMTTIAKPIYPAY.I
461-495: R.VYAALPSQLM(+15.99)RAIFEISVKTTWGGAVPANLARDID.T
748-781: R.LEYLNRLNHHILRIPFPQDALSELQETYLAAFAR.L
129-135: R.NYAGTVQ.Y
1979-1985: M.EFGPPPK(+42.01).T
384-406: R.EPPPTPPATPGATALLSDLTATR.G
2358-2365: R.T(+75.98)ALQPPRT.E
2428-2445: R.DTS(+238.23)PPAEKRAAPVIRVMA.P
1265-1273: Y.Q(+57.02)D(+57.02)QVSFFLR.T

63-84:
DVEIQTVLAVLSPLLGYPHVIR
139-153: K.ITQTLLEPHPPQFIR.A
442-495: R.AHLPADPAAGPDAVEAAVAEHFLNVYC(+57.02)SLVFAVVAESGAVPGDLGETPLEVLQR.A
552-575: R.VSGHPEDVDWGLFATGSTIHQLLR.H
630-647: R.VSGHPEDVDWGLFATGSTIHQLLR.H
792-799: R.YRVTPDVK.V
1206-1224: R.GEITLTYHGNAADETLPAR.H
1229-1245: R.NPTGNSTVAGLTSSDGR.H

191

K8.1

gp35/37

228

4

33-53: SHLGFWQEGWSGQVYQDWLGR
65-87: L.EAVSLNGTRLAAGSPSSEYPNVS.V
137-155: L.ISAFSGSYSSGEPSRTTRI.R
173-183: VPFSATTTTTR

B.2 Supplemental Table2: Hits unique to our mass spectrometry but reported previously
through other methods using Trypsin as digesting enzyme.
Name

Amino
Acid
Size

ORF18

257

Protein UL79
homolog

Gong et al 2014

4

ORF32

454

Capsid vertex
component 1
(CVC-1)

Dai et al 2014

7

Protein detected

Reported
Number of
previously by
unique
other methods peptide hits

ORF38

61

Cytoplasmic
envelopment
protein 3 (CEP-3)

Wu et al 2016

4

ORF42

278

Cytoplasmic
envelopment
protein 1 (CEP-1)

Butnaru et al
2019

3

6

ORF43

605

Portal Protein

DD DünnKittenplon et al,
2019

ORF48

402

ORF48

Sander,G. et al
.2007

6

ORF56

843

DNA primase

Davis et al 2015

6

ORF
K2

204

Viral Interleukin 6
Homolog

Katano,H. et
al.2000

12

B.3

-10lgP
Sequences of Correspondence detected
22-32: S.LEMRLVTMC(+57.02)VK.E
47-57: M(+15.99)YNFGLNVYLLR
119-140: K.LSVGREAVYLHVGLSERGRFLT.L
148-159: LFNLGSVLPC(+57.02)R
224-232: R.LSFNPVNAD.V
149-167: S.VLDARDTPGFRARPLPTSR.D
274-293: E.EPVPPPPGLVFM(+15.99)DDLFINTK.Q
301-313: T.LEAAC(+57.02)RTQGYTLR.Q
133-146: R.SPTVDGVSPPEGAV.A
102-155:
R.ISC(+57.02)PGSNLSLTVRFLYLSLVVAMGAGRNNARSPTVDGVSPPEGAVAHPLEELQR.L
10-17: R.YVGPRC(+57.02)HR.L
10-32: RPSQPVDVDGEPLDVVVDYDPIR
33-51: VSEKGM(+15.99)LLEQSQSPYPALK
37-51: GMLLEQSQSPYPALK
20-36: G.EPLDVVVDYDPIRVSEK.G
35-42:K.GNGELMMR.A
170-189: I.ETLTATAAFVYELSVDDHFR.A
9-21: A.RLTGVPM(+15.99)STHAPK.T
480-506: E.SHLGSSSYC(+57.02)YMC(+57.02)SDSAINTANIYC(+57.02)LIR.Y
464-479:K.DLTNLWESEMFQTYKL.A
555-565:L.VTPPFENVPGK.G
44-54:L.RNPGVFFRQLF.I
156-163:L.VNSIQEQL.M
377-385:L.RKDTC(+57.02)SMSL.A
336-343:D.VTLVHTAR.M
192-222:V.EFRRELSLISSC(+57.02)LNVC(+57.02)WLYHIFIEHITSDVR.R
214-222:F.IEHITSDVR.R
313-321:R.LDLSHFDRR.R
362-384:K.VSLLHIC(+57.02)SYSMEADVPVPGQQLN.T
190-201:R.M(+15.99)ESTRIIGAC(+57.02)PF.A
525-538: R.EAILDIIQLLGPVD.P
497-507: R.WVLDFDLPVC(+57.02)R.D
535-548:L.GPVDPRTHPVYFFK.S
426-439:K.QFFTMLQEDGLERY.W
595-605:V.ALTGILNRTIK.L
701-708:R.NENFLENK.T
33-56: K.DLLIQRLNWMLWVIDEC(+57.02)FRDLC(+57.02)YR.T
39-51:R.LNWMLWVIDEC(+57.02)FR.D
62-73:K.GILEPAAIFHLK.L
62-96:K.GILEPAAIFHLKLPAINDTDHC(+57.02)GLIGFNETSC(+57.02)LKK.L
96-117:K.KLADGFFEFEVLFKFLTTEFGK.S
96-109: K.KLADGFFEFEVLFK.F
97-117:K.LADGFFEFEVLFKFLTTEFGK.S
97-109::K.LADGFFEFEVLFK.F
118-130::K.SVINVDVMELLTK.T
131-142:K.TLGWDIQEELNK.L
166-182:K.YWVRHFASFYVLSAMEK.F
170-182:R.HFASFYVLSAMEK.F

28.41
41.6
27.45
33.37
37.48
37.41
35.18
28.43
28.27
27.63
25.1
44.09
25
25
27.74
32.87
27.17
25.6
27.15
33.22
30.47
28.11
27.03
40.1
25.76
37.34
35.49
36.05
32.42
31.38
27.05
25
25.67
25.14
27.35
25.31
48.85
66.32
40.95
25.72
64.76
47.06
25.94
25.66
50.54
47.99
27.17
51.43

Supplementary Table3: Hits unique to our Study using Trypsin as digesting enzyme.

192

-10lgP
Name

Amino Acid
Size

Number of unique
peptide hits

Protein detected

69-82: K.RGEVFAGETGSIWK.T
70-82: R.GEVFAGETGSIWK.T
396-404: Y.DFKLQDFTK.I
470-482: K.DDISYKDIPPLFK.S
671-677: K.TILDKQQ.L
938-950: R.IPYVFVDAPGSLR.S

6
ORF9

1012

DPOL

ORF23

404

ORF23

6

ORF35

150

ORF35

4

ORF58

357

ORF58

ORF72

257

viral cyclin homolog

ORF
K3

333

E3 ubiquitin-protein
ligase MIR1

vIRF-1

vIRF-3

vIRF-4

449

566

4

Viral IRF like protein 3

911

30-67: T.SPAVAAMVGVSNPEVPMPLLFEKFGTPDSSTLPLYAAR.H
356-389: Q.SAAWLGAGVVELIC(+57.02)DGNPLSEVLGFLAKYMPIQK.E
225-251: R.LGESPVC(+57.02)DFNTVTIM(+15.99)ERANNSITFLPK.L
354-360: D.RQSAAWL.G
193-215: H.NIAQVC(+57.02)ERDIVSLNTDNEAASMF.Y
269-291: R.SMGLENIVSC(+57.02)FSSLYGAELAPAK.T
94-105: D.IDALVDAVADLK.E
87-102: L.KSASNAEEPLIASEPL.A
45-52: R.NLASPDHV.R
120-130: L.TFSAVGVLHTD.G
54-66: W.DVEFFRLVAAPVF.K
32-38: P.AYFGSVL.V
30-42: I.FPAYFGSVLVALR.T
101-120: R.VPFIPGLC(+57.02)VLNC(+57.02)LLLLPYPL.A
172-178: V.GGLLAFR.H
153-160: A.IESGLYDR.L
146-154: R.TEAVLATDV.T
21-44: R.IFYNILEIEPRFLTSDSVFGTFQQ.S
54-82: LLGTWMFSVC(+57.02)HEYNLEPNVVALALNLLDR

5

Viral IRF like protein 1

Viral IRF like protein 4

Sequences of Correspondence detected

2-35: EDEDVPVC(+57.02)WIC(+57.02)NEELGNERFRAC(+57.02)GC(+57.02)TGELENVHR
26-51: AGPSSLVDM(+15.99)LPQGLPGGGYGSMGVIR
250-271: DDNVEPTAVGC(+57.02)DC(+57.02)NNLGAERYR
308-321: Q.GLPGGGYGSMGVIR.K
279-292: Y.VGAQSGDGAYSVSC(+57.02).H

5

246-281: T.AEGQEAVIDWGRLFIRM(+15.99)YYNGEQVHELLTTSQSGC(+57.02)R.I
94-110: K.DWIVC(+57.02)QVNSGKFPGVEW.E
92-117: S.IKDWIVC(+57.02)QVNSGKFPGVEWEDEERTR.F
26-67:
F.KAWSVGATRNVPMGAGRGGGPC(+57.02)LC(+57.02)ARNINTKTPFPTPTAVEW.C
52-58: R.NINTKTP.F
72-80: L.GSPITAFGK.I
128-136: L.HSGSSLWEI.L
30-52: K.ASEVC(+57.02)AADVSGVPRPADMTEPTK.L
559-566: R.ENVLSSSP
478-490: R.MEVPLSFRPEEWR.V
15-24: L.RSASGIASGL.D
35-52: C.AADVSGVPRPADMTEPTK.L
505-547:
T.QGGASATPSAGAPPTPEVAERQEPSSSGIPYVC(+57.02)QGDNM(+15.99)ATGYR.R
752-785: EGDAGEAMLC(+57.02)SWPVGDTLGHLC(+57.02)QSFVPELLRIPR
152-158: R.RSDTREQ.S
435-467: F.EPQPPSAPAPGYAKPSC(+57.02)YNWSPLAEPPATRPIR.A
161-175: S.APAHRPPSPLTWLWR.T
549-568: R.VTTSSGALEVEIIDLTGDSD.T
858-868: R.YLATTAAIPQT.P
677-696: G.NILSELQEEPSSSTRQATDR.R
825-836: Q.VEGWWFGNPNSR.Y
492-501: W.SSGGAPNQGL.S
407-421: R.ETGAEGAC(+57.02)GASTEGR.A

5

7

11

26.31
26.87
44.45
26.41
45.15
30.99
31.71
59.54
40.2
36.59
72.52
33.22
29.35
43.54
28.98
27.76
28.43
28.21
32.22
28.78
25.43
35.76
32.47
26.09
25.94
25.06
26
25
42.27
29.5
30
25.33
25.21
33.62
30.86
31.89
25.72
32.53
31.04
27.9
26.18
25.26
30.84
26.13
37.95
25
53.33
44.03
37.87
36.42
34.83
29.55
28.06

B.4 Supplemental Table 4: Hits reported previously by other labs through MassSpectrometry and detected in our analysis as well using Chymotrypsin as digesting enzyme.
Gene

Protein

ORF6

Major DNAbinding protein
(MBP)

AminoAcid

1133

Previous Report
by MassSpectroscopy

Zhu et al 2005

Number of
Unique
Sequences of Correspondence detected
Peptide Hits

6

77-88: I.DATTASVKLTSY.H
111-120: L.EKLC(+57.02)RESREL.F
627-650: L.LTVIQDIC(+57.02)LTSC(+57.02)M(+15.99)MYEQDNPAVGI.V
755-761: S.YIVGGPY.M
984-990: L.VKRIVGI.N
961-968: F.KKNNVSSM.L

193

ORF7

ORF8

Tripartite terminase
subunit 1 (TRM1)

Envelope
glycoprotein B
(gB)

695

845

Zhu et al 2005

Zhu et al 2005,
Bechtel et al 2005

3

31-37: L.DTKSLAL.T
99-113: L.LHLDITC(+57.02)NKHRSVRF.N
666-672: L.VDKKYGW.I

20

57-63: G.PKSVDFY.Q
63-77: F.Y(+79.97)QFRVC(+57.02)SASIT(+79.97)GELF.R
67-76: R.VC(+57.02)SASITGEL.F
82-92: L.EQTC(+57.02)PDTK(+42.02)DKY.H
82-92: L.EQTC(+57.02)PDTKDKY.H
93-105: Y.HQEGILLVYKKNI.V
117-125: R.KIATSVTVY(+6.01).R
138-155: Y.ELPRPVPLYEISHMDSTY.Q
147-158: Y.E(+57.02)(+57.02)ISH(+57.02)MDSTYQC(+57.02)F.S
202-209: P.V(+42.01)IYAEPGW.F
275-281: L.NHTVVTY.S
287-295: T.SPTPQN(+203.08)RIF.V
364-371: L.TSDINTTL.N
377-390: A.KLASTHVPNGTVQY.F
392-398: F.HT(+27.05)TGGLY.L
402-408: W.QPMSAIN(+14.02).L
466-473: Y.DKLRDGIN.Q
469-476: L.R(+27.99)DGINQVL.E
511-518: Y.GRPVS(-18.01)AKF.V
519-548: F.VGDAISVTEC(+57.02)INVDQSSVNIHKSLRTNSKD.V
532-555: V.DQSSVNIHKSLRTNSKDVC(+57.02)YARPL.V
534-542: Q.S(+28.03)SVNIHKSL.R
572-579: L.GARNEIIL.T
588-594: C.KDTC(+57.02)E(+57.02)HY.F
651-657: L.ASSVFDL.E
675-689: L.REDLDNTID(+1572.99)MNKERF.V
726-739: F.INFIKHPLGGMLMI.I
734-740: L.GGMLMII.I
738-747: L.M(+15.99)IIIVIAIIL.I
751-759: F.M(+31.99)LSRRTNTI.A
767-791: M.IYPDVDRRAPPSGGAPTREEIKNIL.L
809-820: L.KKS(+162.05)TPSVFQRTA.N
817-823: F.Q(+42.01)(+.98)RTANGL.R
13-32: F.AVC(+57.02)SSKRQLGRGEPVWDSVI.H
65-73: L.HRAYPNFTF.D
166-175: E.VLSSGFEPQF.T
194-201: L.VRKPKSRL.A
229-242: L.RISVTAPAQETPVW.G

ORF11

ORF11

407

Zhu et al 2005

5

ORF17

Capsid Scaffolding
Protein (CSP)

534

Zhu et al 2005

3

ORF21

Thymidine kinase

580

Zhu et al 2005,
Bechtel et al 2005

3

ORF22

Envelope
glycoprotein H
(gH)

730

Zhu et al 2005,
Bechtel et al 2005

5

ORF24

ORF24

752

Bechtel et al 2005

7

ORF25

Major capsid
protein (MCP)

1376

Zhu et al 2005,
Bechtel et al 2005

6

ORF26

Triplex capsid
protein 2 (TRX-2)

305

Zhu et al 2005,
Bechtel et al 2005

3

ORF27

ORF27

290

Zhu et al 2005,

4

ORF28

ORF28

102

Zhu et al 2005

3

1-13: MSMTSPSPVTGGM
39-52: VIGACVYCCIRVFL
76-102: GPQAGSHAPPTVGIATQEPY RTIYMPD

ORF33

Cytoplasmic
envelopment
protein 2 (CEP-2)

334

Zhu et al 2005 ,
Bechtel et al 2005

7

35-51: C.TSISPVY(+79.97)DPELVTSYAL.S
47-56: V.TSYALSVPAY.N
50-64: Y.A(+57.02)LSVPAYN(+.98)VSVAILL.H
138-144: L.VHTSQVV.R
185-194: F.C(+57.02)P(+31.99)GVDGMPSL.A

64-91: H.GIFC(+57.02)TGAITSPAFLELASRLADTSHVAR.A
181-197: R.LEDLSTPNFVSPLETLM(+15.99).A
183-199: E.DLSTPNFVSPLETLM(+15.99)AK.A
96-106: L.IRHPSEKGSIF.A
129-167: F.QSPRVC(+57.02)GRPPLPPPNHPPPATRPADASM(+15.99)GDVGWADLQGL.K
392-401: L.SIFRATEGDV.V
233-241: L.KGHATYDEL.T
315-321: F.QMLVAHF.L
584-601: L.SNAVVYEVSEIFLKSAMF.I
597-614: L.KSAMFISAIKPDC(+57.02)SGFNF.S
629-636: S.TPRRGC(+57.02)PL.C
127-139: S.WELTDDC(+57.02)DKPC(+57.02)EF.R
172-179: W.EFEQC(+57.02)FHA.F
319-326: L.VYPGTPAI.Y
372-391:Y.APKDRRAAMKGNLQAC(+57.02)FQRY.A
485-493: I.NINISGDML.H
543-557: F.WTTNFPSVVSSKDGL.N
709-715: F.AALKPQI.V
547-554: P.C(+57.02)PGARGSY.R
836-845: Y.NGPVFADVVN.A
860-868: L.KDILQAGDI.R
1063-1086: F.VGLPSVVRREVRSDAVTFEITHEI.A
1316-1337: F.LDQPC(+57.02)HMLQEAYPTLAASHRVM(+15.99).L
1342-1349: Y.MSNKQTHA.P
72-87: AVLEEVRPDSLRLTRM
156-171: HIYSKISAGAPDDVNM
238-266: TEVFEGVVPDEVTRIDLDQL SVPDDITRM
24-32: R.GGRKKTTVY.L
45-51: D.AIKDAFL.S
52-72: L.SDGIVDM(+15.99)ARKLHRGALPSNSH.N
104-110: V.TPSSIEF.A

194

234-240: L.SNIC(+57.02)PC(+57.02)I.K
291-298: T.GVLDDGTL.V

ORF39

Envelope
glycoprotein M
(gM)

400

Zhu et al 2005

3

ORF45

ORF45

407

Zhu et al 2005

4

ORF47

Envelope
glycoprotein L
(gL)

528

Zhu et al 2005

3

ORF52

ORF52

131

Zhu et al 2005

5

ORF53

Envelope
glycoprotein N
(gN)

110

Zhu et al 2005

2

ORF62

Triplex capsid
protein 1 (TRX-1)

331

Zhu et al 2005,
Bechtel et al 2005

3

ORF63

Inner tegument
protein

927

Zhu et al 2005,
Bechtel et al 2005

5

ORF64

Large tegument
protein
deneddylase

2635

Zhu et al 2005

12

ORF65

Small capsomereinteracting protein
(SCP)

170

Zhu et al 2005

3

ORF68

Packaging protein
UL32 homolog

545

Zhu et al 2005

4

ORF75

ORF75

1296

Zhu et al 2005,
Bechtel et al 2005

K8.1

gp35/37

228

Zhu et al 2005

1-8: M(+15.99)RASKSDR.F
58-66: L.TVRNSAKHL.T
367-400: A.RAKVKDISTPAPRTQYQSDHESDSEIDETQMIFI
18-45: LPIEGAPRRRPPVKFIFPPP PLSSLPGF
94-121: DEDEEDEDEEENDDVQEEDE PEGYPADF
293-395: DVGQKRKRQSTASSGSEDVV RCQRQPNLSRKAVASVIIIS
SGSDTDEEPSSAVSVIVSPS STKGHLPTQSPSTSAHSISS GSTTTAGSRCSDPTRILAST PPL
321-395: SRKAVASVIIISSGSDTDEE PSSAVSVIVSPSSTKGHLPT QSPSTSAHSISSGSTTTAGS
RCSDPTRILASTPPL
22-39: VALPCCAIQASAASTLPL
114-140: TVGFNATTADSSIHNVNIII ISVGKAM
141-167: NRTGSVSGSQTRAKSSSRRA HAGQKGK
18-24: L.T(+79.97)AKISQ(+.98)L.T
25-31: L.TVENREL.R
32-41: L.RKALGSTADP.R
36-42: L.GSTAD(+57.02)PR.D
97-131: L.RIDVC(+57.02)MSDGGTAK(+14.02)PPPGANNRRRRGASTTR(+14.02)AGVDD
18-42: HCWVTANSTGVASSTERSSP STAG.L
52-58: T.SVTTPGF.Y
46-65: AASTRPTVGSLHEALRQAPF
244-263: L.TFFQSGKGFAEVVAM(+15.99)IKDHF.T
297-315: DSHPVHQSLNVKGTSLPVL
540-610: Y.FHIM(+15.99)DILEERHSQDALY.N
601-613: L.EERHSQDALYNLL.D
134-140: Y.ADQIAGF.K
104-129: S.QPPQNTAPAQPPTSDDTLNNC(+57.02)TLLKL.L
529-547: Y.DEDIVRSPLFADAFTKSHL.L
893-900: I.TDPNGAHF.H
46-58: E.TPLVDRASLDDVL.E
779-787: L.QSAATAEHH.L
571-585: Y.STAAPSKCTHVLQFF.I
892-900: N.ITDPNGAHF.H
146-155: A.GAIVVK(+57.02)DK(+42.01)TY.Y
1178-1192: H.GEQAWKKIQQAFKDF.N
1541-1551: L.S(+75.98)PLRVKGGKAA.V
681-706: T.ARLKPNFNIVC(+57.02)ARQDAQTIQDGVGLL.R
2397-2410: L.ETKTTPPSTPPHAI.D
1566-1574: L.VQEAEQAGL.L
90-104: L.RTDDWATKIFQSPEF.Y
5-24: KVRDPVIQERLDHDYAHHPL
78-100: RDQKPRERADRVSAASAYDA GTF
148-170: SSTTETAAPAVADARKPPSG KKK
40-57: TQIHQSLQPSSPCRVCQL
174-224: KTSWPRTDKEEATGPTPCCQ ITDTTTAPASGIPELARATF CGASRPTKPSL
183-195: K.EEATGPTPC(+57.02)C(+57.02)QIT.D
355-367: IRGCTPQEIHKHL
124-135: L.QEWARVEVGRHL.V
168-192: L.EVPEGPQPVARPHIEDDVIM(+15.99)QAVMI.S
180-201: P.HIEDDVIM(+15.99)QAVMISLGADLLPL.A
666-690: A.WRGQAMAMGEQAYKMATNVSTGATY.A
1011-1024: F.SC(+57.02)PTSPRRVAALVL.P
1122-1133: L.GVVGRSESSPYT.Y

6

4

70-121: NGTRLAAGSPSSEYPNVSVS VEDTSASGSGEDAIDESGSG EEERPVTSHVTF
123-132: TQSVQATTEL
145-151: Y.S(-18.01)SGEPSR.T
145-197: SSGEPSRTTRIRVSPVAENG RNSGASNRVPFSATTTTTRG RDAHYNAEIRTHL

B.5 Supplemental Table 5: Hits reported previously by other labs through MassSpectrometry and detected in our analysis as well using Chymotrypsin as digesting enzyme.

195

-10lgP
Name

Amino
Acid
Size

Reported
previously by
other methods

Protein detected

Number of
unique
peptide hits

Sequences of Correspondence detected

25
28.53
26.66
26.95

ORF18

257

Protein UL79
homolog

Gong et al 2014

4

51-81: REATANAGTYDEVVLGRKVP AEVW
100-108: L.C(+57.02)EAYRDSLW.M
205-226: VWASETGYPGPVEAVCRDIR SM
233-248: AVSGYLPAPSEAQLAY

ORF32

454

Capsid vertex
component 1 (CVC1)

Dai et al 2014

4

48-79: SRSPGSSRRLVVCGKRVLPG EENQLASSPSGL
159-165: R.ATPDPAL.T
204-237: DPPVSQKGPARTRHRPPPVR LSFNPVNADVPATW
313-334: RQRVPVAIPRDAEIADAVKS HF

25
29.43
25.01
25

ORF38

61

Cytoplasmic
envelopment protein
3 (CEP-3)

Wu et al 2016

3

5-28: LSICKRPSQPVDVDGEPLDV VVDY
11-28: R.PSQPVDVDGEPLDVVVDY.D
41-61: EQSQSPYPALKKKKKNKEAI Y

26
45.19
25

ORF42

278

Cytoplasmic
envelopment protein
1 (CEP-1)

Butnaru et al
2019

3

16-51: STHAPKTRESEEACPVYPHP VVPRLVLEVHRKNNAL
133-147: L.ENC(+57.02)RDMSPTFLRSII.C
222-243: KLESSGENEDDKQTCADPVN IF
156-163: L.VNSIQEQL.M
383-406: L.EKERELC(+57.02)M(+15.99)KRLKC(+57.02)IETQLSHQQPG.D
4-19: R.M(+15.99)NPGLGSSISVHPSEL.S
383-416:
L.EKERELC(+57.02)M(+15.99)KRLKC(+57.02)IETQLSHQQPGDAKGPGSVNL.L
429-442: L.QDPSLQLTSSHIPS.G

26
25.18
25

214-221: F.IEHITSDV.R
214-223: F.IEHITSDVRR.L
260-276: R.KPWKELSVSRINVEARL.L
247-254: L.ETEAIDRT.I
726-735: E.TLSGRSIEDW.L
353-360: L.VGERC(+57.02)VYW.C
40-46: F.FSVLHDL.F

26.82
25.08
28.26
40.18
29.4
25.88
25.95
86.52
36.29
34.9
29.75
27.62
26.81
26

ORF43

605

Portal Protein

DD DünnKittenplon et al,
2019

5

ORF48

402

ORF48

Sander,G. et al
.2007

3

ORF56

843

DNA primase

Davis et al 2015

4

ORF
K2

204

Viral Interleukin 6
Homolog

Katano,H. et
al.2000

7

176-183: Y.VLSAMEKF.A
45-55: W.VIDEC(+57.02)FRDLC(+57.02)Y.R
178-185: L.S(+154.00)AMEKFAG.Q
184-203: F.AGQ(+.98)AVRVLN(+.98)SIPDVTPDVHD.K
192-199: L.NSIPDVTP.D
8-15:W.SILLVGSL.L
17-29: L.V(+42.01)SGTRGK(+42.01)LPDAPE.F

35.01
25.49
25.53
27.14
25.97

B.6 Supplemental Table 6: Hits reported previously by other labs through MassSpectrometry and detected in our analysis as well using Chymotrypsin as digesting enzyme.
-10lgP
Name

Amino Acid
Size

Number of unique peptide
hits

Protein detected

ORF9

1012

DPOL

ORF23

404

ORF23

4

ORF35

150

ORF35

3

ORF58

357

ORF58

4

ORF72

257

viral cyclin homolog

ORF
K3

333

E3 ubiquitin-protein ligase
MIR1

4

4

3

Sequences of Correspondence detected

154-164: Y.FYTLAPQGVNL.T
323-336: L.HTVGNDKPYTRMLL.G
933-940: P.QIHDRIPY.V
989-999: F.QNNTSATVAIL.Y
103-124: HSKPVVRGHEFEDTQILPEC RL
169-190: DPESPLPRHPITPRAGQTRS IL
193-215: H.NIAQVC(+57.02)ERDIVSLNTDNEAASMF.Y
325-338: REPIRQPPDCSKVL
2-15: DSTNSKREFIKSAL
83-97: RQPRDLPRVADIDAL
116-137: EENGEETPTHSSSEIKDTIV RW

34.08
30.27
27.7
31.12
25.01
26.97
27.23
25.31
25.62
28.53
25.93

65-74: L.C(+57.02)PAAQKQLDR.R
116-130: L.LPYPLATATAVYQAP.P
215-222: Y.C(+57.02)RREVVVF.V
350-357: L.SVINKVVG
1-11: MATANNPPSGL
85-93: IKQVSKEHF
185-204: VDPKTGSLPASIISAAGCAL
206-224: VPANVIPQDTHSGGVVPQL
76-91: L.TYQEGLELIVFIFIMT.L
139-152: L.GAFFHM(+15.99)MRHVGRAY.A
279-292: Y.VGAQSGDGAYSVSC(+57.02).H

27.92
29.48
25.43
25
30
26.23
25.9
25
25.04
27.54
25.13

196

vIRF-1

449

Viral IRF like protein 1

4

vIRF-3

566

Viral IRF like protein 3

3

vIRF-4

911

Viral IRF like protein 4

5

23-73: SQGSPGTSGSGAPCDEPSRS ESPGEGPSGTGGSAAAGDIT
RQAVVAAITEW
175-189: L.QEIGKGISQDGHHFL.V
334-340: L.TSSC(+57.02)NGI.F
385-399: ANSPLPAPSHVTCPL
79-96: GKICTTSRRLRRLPGEEY
128-136: L.HSGSSLWEI.L
278-293: L.GIPEDVIATSQPGGDT.D
141-177: L.LSPPMQTTATRRSDTREQSYEEAGAAAPAPPKAPSGL.R
492-501: W.SSGGAPNQGL.S
672-679: W.EEGLGNIL.S
555-572: L.EVEIIDLTGDSDTPST.T
871-879: L.SVNPVTC(+57.02)GT.V

25.03
26.47
25.44
25
25
26.08
25.01
26.12
30.02
29.65
25.01
25

B.7 Supplemental Table 7: Hits detected in our study using Chymotrypsin as digesting
enzyme, not found by Trypsin.
-10lgP
Name

Amino Acid Size

ORF44

788

Protein detected

Number of unique peptide hits

DNA Replication Helicase

Sequences of Correspondence detected

12-19: D.EPSPGFIL.N
55-64: F.DPLEDEGPFL.P
225-241: W.LDTPLYRNGAVPC(+57.02)IVC(+57.02)V.G
511-520: H.GVKQGHEEFL.R
616-622: F.VSTSPGL.H

5

B.8 Supplemental Table 8: Example of de novo hits via de novo sequencing feature of
PEAKS DB with cut-off ALC% at 75%.
Sequence

ALC%

aa Scoring

PTMs

EC(+57.02)C(+57.02)HGDLLEC(+57.02)ADDRWRR

aa
Length
17

93

Carbamidomethylation

APSAEVEMTAYVLLAHVTAQPAPGMVGHSK

30

93

LKEC(+57.02)C(+57.02)DKPLLEK

12

92

98 98 98 97 86 94 95 98 98 97 96 94 94 91 91 82
86
98 97 96 96 98 99 100 100 99 99 99 99 100 100
99 99 99 98 97 96 96 96 94 83 89 89 59 60 84 97
97 96 97 99 98 97 96 94 95 78 74 81

GDSGGPLLLHK

11

88

87 97 97 94 93 97 99 99 85 71 57

N/A

VPLPVSVSVEF

11

87

98 96 99 91 85 73 92 86 73 78 90

N/A

HTM(+15.99)SGVASVESSSGSAVGSPNR

22

85

N/A

C(+57.02)VALLTLTY

9

85

95 94 89 89 49 71 92 95 97 99 98 99 99 90 96 95
90 71 87 46 54 82
96 96 98 99 99 90 73 55 63

SPQELLC(+57.02)GASLLSDR

15

85

97 97 95 97 99 99 99 88 93 94 93 88 35 41 62

Carbamidomethylation

LLLYALLPDGEVVGDWK

17

84

N/A

ELNDLLSQLGLRKLF

15

83

87 88 79 93 93 97 99 98 97 89 97 97 94 63 78 39
48
95 96 95 99 100 100 98 93 94 30 60 90 89 60 54

ASFSVLGDLLGSAM(+15.99)R

15

80

68 73 85 94 96 99 96 97 98 96 68 73 66 40 59

N/A

LTESALSPL

9

77

95 67 62 88 54 71 98 90 73

N/A

FLLPQLVK

8

76

92 97 97 86 73 41 41 80

N/A

LFFTHADLGM(+15.99)LEAEQL

16

75

95 91 67 68 94 94 94 94 82 94 95 50 21 21 43 93

Oxidation (M)

RTSTPLPVSVSVEFAVAATDC(+57.02)ALK

24

75

51 55 45 89 93 96 59 55 56 90 91 88 92 96 92 91
92 91 80 75 60 22 48 86

Carbamidomethylation

197

N/A
Carbamidomethylation

Carbamidomethylation

N/A

30.76
30.37
26.11
35.07
27.95

Appendix C. Supplementary data from
Chapter 4
C.1 The B cell analysis gating Scheme utilized in this study based on our previous studies
(Aalam F, 2020).

A
Viable Cells

Viability-V510

FSC-A

(5)

(6)

CD138-V450

IgD-APC H7

CD38-APC

B

CD38 low (7)

(9)

(11)
IgD-APC H7

(7) (8)

(10)

All Events

(14)

(12)
(13)

(1) All CD19+
(2) CD19+CD20(3) CD19+CD20+
(4) All plasma cells
(5) CD20- plasma cells
(6) CD20+ plasma cells
(8) Transitional
(9) Plasmablast
(10) Germinal Center
(11) Naive
(12) MZ-like
(13) Memory
(14) Double negative

CD27-PE

Lymphocytes

(1)

Defined B cell lineages

Single Cells

Viable/CD19-

(1)

198
H7

NOT Plasma Cells

(3)

CD20-PE Cy7

CD19+CD20+ (3)

CD38-APC

(4)

CD19+CD20- (2)

CD38-APC

CD38-APC

All B cells (1)

(2)

CD19-PerCP Cy5.5

FSC-H

SSC-A

Single Cells

SSC-A

Lymphocytes

All Events

C.2

UV Inactivation to study the early effects of △11 mutant virus vs. WT virus.
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